<!DOCTYPE html><html lang="en" class="bg-surface-base antialiased"><head><meta charSet="utf-8"/><meta name="viewport" content="width=device-width, initial-scale=1, interactive-widget=resizes-content"/><link rel="stylesheet" href="/_next/static/css/62c4caba71dfda84.css" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/eb3d87f98fe1565f.css" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/1b5e561215938d4d.css" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/0227d069a630d414.css" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl" data-precedence="next"/><link rel="stylesheet" href="/_next/static/css/f87fff2ab93d05a7.css" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl" data-precedence="next"/><link rel="preload" as="script" fetchPriority="low" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl" href="/_next/static/chunks/webpack-e121ed42680f327e.js"/><script src="/_next/static/chunks/78a669d9-e7993486b22c4915.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/40c4a5a7-abdabb07419d1cfc.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/2230-f7c87dc9fa57c408.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/main-app-536d4b8fca62396a.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/63f0ec43-8ee6a76d70472249.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/7670-7326298c9856172b.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/282-691fffb366e24ca5.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/7515-336759ef5dad2b52.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/927-34e2a6da3e15e26b.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/5855-243eeca8f0e4cabd.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/4393-1c8dff25ec904469.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/2225-454cf9f44775e7ce.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/7618-43536a8fb0dd3bfe.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/7720-3a1e7e411adba2d3.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/7086-1f1c4891d766e04f.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/app/global-error-4d07d20223cd4b4c.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/8208b75a-a48e5a4507a0de91.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/5497-ab85ef3ea59dd353.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/6281-c6e84786dade3614.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/2660-d983a7f287e89f18.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/5002-9735c25beda556ba.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/3655-6717081f7512305a.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/8945-e4e3cf487f5e27c7.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/9214-a10614844a67ba31.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/4789-2080f6497f78b5b6.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/app/layout-226f2bd71acf9f9e.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/24cf1b50-159cca90b09285e0.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/9ffa21ba-c069766d809bd4c7.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/600-9a9fcafaaa6c1c4c.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/5448-2a3cfd853d899c9a.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/8-8ca70ca619d8e099.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/app/error-4a29e9399afba038.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><script src="/_next/static/chunks/app/not-found-dd95690acf732f18.js" async="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script><meta name="next-size-adjust" content=""/><title>Grokipedia</title><meta name="description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><link rel="icon" type="image/x-icon" href="/favicon.ico" sizes="48x48"/><link rel="icon" href="/images/icon-dark.png" media="(prefers-color-scheme: light)" type="image/png"/><link rel="icon" href="/images/icon-light.png" media="(prefers-color-scheme: dark)" type="image/png"/><link rel="apple-touch-icon" href="/icon-192x192.png"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><meta property="og:title" content="Grokipedia"/><meta property="og:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta property="og:url" content="https://grokipedia.com"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en_US"/><meta property="og:type" content="website"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Grokipedia"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Grokipedia"/><meta name="twitter:description" content="Grokipedia is an open source, comprehensive collection of all knowledge."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><title>Hairy cell leukemia</title><meta name="description" content="Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes.[1] The incidence of hairy cell leukemia (HCL) is 0.28-0.30 cases per 100,000 people in Europe and the United States and the prevalence is approximately 3.12 cases per 100,000 in Europe with a lower prevalence in Asia, Africa and the Middle East.[2] HCL has an indolent course but patients frequently relapse. Despite this, with treatment, life expectancy is usually the same as..."/><meta name="author" content="system"/><link rel="manifest" href="/manifest.webmanifest"/><meta name="keywords" content="HCL, Hairy cell leukaemia, Leukemic reticuloendotheliosis"/><meta name="robots" content="index, follow"/><meta name="googlebot" content="index, follow, max-snippet:-1"/><link rel="canonical" href="https://grokipedia.com/page/Hairy_cell_leukemia"/><meta property="og:title" content="Hairy cell leukemia"/><meta property="og:description" content="Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes.[1] The incidence of hairy cell leukemia (HCL) is 0.28-0.30 cases per 100,000 people in Europe and the United States and the prevalence is approximately 3.12 cases per 100,000 in Europe with a lower prevalence in Asia, Africa and the Middle East.[2] HCL has an indolent course but patients frequently relapse. Despite this, with treatment, life expectancy is usually the same as..."/><meta property="og:url" content="https://grokipedia.com/page/Hairy_cell_leukemia"/><meta property="og:site_name" content="Grokipedia"/><meta property="og:locale" content="en"/><meta property="og:image" content="https://grokipedia.com/icon-512x512.png"/><meta property="og:image:width" content="512"/><meta property="og:image:height" content="512"/><meta property="og:image:alt" content="Hairy cell leukemia"/><meta property="og:type" content="article"/><meta property="article:modified_time" content="1970-01-21T09:19:12.815Z"/><meta name="twitter:card" content="summary"/><meta name="twitter:creator" content="@Grokipedia"/><meta name="twitter:title" content="Hairy cell leukemia"/><meta name="twitter:description" content="Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes.[1] The incidence of hairy cell leukemia (HCL) is 0.28-0.30 cases per 100,000 people in Europe and the United States and the prevalence is approximately 3.12 cases per 100,000 in Europe with a lower prevalence in Asia, Africa and the Middle East.[2] HCL has an indolent course but patients frequently relapse. Despite this, with treatment, life expectancy is usually the same as..."/><meta name="twitter:image" content="https://grokipedia.com/icon-512x512.png"/><link rel="icon" href="/favicon.ico" type="image/x-icon" sizes="16x16"/><meta name="sentry-trace" content="3572bce1882f1c7d3707b91495294854-427e1195e6b284ec-1"/><meta name="baggage" content="sentry-environment=production,sentry-public_key=5f2258f71198ee26a355127af230c3a6,sentry-trace_id=3572bce1882f1c7d3707b91495294854,sentry-org_id=4508179396558848,sentry-transaction=GET%20%2Fpage%2F%5Bslug%5D,sentry-sampled=true,sentry-sample_rand=0.6076450616237707,sentry-sample_rate=1"/><script src="/_next/static/chunks/polyfills-42372ed130431b0a.js" noModule="" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl"></script></head><body class="flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b"><div hidden=""><!--$--><!--/$--></div><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">((a,b,c,d,e,f,g,h)=>{let i=document.documentElement,j=["light","dark"];function k(b){var c;(Array.isArray(a)?a:[a]).forEach(a=>{let c="class"===a,d=c&&f?e.map(a=>f[a]||a):e;c?(i.classList.remove(...d),i.classList.add(f&&f[b]?f[b]:b)):i.setAttribute(a,b)}),c=b,h&&j.includes(c)&&(i.style.colorScheme=c)}if(d)k(d);else try{let a=localStorage.getItem(b)||c,d=g&&"system"===a?window.matchMedia("(prefers-color-scheme: dark)").matches?"dark":"light":a;k(d)}catch(a){}})("class","theme","dark",null,["light","dark"],null,true,true)</script><header class="h-16 bg-surface-base fixed top-0 z-50 w-full"><div class="hidden h-full grid-cols-[1fr_3fr_1fr] items-center gap-4 !py-0 md:grid max-w-full py-6 px-4 w-full mx-auto"><div class="-ml-2 justify-self-start"><a class="cursor-pointer" href="/"><svg width="200" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="mx-auto flex w-full"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full px-3 shadow-none sm:w-80 focus-visible:z-1 mx-auto h-full w-full rounded-full bg-surface-l1" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div><div class="flex items-center gap-2 justify-self-end"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0" type="button" id="radix-_R_7apfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button></div></div><div class="flex h-full items-center md:hidden justify-between max-w-full py-6 px-4 w-full mx-auto pt-8"><div class="flex items-center"><div class="-ml-2"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button" aria-label="Toggle table of contents"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-list h-6 w-6"><path d="M3 12h.01"></path><path d="M3 18h.01"></path><path d="M3 6h.01"></path><path d="M8 12h13"></path><path d="M8 18h13"></path><path d="M8 6h13"></path></svg></button></div><a class="cursor-pointer" href="/"><svg width="160" height="auto" viewBox="0 0 955 225" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M99.6937 159.214C90.008 159.214 81.5652 157.414 74.3652 153.814C67.1652 150.214 61.5509 144.986 57.5223 138.129C53.5794 131.271 51.608 123.043 51.608 113.443C51.608 103.843 53.5794 95.4857 57.5223 88.3714C61.5509 81.2572 67.1652 75.7286 74.3652 71.7857C81.6509 67.8429 90.1794 65.8714 99.9509 65.8714C103.208 65.8714 106.679 66.1286 110.365 66.6429C114.051 67.0714 117.222 67.6714 119.879 68.4429C121.508 68.8714 123.008 69.2572 124.379 69.6C125.751 69.9429 127.122 70.1143 128.494 70.1143C129.522 70.1143 130.551 69.9857 131.579 69.7286C131.751 73.5 131.922 77.4 132.094 81.4286C132.265 85.4572 132.522 89.6572 132.865 94.0286C131.065 94.2857 129.565 94.3714 128.365 94.2857C126.651 86.4 123.522 80.5714 118.979 76.8C114.437 72.9429 108.394 71.0143 100.851 71.0143C94.8509 71.0143 89.708 72.1286 85.4223 74.3572C81.2223 76.5 77.7937 79.4572 75.1366 83.2286C72.5652 87 70.6794 91.3714 69.4794 96.3429C68.2794 101.229 67.6794 106.457 67.6794 112.029C67.6794 120.171 68.9223 127.371 71.408 133.629C73.8937 139.886 77.6652 144.814 82.7223 148.414C87.8652 151.929 94.2937 153.686 102.008 153.686C104.408 153.686 107.065 153.471 109.979 153.043C112.894 152.529 115.679 151.757 118.337 150.729V134.529C118.337 131.871 118.208 129.814 117.951 128.357C117.779 126.814 117.222 125.7 116.279 125.014C115.422 124.329 114.008 123.857 112.037 123.6C110.151 123.257 107.537 122.957 104.194 122.7C103.937 121.329 103.937 119.957 104.194 118.586C105.994 118.586 108.179 118.629 110.751 118.714C113.322 118.714 115.894 118.757 118.465 118.843C121.122 118.843 123.308 118.843 125.022 118.843C127.679 118.843 130.722 118.8 134.151 118.714C137.665 118.629 140.665 118.586 143.151 118.586C143.322 119.871 143.322 121.2 143.151 122.571C139.637 123 137.108 123.429 135.565 123.857C134.022 124.286 133.079 125.143 132.737 126.429C132.394 127.714 132.222 129.9 132.222 132.986V137.1C132.222 141.129 132.308 144.514 132.479 147.257C132.737 150 132.951 151.971 133.122 153.171C121.208 157.2 110.065 159.214 99.6937 159.214ZM148.19 157.414C147.933 156.043 147.933 154.714 148.19 153.429C151.105 153.257 153.248 153 154.619 152.657C155.99 152.229 156.89 151.371 157.319 150.086C157.748 148.8 157.962 146.743 157.962 143.914V115.114C157.962 111.771 157.79 109.286 157.448 107.657C157.19 106.029 156.376 104.914 155.005 104.314C153.719 103.629 151.49 103.071 148.319 102.643C148.062 101.443 148.062 100.329 148.319 99.3C151.748 98.6143 155.09 97.8429 158.348 96.9857C161.605 96.0429 165.033 94.8429 168.633 93.3857L170.819 94.1572V105.471C176.819 97.8429 182.948 94.0286 189.205 94.0286C192.205 94.0286 194.433 94.8429 195.89 96.4714C197.348 98.0143 198.076 99.7714 198.076 101.743C198.076 104.057 197.305 105.857 195.762 107.143C194.219 108.343 192.462 108.943 190.49 108.943C188.862 108.943 187.233 108.514 185.605 107.657C184.062 106.8 182.905 105.471 182.133 103.671C179.219 103.671 176.605 104.829 174.29 107.143C172.062 109.371 170.948 111.986 170.948 114.986V142.629C170.948 145.971 171.119 148.371 171.462 149.829C171.89 151.286 172.919 152.229 174.548 152.657C176.262 153 179.005 153.257 182.776 153.429C182.948 154.629 182.948 155.957 182.776 157.414C179.862 157.414 176.862 157.371 173.776 157.286C170.69 157.2 167.519 157.157 164.262 157.157C161.09 157.157 158.262 157.2 155.776 157.286C153.376 157.371 150.848 157.414 148.19 157.414ZM229.285 158.829C223.028 158.829 217.542 157.5 212.828 154.843C208.199 152.1 204.599 148.371 202.028 143.657C199.457 138.857 198.171 133.371 198.171 127.2C198.171 120.514 199.499 114.686 202.157 109.714C204.899 104.743 208.714 100.886 213.599 98.1429C218.485 95.4 224.099 94.0286 230.442 94.0286C236.699 94.0286 242.142 95.4 246.771 98.1429C251.399 100.886 254.999 104.657 257.571 109.457C260.142 114.257 261.428 119.7 261.428 125.786C261.428 132.043 260.057 137.7 257.314 142.757C254.657 147.729 250.928 151.671 246.128 154.586C241.328 157.414 235.714 158.829 229.285 158.829ZM212.699 125.657C212.699 134.4 214.114 141.343 216.942 146.486C219.857 151.543 224.185 154.071 229.928 154.071C235.414 154.071 239.614 151.671 242.528 146.871C245.442 141.986 246.899 135.471 246.899 127.329C246.899 118.671 245.442 111.771 242.528 106.629C239.614 101.486 235.371 98.9143 229.799 98.9143C224.314 98.9143 220.071 101.271 217.071 105.986C214.157 110.7 212.699 117.257 212.699 125.657ZM267.394 157.414C267.308 157.071 267.265 156.729 267.265 156.386C267.265 156.043 267.265 155.7 267.265 155.357C267.265 155.014 267.265 154.714 267.265 154.457C267.265 154.114 267.308 153.771 267.394 153.429C270.308 153.257 272.451 153 273.822 152.657C275.194 152.229 276.094 151.371 276.522 150.086C276.951 148.8 277.165 146.743 277.165 143.914V79.5C277.165 76.8429 276.908 74.8714 276.394 73.5857C275.965 72.2143 274.979 71.2714 273.437 70.7572C271.979 70.1572 269.751 69.7286 266.751 69.4714C266.665 69.1286 266.622 68.8286 266.622 68.5714C266.622 68.3143 266.622 68.0572 266.622 67.8C266.622 67.4572 266.622 67.1572 266.622 66.9C266.622 66.6429 266.665 66.3429 266.751 66C270.179 65.5714 273.694 64.9286 277.294 64.0714C280.894 63.1286 284.579 61.8429 288.351 60.2143L290.537 60.9857C290.451 62.8714 290.365 65.0143 290.279 67.4143C290.279 69.8143 290.279 72.4286 290.279 75.2572V122.957C291.308 122.957 292.165 122.786 292.851 122.443C293.537 122.1 294.094 121.757 294.522 121.414C294.694 121.243 295.037 120.943 295.551 120.514C296.065 120 296.965 119.1 298.251 117.814C299.537 116.529 301.379 114.6 303.779 112.029C306.008 109.543 307.765 107.614 309.051 106.243C310.422 104.786 311.108 103.586 311.108 102.643C311.108 101.957 310.508 101.4 309.308 100.971C308.194 100.457 306.651 100.157 304.679 100.071C304.594 99.7286 304.551 99.3857 304.551 99.0429C304.551 98.7 304.551 98.3572 304.551 98.0143C304.551 97.6714 304.551 97.3286 304.551 96.9857C304.551 96.6429 304.594 96.3 304.679 95.9572C306.394 95.9572 308.537 96 311.108 96.0857C313.765 96.1714 316.122 96.2143 318.179 96.2143C319.208 96.2143 320.665 96.2143 322.551 96.2143C324.522 96.1286 326.494 96.0857 328.465 96.0857C330.437 96.0857 331.894 96.0857 332.837 96.0857C332.922 96.4286 332.965 96.7714 332.965 97.1143C333.051 97.4572 333.094 97.8 333.094 98.1429C333.094 98.4857 333.051 98.8286 332.965 99.1714C332.965 99.4286 332.922 99.7286 332.837 100.071C328.379 100.157 324.608 101.271 321.522 103.414C318.437 105.471 315.479 107.914 312.651 110.743L303.394 120L321.137 143.4C323.022 145.886 324.565 147.857 325.765 149.314C327.051 150.686 328.422 151.671 329.879 152.271C331.337 152.871 333.351 153.257 335.922 153.429C336.094 154.629 336.094 155.957 335.922 157.414C334.808 157.414 333.137 157.371 330.908 157.286C328.765 157.2 325.379 157.157 320.751 157.157C320.065 157.157 319.037 157.157 317.665 157.157C316.294 157.157 315.008 157.243 313.808 157.414C313.808 156.471 313.294 155.186 312.265 153.557C311.237 151.843 310.422 150.6 309.822 149.829C309.565 149.4 308.922 148.5 307.894 147.129C306.865 145.671 305.622 144 304.165 142.114C302.794 140.143 301.379 138.171 299.922 136.2C298.465 134.143 297.137 132.343 295.937 130.8C294.994 129.514 294.094 128.529 293.237 127.843C292.465 127.071 291.479 126.686 290.279 126.686V142.629C290.279 145.971 290.408 148.371 290.665 149.829C291.008 151.286 291.737 152.229 292.851 152.657C294.051 153 295.851 153.257 298.251 153.429C298.422 154.714 298.422 156.043 298.251 157.414C296.022 157.414 293.665 157.371 291.179 157.286C288.779 157.2 286.165 157.157 283.337 157.157C280.594 157.157 277.894 157.2 275.237 157.286C272.579 157.371 269.965 157.414 267.394 157.414ZM369.34 157.414C366.94 157.414 364.454 157.371 361.883 157.286C359.311 157.2 356.526 157.157 353.526 157.157C350.783 157.157 347.997 157.2 345.169 157.286C342.426 157.371 339.769 157.414 337.197 157.414C336.94 156.043 336.94 154.714 337.197 153.429C340.111 153.257 342.254 153 343.626 152.657C344.997 152.229 345.897 151.371 346.326 150.086C346.754 148.8 346.969 146.743 346.969 143.914V115.114C346.969 111.771 346.84 109.286 346.583 107.657C346.326 106.029 345.511 104.914 344.14 104.314C342.854 103.629 340.583 103.071 337.326 102.643C337.069 101.443 337.069 100.329 337.326 99.3C341.097 98.6143 344.697 97.7572 348.126 96.7286C351.554 95.7 354.854 94.5857 358.026 93.3857L360.211 94.1572C360.126 96.8143 360.04 99.3 359.954 101.614C359.954 103.929 359.954 106.114 359.954 108.171V142.629C359.954 145.971 360.126 148.371 360.469 149.829C360.897 151.286 361.754 152.229 363.04 152.657C364.411 153 366.511 153.257 369.34 153.429C369.597 154.714 369.597 156.043 369.34 157.414ZM343.626 71.5286C343.626 69.0429 344.483 66.9429 346.197 65.2286C347.997 63.5143 350.14 62.6572 352.626 62.6572C355.026 62.6572 357.083 63.5143 358.797 65.2286C360.597 66.9429 361.497 69 361.497 71.4C361.497 73.6286 360.64 75.6857 358.926 77.5715C357.211 79.3714 355.026 80.2714 352.369 80.2714C349.969 80.2714 347.911 79.4143 346.197 77.7C344.483 75.9857 343.626 73.9286 343.626 71.5286ZM372.678 188.914C372.592 187.543 372.592 186.214 372.678 184.929C375.678 184.757 377.864 184.457 379.235 184.029C380.607 183.6 381.464 182.743 381.807 181.457C382.235 180.257 382.45 178.286 382.45 175.543V115.114C382.45 111.771 382.278 109.286 381.935 107.657C381.678 106.029 380.864 104.914 379.492 104.314C378.207 103.629 375.978 103.071 372.807 102.643C372.635 101.443 372.635 100.329 372.807 99.3C376.321 98.6143 379.75 97.8 383.092 96.8572C386.435 95.9143 389.907 94.7572 393.507 93.3857L395.307 94.2857C395.221 96.4286 395.178 98.2714 395.178 99.8143C395.178 101.271 395.178 102.686 395.178 104.057C398.521 100.543 401.821 98.0143 405.078 96.4714C408.335 94.8429 411.807 94.0286 415.492 94.0286C420.892 94.0286 425.435 95.4429 429.121 98.2714C432.892 101.1 435.764 104.786 437.735 109.329C439.707 113.871 440.692 118.8 440.692 124.114C440.692 130.371 439.321 136.157 436.578 141.471C433.921 146.7 430.192 150.9 425.392 154.071C420.592 157.243 415.021 158.829 408.678 158.829C406.192 158.829 403.835 158.614 401.607 158.186C399.378 157.843 397.278 157.329 395.307 156.643V174C395.307 177.343 395.564 179.743 396.078 181.2C396.592 182.657 397.707 183.557 399.421 183.9C401.135 184.329 403.835 184.629 407.521 184.8C407.607 186.171 407.607 187.543 407.521 188.914C404.607 188.914 401.65 188.871 398.65 188.786C395.735 188.7 392.521 188.657 389.007 188.657C385.664 188.657 382.792 188.7 380.392 188.786C377.992 188.871 375.421 188.914 372.678 188.914ZM395.178 146.1C398.864 151.414 403.75 154.071 409.835 154.071C414.121 154.071 417.507 152.871 419.992 150.471C422.564 148.071 424.407 144.943 425.521 141.086C426.721 137.229 427.321 133.157 427.321 128.871C427.321 124.586 426.764 120.386 425.65 116.271C424.535 112.157 422.692 108.771 420.121 106.114C417.635 103.371 414.207 102 409.835 102C404.607 102 399.721 104.529 395.178 109.586V146.1ZM477.335 158.829C471.25 158.829 466.107 157.414 461.907 154.586C457.707 151.757 454.493 147.986 452.264 143.271C450.121 138.471 449.05 133.2 449.05 127.457C449.05 121.543 450.164 116.057 452.393 111C454.707 105.943 458.05 101.871 462.421 98.7857C466.793 95.6143 472.107 94.0286 478.364 94.0286C485.907 94.0286 491.778 96.3 495.978 100.843C500.264 105.3 502.407 111.086 502.407 118.2C502.407 119.057 502.364 119.829 502.278 120.514C502.278 121.114 502.235 121.629 502.15 122.057L461.65 121.671C461.65 122.014 461.65 122.314 461.65 122.571C461.65 130.971 463.578 137.571 467.435 142.371C471.293 147.171 476.693 149.571 483.635 149.571C489.464 149.571 495.207 147.686 500.864 143.914C501.721 144.943 502.364 145.929 502.793 146.871C495.507 154.843 487.021 158.829 477.335 158.829ZM462.035 116.914L488.65 116.4C488.735 116.229 488.778 116.014 488.778 115.757C488.778 115.414 488.778 115.2 488.778 115.114C488.778 110.486 487.75 106.629 485.693 103.543C483.721 100.457 480.764 98.9143 476.821 98.9143C473.135 98.9143 469.921 100.414 467.178 103.414C464.435 106.414 462.721 110.914 462.035 116.914ZM559.644 158.957L557.587 158.057L557.073 149.186C554.073 152.443 550.987 154.886 547.816 156.514C544.73 158.057 541.302 158.829 537.53 158.829C532.216 158.829 527.544 157.414 523.516 154.586C519.573 151.671 516.53 147.9 514.387 143.271C512.244 138.643 511.173 133.629 511.173 128.229C511.173 121.971 512.502 116.271 515.159 111.129C517.902 105.986 521.716 101.871 526.602 98.7857C531.573 95.6143 537.359 94.0286 543.959 94.0286C545.93 94.0286 547.987 94.2 550.13 94.5429C552.273 94.8 554.502 95.2714 556.816 95.9572V79.5C556.816 76.8429 556.559 74.8714 556.044 73.5857C555.53 72.2143 554.502 71.2714 552.959 70.7572C551.502 70.1572 549.273 69.7286 546.273 69.4714C546.016 68.3572 546.016 67.2 546.273 66C549.702 65.5714 553.216 64.9286 556.816 64.0714C560.416 63.1286 564.102 61.8429 567.873 60.2143L570.059 60.9857C569.973 62.8714 569.887 65.0143 569.802 67.4143C569.802 69.8143 569.802 72.4286 569.802 75.2572V139.029C569.802 142.286 569.93 144.729 570.187 146.357C570.445 147.986 571.216 149.143 572.502 149.829C573.787 150.429 575.973 150.986 579.059 151.5C579.316 152.614 579.316 153.771 579.059 154.971C575.63 155.486 572.287 156.043 569.03 156.643C565.773 157.243 562.644 158.014 559.644 158.957ZM556.944 106.886C553.259 101.829 548.416 99.3 542.416 99.3C536.502 99.3 532.044 101.486 529.044 105.857C526.044 110.143 524.544 116.1 524.544 123.729C524.544 128.186 525.144 132.471 526.344 136.586C527.544 140.7 529.516 144.086 532.259 146.743C535.002 149.4 538.644 150.729 543.187 150.729C548.93 150.729 553.516 148.243 556.944 143.271V106.886ZM615.699 157.414C613.299 157.414 610.813 157.371 608.242 157.286C605.67 157.2 602.885 157.157 599.885 157.157C597.142 157.157 594.356 157.2 591.527 157.286C588.785 157.371 586.127 157.414 583.556 157.414C583.299 156.043 583.299 154.714 583.556 153.429C586.47 153.257 588.613 153 589.985 152.657C591.356 152.229 592.256 151.371 592.685 150.086C593.113 148.8 593.327 146.743 593.327 143.914V115.114C593.327 111.771 593.199 109.286 592.942 107.657C592.685 106.029 591.87 104.914 590.499 104.314C589.213 103.629 586.942 103.071 583.685 102.643C583.427 101.443 583.427 100.329 583.685 99.3C587.456 98.6143 591.056 97.7572 594.485 96.7286C597.913 95.7 601.213 94.5857 604.385 93.3857L606.57 94.1572C606.485 96.8143 606.399 99.3 606.313 101.614C606.313 103.929 606.313 106.114 606.313 108.171V142.629C606.313 145.971 606.485 148.371 606.827 149.829C607.256 151.286 608.113 152.229 609.399 152.657C610.77 153 612.87 153.257 615.699 153.429C615.956 154.714 615.956 156.043 615.699 157.414ZM589.985 71.5286C589.985 69.0429 590.842 66.9429 592.556 65.2286C594.356 63.5143 596.499 62.6572 598.985 62.6572C601.385 62.6572 603.442 63.5143 605.156 65.2286C606.956 66.9429 607.856 69 607.856 71.4C607.856 73.6286 606.999 75.6857 605.285 77.5715C603.57 79.3714 601.385 80.2714 598.727 80.2714C596.327 80.2714 594.27 79.4143 592.556 77.7C590.842 75.9857 589.985 73.9286 589.985 71.5286ZM665.837 158.571C660.18 158.571 656.623 155.743 655.165 150.086C649.08 155.914 642.865 158.829 636.523 158.829C632.151 158.829 628.423 157.543 625.337 154.971C622.337 152.314 620.837 148.671 620.837 144.043C620.837 132.729 632.365 125.614 655.423 122.7C655.423 120.643 655.423 118.543 655.423 116.4C655.508 114.257 655.551 111.986 655.551 109.586C655.551 106.586 654.437 104.271 652.208 102.643C650.065 100.929 647.451 100.071 644.365 100.071C642.137 100.071 640.251 100.414 638.708 101.1C638.708 103.071 638.28 105.086 637.423 107.143C636.565 109.2 635.365 110.957 633.823 112.414C632.365 113.786 630.565 114.471 628.423 114.471C626.537 114.471 625.037 113.957 623.923 112.929C622.894 111.814 622.38 110.486 622.38 108.943C622.38 106.886 623.323 104.957 625.208 103.157C627.18 101.271 629.665 99.6857 632.665 98.4C635.665 97.0286 638.794 95.9572 642.051 95.1857C645.308 94.4143 648.223 94.0286 650.794 94.0286C653.965 94.0286 656.88 94.6286 659.537 95.8286C662.28 96.9429 664.465 98.6572 666.094 100.971C667.808 103.2 668.665 105.986 668.665 109.329C668.665 111.386 668.623 114.086 668.537 117.429C668.451 120.686 668.365 124.2 668.28 127.971C668.28 131.657 668.237 135.171 668.151 138.514C668.065 141.857 668.023 144.557 668.023 146.614C668.023 149.357 669.223 150.729 671.623 150.729C673.165 150.729 675.523 150.214 678.694 149.186C679.037 149.614 679.251 150.086 679.337 150.6C679.508 151.114 679.637 151.586 679.723 152.014C677.58 154.329 675.308 156 672.908 157.029C670.594 158.057 668.237 158.571 665.837 158.571ZM655.165 146.614L655.423 127.329C647.537 128.357 642.094 130.029 639.094 132.343C636.18 134.657 634.723 137.614 634.723 141.214C634.723 144.214 635.494 146.529 637.037 148.157C638.665 149.7 640.68 150.471 643.08 150.471C644.623 150.471 646.337 150.129 648.223 149.443C650.194 148.757 652.508 147.814 655.165 146.614Z" fill="currentColor"></path><rect x="715" y="65" width="195" height="105" rx="52.5" fill="currentColor" fill-opacity="0.05"></rect><path d="M767.529 142.875L754.049 107.938H762.552L769.309 127.582C769.705 128.812 770.078 130.032 770.43 131.24C770.781 132.449 771.078 133.559 771.32 134.569H771.616C771.858 133.559 772.144 132.449 772.473 131.24C772.825 130.032 773.198 128.812 773.594 127.582L780.186 107.938H788.689L775.472 142.875H767.529ZM810.856 143.633C806.901 143.633 803.528 142.71 800.737 140.865C797.969 138.997 795.871 136.305 794.442 132.79C793.014 129.252 792.3 124.989 792.3 120.001V118.255C792.3 113.245 793.014 108.982 794.442 105.467C795.871 101.929 797.969 99.2373 800.737 97.3916C803.528 95.5239 806.901 94.5901 810.856 94.5901C814.789 94.5901 818.129 95.5129 820.875 97.3586C823.644 99.2043 825.731 101.907 827.138 105.467C828.566 109.004 829.28 113.267 829.28 118.255V120.001C829.28 124.989 828.577 129.252 827.171 132.79C825.764 136.327 823.677 139.019 820.908 140.865C818.162 142.71 814.811 143.633 810.856 143.633ZM810.889 136.382C813.064 136.382 814.877 135.789 816.327 134.602C817.799 133.416 818.898 131.658 819.623 129.329C820.348 126.978 820.711 124.066 820.711 120.595V117.694C820.711 114.223 820.337 111.311 819.59 108.96C818.865 106.609 817.777 104.84 816.327 103.654C814.877 102.445 813.064 101.841 810.889 101.841C808.714 101.841 806.879 102.434 805.385 103.621C803.912 104.785 802.792 106.554 802.023 108.927C801.276 111.278 800.902 114.201 800.902 117.694V120.595C800.902 124.044 801.287 126.945 802.056 129.296C802.825 131.647 803.945 133.416 805.418 134.602C806.89 135.789 808.714 136.382 810.889 136.382ZM838.988 143.205C838 143.205 837.099 142.985 836.286 142.545C835.495 142.106 834.879 141.491 834.44 140.7C834.001 139.909 833.781 139.019 833.781 138.03C833.781 137.019 834.001 136.118 834.44 135.327C834.879 134.536 835.495 133.921 836.286 133.482C837.099 133.042 838 132.823 838.988 132.823C839.977 132.823 840.867 133.042 841.658 133.482C842.449 133.921 843.064 134.536 843.504 135.327C843.943 136.118 844.163 137.019 844.163 138.03C844.163 139.019 843.943 139.909 843.504 140.7C843.064 141.491 842.449 142.106 841.658 142.545C840.867 142.985 839.977 143.205 838.988 143.205ZM857.365 142.875V104.511L846.39 111.663V103.357L858.453 95.3481H865.802V142.875H857.365Z" fill="currentColor"></path></svg></a></div><div class="flex items-center gap-1"><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover px-4 py-2 w-9 h-9 flex-shrink-0 [&amp;_svg]:!w-5" type="button" id="radix-_R_aipfiumdb_" aria-haspopup="menu" aria-expanded="false" data-state="closed"><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 rotate-0 scale-100 transition-all dark:-rotate-90 dark:scale-0" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M12 18a6 6 0 1 1 0-12 6 6 0 0 1 0 12m0-2a4 4 0 1 0 0-8 4 4 0 0 0 0 8M11 1h2v3h-2zm0 19h2v3h-2zM3.515 4.929l1.414-1.414L7.05 5.636 5.636 7.05zM16.95 18.364l1.414-1.414 2.121 2.121-1.414 1.414zm2.121-14.85 1.414 1.415-2.121 2.121-1.414-1.414zM5.636 16.95l1.414 1.414-2.121 2.121-1.414-1.414zM23 11v2h-3v-2zM4 11v2H1v-2z"></path></svg></span><span class="inline-flex items-center justify-center p-0 m-0 w-6 h-6 absolute rotate-90 scale-0 transition-all dark:rotate-0 dark:scale-100" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-6 h-6" focusable="false" style="fill:currentColor"><path d="M10 7a7 7 0 0 0 12 4.9v.1c0 5.523-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2h.1A6.98 6.98 0 0 0 10 7m-6 5a8 8 0 0 0 15.062 3.762A9 9 0 0 1 8.238 4.938 8 8 0 0 0 4 12"></path></svg></span><span class="sr-only">Toggle theme</span></button><button class="focus-visible:ring-ring inline-flex items-center justify-center gap-x-2 whitespace-nowrap rounded-full text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary hover:bg-overlay-hover h-9 w-9" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-search h-5 w-5"><circle cx="11" cy="11" r="8"></circle><path d="m21 21-4.3-4.3"></path></svg></button></div></div></header><div class="bg-surface-base fixed right-0 top-16 z-50 h-[calc(100vh-4rem)] w-full transform border-l transition-transform duration-300 ease-in-out sm:w-1/2 md:hidden translate-x-full"><div class="flex flex-col gap-4 p-4"><div class="flex flex-row gap-2"><button class="focus-visible:ring-ring inline-flex items-center gap-x-2 whitespace-nowrap text-sm font-medium transition-colors focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 border-input text-primary hover:border-primary/15 border hover:bg-overlay-hover py-2 max-w-full shadow-none sm:w-80 h-10 w-full justify-start rounded-full bg-surface-l1 px-4" type="button"><div class="flex items-center justify-between sm:w-full gap-4"><div class="flex items-center justify-start gap-2"><span class="inline-flex items-center justify-center p-0 m-0 w-4 h-4 text-muted" data-namespace="@xai/icons" data-slot="icon"><svg xmlns="http://www.w3.org/2000/svg" fill="currentColor" viewBox="0 0 24 24" aria-hidden="true" class="w-4 h-4" focusable="false" style="fill:currentColor"><path d="m18.031 16.617 4.283 4.282-1.415 1.415-4.282-4.283A8.96 8.96 0 0 1 11 20c-4.968 0-9-4.032-9-9s4.032-9 9-9 9 4.032 9 9a8.96 8.96 0 0 1-1.969 5.617m-2.006-.742A6.98 6.98 0 0 0 18 11c0-3.867-3.133-7-7-7s-7 3.133-7 7 3.133 7 7 7a6.98 6.98 0 0 0 4.875-1.975z"></path></svg></span><p class="text-sm text-muted hidden sm:block">Search</p></div><span class="hidden sm:block"><div class="bg-foreground/10 text-muted inline-flex items-center rounded-md px-1 py-0.5 text-center font-sans text-xs font-normal tracking-widest rtl:space-x-reverse"><span>âŒ˜</span><span class="text-xs">K</span></div></span></div></button></div></div></div><div><div class="min-[1350px]:grid min-[1350px]:grid-cols-[1fr_3fr_1fr]"><nav class="bg-surface-base hidden h-[calc(100vh-4rem)] overflow-y-auto px-6 pb-32 min-[1350px]:sticky min-[1350px]:top-16 min-[1350px]:block scrollbar-none [-ms-overflow-style:none] [scrollbar-width:none] [&amp;::-webkit-scrollbar]:hidden [overscroll-behavior:contain] pt-8"><ul class="space-y-2 text-sm"><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#hairy-cell-leukemia" class="transition-opacity hover:opacity-100 opacity-50">Hairy cell leukemia</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#signs-and-symptoms" class="transition-opacity hover:opacity-100 opacity-50">Signs and symptoms</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#cause" class="transition-opacity hover:opacity-100 opacity-50">Cause</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#pathophysiology" class="transition-opacity hover:opacity-100 opacity-50">Pathophysiology</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#diagnosis" class="transition-opacity hover:opacity-100 opacity-50">Diagnosis</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#classification" class="transition-opacity hover:opacity-100 opacity-50">Classification</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#hcl-v" class="transition-opacity hover:opacity-100 opacity-50">HCL-V</a></li><li style="padding-left:0rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#treatment" class="transition-opacity hover:opacity-100 opacity-50">Treatment</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#first-line-therapy" class="transition-opacity hover:opacity-100 opacity-50">First-line therapy</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#second-line-therapy" class="transition-opacity hover:opacity-100 opacity-50">Second-line therapy</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#prognosis" class="transition-opacity hover:opacity-100 opacity-50">Prognosis</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#treatment-success" class="transition-opacity hover:opacity-100 opacity-50">Treatment success</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#lifespan" class="transition-opacity hover:opacity-100 opacity-50">Lifespan</a></li><li style="padding-left:1.5rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#follow-up-care" class="transition-opacity hover:opacity-100 opacity-50">Follow-up care</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#epidemiology" class="transition-opacity hover:opacity-100 opacity-50">Epidemiology</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#research-directions" class="transition-opacity hover:opacity-100 opacity-50">Research directions</a></li><li style="padding-left:0.75rem" class="flex items-start gap-2"><div class="bg-foreground mt-[0.5rem] h-1 w-1 flex-shrink-0 transition-opacity opacity-0"></div><a href="#references" class="transition-opacity hover:opacity-100 opacity-50">References</a></li></ul></nav><div class="relative top-16 pb-32 pt-8 px-4 md:px-8"><div class="mx-auto max-w-[850px]"><button data-state="closed" type="button" class="flex items-center"><div class="text-fg-tertiary mb-2 flex cursor-help items-center gap-2 text-sm"><span class="inline-flex items-center justify-center p-0 m-0" data-namespace="@xai/icons" data-slot="icon" style="height:16px;width:16px"><svg xmlns="http://www.w3.org/2000/svg" fill="none" viewBox="0 0 33 33" aria-hidden="true" class="" focusable="false" style="fill:currentColor;height:16px;width:16px"><path fill="currentColor" d="m13.237 21.04 11.082-8.19c.543-.4 1.32-.244 1.578.38 1.363 3.288.754 7.241-1.957 9.955-2.71 2.714-6.482 3.31-9.93 1.954l-3.765 1.745c5.401 3.697 11.96 2.782 16.059-1.324 3.251-3.255 4.258-7.692 3.317-11.693l.008.009c-1.365-5.878.336-8.227 3.82-13.031q.123-.17.247-.345l-4.585 4.59v-.014L13.234 21.044M10.95 23.031c-3.877-3.707-3.208-9.446.1-12.755 2.446-2.449 6.454-3.448 9.952-1.979L24.76 6.56c-.677-.49-1.545-1.017-2.54-1.387A12.465 12.465 0 0 0 8.675 7.901c-3.519 3.523-4.625 8.94-2.725 13.561 1.42 3.454-.907 5.898-3.251 8.364-.83.874-1.664 1.749-2.335 2.674l10.583-9.466"></path></svg></span><span>Fact-checked by Grok<!-- --> <!-- -->4 days ago</span></div></button><article class="text-[16px]"><h1 id="hairy-cell-leukemia" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Hairy cell leukemia<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>













<!-- -->
<span class="mb-4 block break-words text-[1em] leading-7">Hairy cell leukemia is an uncommon <span class="inline text-[1em] leading-7">hematological malignancy</span> characterized by an accumulation of abnormal <span class="inline text-[1em] leading-7">B lymphocytes</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[1]</sup> The incidence of hairy cell leukemia (HCL) is 0.28-0.30 cases per 100,000 people in Europe and the United States and the prevalence is approximately 3.12 cases per 100,000 in Europe with a lower prevalence in Asia, Africa and the Middle East.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g1abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">HCL has an indolent course but patients frequently relapse. Despite this, with treatment, life expectancy is usually the same as that for the general population.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_41qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">HCL was originally described as histiocytic leukemia, malignant reticulosis, or lymphoid myelofibrosis in publications dating back to the 1920s. The disease was formally named leukemic reticuloendotheliosis, and its characterization was significantly advanced by <span class="inline text-[1em] leading-7">Bertha Bouroncle</span> and colleagues at the <span class="inline text-[1em] leading-7">Ohio State University College of Medicine</span> in 1958. Its common name, which was coined in 1966,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[3]</sup> is derived from the &quot;hairy&quot; appearance of the cytoplasmic projections from malignant B cells under a microscope.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_g2abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[4]</sup></span>
<h2 id="signs-and-symptoms" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Signs and symptoms<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">In HCL, the &quot;hairy cells&quot; (malignant B lymphocytes) accumulate in the bone marrow, interfering with the production of normal white blood cells, red blood cells, and platelets. Consequently, patients may develop infections related to low white blood cell count, anemia and fatigue due to a lack of red blood cells, or easy bleeding due to a low platelet count.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Splenomegaly is present in 70-100% of patients and may cause abdominal fullness, discomfort, or pain below the ribs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_43qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Platelet function may be somewhat impaired in HCL patients, although this does not appear to have any significant practical effect.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[6]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Patients with a high tumor burden may also have somewhat reduced levels of cholesterol,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> especially in patients with an enlarged spleen.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_84qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[8]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Those with HCL rarely have constitutional symptoms such as fevers, chills, weight loss or rigors. 20-30% may have opportunistic infections due to an impairment in immune function. Rarely, in recurrent disease, bone lesions may be present which can be confused for other malignancies such as multiple myeloma.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_45abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<h2 id="cause" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Cause<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">As with many cancers, the cause of HCL is unknown. Recent studies suggest possible associations with certain environmental exposures. Tobacco smoking appears to have a protective effect.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_46abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup> Ionizing radiation, farming, exposure to pesticides, petroleum derivatives, and diesel exhaust are suspected risk factors, though causation is not established.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[9]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_a6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">A 2011 study identified somatic <em>BRAF</em> V600E mutations in all 47 HCL patients studied, and no such mutations in the 193 peripheral B-cell lymphomas/leukemias other than HCL.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_86qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup> This mutation is now confirmed in nearly all (90-100%) classic HCL cases and is considered a key driver.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c6qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[11]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The U.S. Institute of Medicine (IOM) found a correlation which permits an association between exposure to herbicides and later development of chronic B-cell leukemias and lymphomas in general. The IOM report emphasizes that neither animal nor human studies indicate an association of herbicides with HCL specifically. However, the IOM extrapolated data from chronic lymphocytic leukemia and non-Hodgkin lymphoma to conclude that HCL and other rare B-cell neoplasms may share this risk factor.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[12]</sup> Based on this, the U.S. Department of Veterans Affairs recognizes chronic B-cell leukemias, including HCL, as presumptive conditions for veterans exposed to Agent Orange.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Human T-lymphotropic virus 2 (HTLV-2) has been isolated in a small number of patients with the variant form of HCL.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_47qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[13]</sup> In the 1980s, HTLV-2 was identified in a patient with a T-cell lymphoproliferative disease; this patient later developed HCL, but HTLV-2 was not found in the hairy cell clones.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_87qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[14]</sup> There is no evidence that HTLV-2 causes any sort of hematological malignancy, including HCL.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c7qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[15]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">In a small population-based study, there was an increased incidence of HCL in those who used or handled pesticides.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_48abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[10]</sup></span>
<h2 id="pathophysiology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Pathophysiology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Pancytopenia</span> in HCL is caused primarily by marrow failure and <span class="inline text-[1em] leading-7">splenomegaly</span>. Bone-marrow failure is caused by the accumulation of hairy cells and reticulin <span class="inline text-[1em] leading-7">fibrosis</span> in the bone marrow, as well as by the detrimental effects of dysregulated cytokine production.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_e9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> Splenomegaly reduces blood counts through sequestration, marginalization, and destruction of healthy blood cells inside the spleen.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_i9abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Hairy cells are nearly mature <span class="inline text-[1em] leading-7">B cells</span>, which are activated clonal cells with signs of <em><span class="inline text-[1em] leading-7">VH</span></em> gene differentiation.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_c9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup> They may be related to pre-plasma <span class="inline text-[1em] leading-7">marginal zone</span> B cells<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_k9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> or <span class="inline text-[1em] leading-7">memory B cells</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_s9qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Cytokine</span> production is disturbed in HCL. Hairy cells produce and thrive on <span class="inline text-[1em] leading-7">TNF-alpha</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> This cytokine also suppresses normal production of healthy blood cells in the bone marrow.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eaabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Unlike healthy B cells, hairy cells express and secrete an immune system protein called <span class="inline text-[1em] leading-7">interleukin-2 receptor</span> (IL-2R).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8aqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> In HCL-V, only part of this receptor is expressed.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_caqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> As a result, disease status can be monitored by measuring changes in the amount of IL-2R in the blood serum.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_gaqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Hairy cells respond to normal production of some cytokines by <span class="inline text-[1em] leading-7">T cells</span> with increased growth. Treatment with interferon-alpha suppresses the production of this pro-growth cytokine from T cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8babav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> A low level of T cells, which is commonly seen after treatment with <span class="inline text-[1em] leading-7">cladribine</span> or <span class="inline text-[1em] leading-7">pentostatin</span>, and the consequent reduction of these cytokines, is also associated with reduced levels of hairy cells.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Nearly all cases of HCL have the <span class="inline text-[1em] leading-7"><em>BRAF</em></span> mutation V600E, which drives the disease through constitutive activation of the MAPK/ERK signaling pathway, promoting survival and accumulation of the neoplastic cells in the bone marrow and spleen.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8bqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[18]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_abqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The BRAF V600E mutation leads to resistance to apoptosis and enhanced responsiveness to microenvironmental stimuli. Prior to the identification of BRAF mutations, only a few genomic imbalances had been reported in hairy cells, such as trisomy 5.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ebqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> Subsequent genomic studies have identified recurrent copy number alterations, including deletions of 7q and 13q and gains of 5q.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ibqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The <span class="inline text-[1em] leading-7">expression of genes</span> is also dysregulated in a complex and specific pattern. The cells underexpress 3p24, 3p21, 3q13.3-q22, 4p16, 11q23, 14q22-q24, 15q21-q22, 15q24-q25, and 17q22-q24 and overexpress 13q31 and Xq13.3-q21.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qbqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[19]</sup> It has not yet been demonstrated that any of these changes have any practical significance to the patient.</span>
<h1 id="diagnosis" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Diagnosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">The diagnosis of HCL may be suggested by abnormal results on a <span class="inline text-[1em] leading-7">complete blood count</span> (CBC), but additional testing is necessary to confirm the diagnosis. A CBC normally shows low counts for white blood cells, red blood cells, and platelets in HCL patients, with monocytopenia (absolute monocyte count &lt; 0.1 Ã— 10^9/L) present in almost all cases. However, if large numbers of hairy cells are in the blood stream, then normal or even <span class="inline text-[1em] leading-7">high lymphocyte counts</span> may be found.</span>
<span class="mb-4 block break-words text-[1em] leading-7">On physical examination, 80â€“90% of patients have an <span class="inline text-[1em] leading-7">enlarged spleen</span>, which can be massive.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8dabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> This is less likely among patients who are diagnosed at an early stage. Peripheral <span class="inline text-[1em] leading-7">lymphadenopathy</span> (enlarged lymph nodes) is uncommon (less than 5% of patients), but abdominal lymphadenopathy is a relatively common finding on <span class="inline text-[1em] leading-7">computed tomography</span> scans.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_kdabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The most important laboratory finding is the presence of hairy cells in the bloodstream.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> Hairy cells are abnormal white blood cells with hair-like projections of <span class="inline text-[1em] leading-7">cytoplasm</span>; they can be seen by examining a <span class="inline text-[1em] leading-7">blood smear</span> or <span class="inline text-[1em] leading-7">bone marrow biopsy</span> specimen. The blood film examination is done by <span class="inline text-[1em] leading-7">staining</span> the blood cells with <span class="inline text-[1em] leading-7">Wright&#x27;s stain</span> and looking at them under a <span class="inline text-[1em] leading-7">microscope</span>. Hairy cells are visible in this test in about 85% of cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_10dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup> Along with the characteristic surface projections, hairy cells also have large amounts of cytoplasm, an oval (sometimes cleaved) nuclei with homogenous chromatin and without distinct nucleoli giving the cells a &quot;fried egg&quot; appearance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_14dqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Most patients require a bone-marrow biopsy for final diagnosis. The bone marrow biopsy is used both to confirm the presence of HCL and also the absence of any additional diseases, such as <span class="inline text-[1em] leading-7">Splenic marginal zone lymphoma</span> or <span class="inline text-[1em] leading-7">B-cell prolymphocytic leukemia</span>. The bone marrow in HCL may show a diffuse infiltration of leukemic cells or an interstitial infiltration with partial preservation of fat and hematopoietic stem cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ceabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The diagnosis can be confirmed by viewing the cells with a special stain known as <span class="inline text-[1em] leading-7">tartrate resistant acid phosphatase</span> (TRAP). While TRAP and DBA.44 are useful, immunohistochemistry for BRAF V600E and annexin A1 provides more accurate results.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Definitively diagnosing HCL is also possible through <span class="inline text-[1em] leading-7">flow cytometry</span> on blood or bone marrow. The hairy cells are larger than normal and positive for <span class="inline text-[1em] leading-7">CD19</span>, <span class="inline text-[1em] leading-7">CD20</span>, <span class="inline text-[1em] leading-7">CD22</span>, <span class="inline text-[1em] leading-7">CD11c</span>, <span class="inline text-[1em] leading-7">CD25</span>, <span class="inline text-[1em] leading-7">CD103</span>, <span class="inline text-[1em] leading-7">CD123</span>, and <span class="inline text-[1em] leading-7">FMC7</span> antigens.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18eqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[20]</sup> (<span class="inline text-[1em] leading-7">CD103</span>, <span class="inline text-[1em] leading-7">CD22</span>, and <span class="inline text-[1em] leading-7">CD11c</span> are strongly expressed.)<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1oeqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[21]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Annexin A1</span> and the BRAF v600E mutant protein are the most sensitive and specific cell markers associated with HCL. Diseases mimicking HCL are usually negative for both markers.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6fabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Hairy cell leukemia-variant (HCL-V), which shares some characteristics with B cell prolymphocytic leukemia (B-PLL), does not show CD25 (also called the interleukin-2 receptor, alpha).</span>
<span class="mb-4 block break-words text-[1em] leading-7">The differential diagnoses include several kinds of anemia, including <span class="inline text-[1em] leading-7">myelophthisis</span> and <span class="inline text-[1em] leading-7">aplastic anemia</span>,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[22]</sup> and most kinds of blood neoplasms, including hypoplastic <span class="inline text-[1em] leading-7">myelodysplastic syndrome</span>, atypical chronic lymphocytic leukemia, <span class="inline text-[1em] leading-7">B-cell prolymphocytic leukemia</span>, or idiopathic <span class="inline text-[1em] leading-7">myelofibrosis</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_sgabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[17]</sup></span>
<h2 id="classification" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Classification<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The &quot;classic&quot; form is often implied, but hairy cell leukemia-variant has also been described.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4habav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<h3 id="hcl-v" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">HCL-V<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">Hairy cell leukemia-variant (HCL-V) is usually described as a prolymphocytic variant of HCL.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup> It was first described in 1980.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8iabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[25]</sup> About 10-20% of people with HCL have this variant form of the disease, representing approximately 100-260 new cases of HCL-V each year in the U.S. While classic HCL primarily affects men, HCL-V is more evenly divided between males and females.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ciabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> While the disease can appear at any age, the median age at diagnosis is over 70.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_giabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[27]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Similar to <span class="inline text-[1em] leading-7">B-cell prolymphocytic leukemia</span> (B-PLL) in <span class="inline text-[1em] leading-7">chronic lymphocytic leukemia</span>, HCL-V is a more aggressive disease. Historically, it has been considered less likely to be treated successfully than is classic HCL, and remissions have tended to be shorter. The introduction of combination therapy with concurrent rituximab and cladribine therapy, though, has shown excellent results in early follow-up.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ciqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[28]</sup> As of 2016, this therapy is considered the first-line treatment of choice for many people with HCL-V.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_giqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[29]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Many older treatment approaches, such as interferon-alpha, the combination chemotherapy regimen &quot;CHOP&quot;, and common alkylating agents such as <span class="inline text-[1em] leading-7">cyclophosphamide</span>, showed very little benefit.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8jabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup> Pentostatin and cladribine administered as monotherapy (without concurrent rituximab) provide some benefit to many people with HCL-V, but typically induce shorter remission periods and lower response rates than when they are used in classic HCL. More than half of people respond partially to splenectomy.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_cjabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">HCL-V differs from classic HCL principally in these respects:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Higher <span class="inline text-[1em] leading-7">white blood cell</span> counts, sometimes exceeding 100,000 cells per microliter</li>
<li class="text-[1em]">A more aggressive course of disease requiring more frequent treatment</li>
<li class="text-[1em]">Hairy cells with an unusually large <span class="inline text-[1em] leading-7">nucleolus</span> for their size</li>
<li class="text-[1em]">Production of little excess <span class="inline text-[1em] leading-7">fibronectin</span> produced by classic hairy cells<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4gkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[30]</sup> to interfere with bone marrow biopsies</li>
<li class="text-[1em]">Low or no cell-surface expression of CD25 (interleukin-2 [IL-2] receptor alpha chain, or p55).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2kkabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[31]</sup></li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">Low levels of CD25, a part of the receptor for a key immunoregulating hormone, may explain why HCL-V cases are generally much more resistant to treatment by immune-system hormones.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4kqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[24]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">HCL-V, which usually features a high proportion of hairy cells without a functional <em><span class="inline text-[1em] leading-7">p53</span></em> <span class="inline text-[1em] leading-7">tumor suppressor gene</span>, is somewhat more likely to transform into a higher-grade malignancy. A typical transformation rate of 5-6% has been postulated in the UK, similar to the <span class="inline text-[1em] leading-7">Richter&#x27;s transformation</span> rate for <span class="inline text-[1em] leading-7">splenic lymphoma with villous lymphocytes</span> (SLVL) and CLL.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_klabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[26]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_mlabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[32]</sup> Among HCL-V patients, the most aggressive cases normally have the least amount of p53 gene activity.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qlabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[33]</sup> Hairy cells without the <em>p53</em> gene tend, over time, to displace the less aggressive p53(+) hairy cells.</span>
<span class="mb-4 block break-words text-[1em] leading-7">Some evidence suggests that a rearrangement of the immunoglobulin gene <em>VH4-34</em> , which is found in about 40% of HCL-V patients and 10% of classic HCL patients, may be a more important poor prognostic factor than variant status, with HCL-V patients without the VH4-34 rearrangement responding about as well as classic HCL patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8lqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[34]</sup></span>
<h1 id="treatment" class="group relative mb-2 scroll-mt-24 font-serif text-[2.125em] font-semibold tracking-[-1px] [&amp;:not(:first-child)]:mt-14" node="[object Object]">Treatment<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h1>
<span class="mb-4 block break-words text-[1em] leading-7">Several treatments are available, and successful control of the disease is common.</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Not everyone requires treatment immediately. Due to the indolent nature of HCL, a &quot;<span class="inline text-[1em] leading-7">watchful waiting</span>&quot; approach may be done for those without significant cytopenia (low hemoglobin, <span class="inline text-[1em] leading-7">absolute neutrophil count</span>, and platelet count), symptomatic organomegaly, recurrent infections or constitutional symptoms. This watchful waiting approach is used in about 10-20% of people.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1knabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
</ul>
<h3 id="first-line-therapy" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">First-line therapy<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Purine analogs</span> such as <span class="inline text-[1em] leading-7">cladribine</span> and <span class="inline text-[1em] leading-7">pentostatin</span> are the first-line therapies for HCL. Purine analogs are very effective in the treatment of HCL, achieving remission rates of 80-90%; with remission being defined as normal or near normal blood counts, no palpable splenomegaly and no hairy cells on bone marrow biopsy or peripheral blood without immunostaining, or minimal hairy cells with immunostaining (known as measurable residual disease).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_eoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The benefits of treating measurable residual disease are not well established.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_ioabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The median relapse free time for purine analogs is greater than 10 years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_moabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The possible side effects of purine analogs include rash, fever, neutropenia, infections and a low T-cell counts (especially CD4+ T-cells).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_qoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Purine analogs may cause immunosuppression over time and should not be used if the patients have an active infection.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_uoabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Rituximab</span>, the anti-CD20 monoclonal antibody, may be added to purine analogs during initial treatment and is associated with increasing the remission rate to nearly 100%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6oqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> Purine analogs may be restarted in those with relapsed disease, with or without rituximab.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_aoqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Cladribine can be administered by injection under the skin, by infusion over a few hours into a vein (intravenous - IV), or by a pump worn by the patient that provides a slow drip into a vein throughout the day. Most patients receive cladribine by IV infusion once a day for five to seven days, but more patients are being given the option of taking this drug once a week for six weeks. The different dosing schedules used with cladribine are roughly equally effective and safe.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[35]</sup> Relatively few patients have significant side effects other than fatigue and a high fever caused by the cancer cells dying, although complications such as infection and acute kidney failure have been seen. Pentostatin is chemically similar to cladribine, and has a similar success rate and side effect profile, but it is always given over a much longer period of time, usually one dose by IV infusion every two weeks for 3â€“6 months.</span>
<span class="mb-4 block break-words text-[1em] leading-7">During the weeks following treatment, the patients&#x27; immune systems are severely weakened, but their bone marrow will begin to produce normal blood cells again. Treatment often results in long-term remission. If the cancer cells return, the treatment may be repeated and should again result in remission, although the treatment response may decline with repeated treatment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4pqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[36]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Cladribine</span> induced complete responses in patients with hairy cell leukemia resistant to pentostatin, suggesting a lack of cross-resistance..<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_6qabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[37]</sup></span>
<h3 id="second-line-therapy" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Second-line therapy<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">If a patient is resistant to either cladribine or pentostatin, or in those with relapsed disease, then second-line therapy is pursued.</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">BRAF inhibitors such as <span class="inline text-[1em] leading-7">vemurafenib</span> or <span class="inline text-[1em] leading-7">dabrafenib</span> inhibit the <span class="inline text-[1em] leading-7">MAPK/ERK pathway</span> which is constitutively active in those with a BRAF V600E kinase activating mutation (which is 95% of those with HCL). Constitutively active MAPK kinase activity is what leads to disease activity in HCL by increasing cell survival, increasing proliferation and reducing apoptosis of the leukemic cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_44rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> BRAF inhibitors have an overall response rate of greater than 90% with a complete response of 30-35% in people with relapsed or refractory HCL.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> They are also known to have less toxic effects than the purine analogs.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_64rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> They may be combined with rituximab to increase the remission rate. The median duration of response with BRAF inhibitors is 1.5 years (more than 3 years if combined with rituximab), after which remission occurs. BRAF inhibitors with or without rituximab may be restarted if there is relapsed disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_74rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
<li class="text-[1em]">Ritixumab: Two partial and 10 complete responses resulted from 15 patients with relapsed disease, for a total of 80% responding.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_18rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[38]</sup> The median response time is greater than 3 years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_28rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[39]</sup> Rituximab has successfully induced a complete response in Hairy Cell-Variant.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_38rqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[40]</sup></li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">Rituximab may cause a <span class="inline text-[1em] leading-7">serum sickness</span> reaction which presents with fevers, joint pain and rash approximately 4-10 days after any infusion. The reaction is successfully treated with steroids.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_8sabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[41]</sup></span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">BTK inhibitors such as ibrutinib may be used for relapsed or refractory HCL, with an overall response rate of 54% and 36-month progression-free survival of 73% as of 2025.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_14sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[5]</sup></li>
<li class="text-[1em]">If progression of disease or relapse is seen in those previously on BRAF inhibitors plus rituximab, the combination can be retried. Or a BRAF inhibitor can be restarted plus MEK inhibitors <span class="inline text-[1em] leading-7">trametinib</span> or <span class="inline text-[1em] leading-7">cobimetinib</span>.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_38sqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></li>
<li class="text-[1em]">Interferon-alpha is an immune system hormone that is very helpful to a relatively small number of patients, and somewhat helpful to most patients. Standard interferon alfa is no longer available as production has been halted; pegylated interferon (e.g., ropeginterferon alfa-2b-njft) may be substituted but is not FDA-approved for HCL. In about 65% of patients,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1csqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[43]</sup> the drug helps stabilize the disease or produce a slow, minor improvement for a partial response.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_2csqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[44]</sup> Some patients can achieve the negativization of minimal residual disease by BRAF-V600E status <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_3csqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[45]</sup></li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">Some patients tolerate IFN-alpha very well after the first few weeks, while others find that its characteristic <span class="inline text-[1em] leading-7">flu-like symptoms</span> persist. About 10% of patients develop a level of <span class="inline text-[1em] leading-7">depression</span>.</span>
<span class="mb-4 block break-words text-[1em] leading-7">A drop in blood counts is usually seen during the first 1â€“2 months of treatment. Most patients find that their blood counts get worse for a few weeks immediately after starting treatment, although some patients find their blood counts begin to improve within just 2 weeks.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4tqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Typically, 6 months are needed to figure out whether this therapy is useful. Common criteria for treatment success include:</span>
<ul class="marker:text-primary my-4 ml-6 list-disc space-y-2 text-[1em]">
<li class="text-[1em]">Normalization of hemoglobin levels (above 12.0 g/dL),</li>
<li class="text-[1em]">A normal or somewhat low platelet count (above 100 K/Î¼L), and</li>
<li class="text-[1em]">A normal or somewhat low absolute neutrophil count (above 1.5 K/Î¼L).<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_1cuqbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[46]</sup></li>
</ul>
<span class="mb-4 block break-words text-[1em] leading-7">Pegylated interferon-alpha may be considered for pregnant women with active HCL, or splenectomy/watchful waiting as alternatives.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_4vabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<h2 id="prognosis" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Prognosis<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<h3 id="treatment-success" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Treatment success<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">First-line therapy with cladribine or pentostatin achieves overall response rates exceeding 95% in classic hairy cell leukemia (HCL), with complete response (CR) rates of 76-85%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_50qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[47]</sup> Combining cladribine with rituximab yields CR in nearly 100% of patients.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_90qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> A majority of patients can expect relapse-free survival of about 10 years or longer after a single course, though relapses occur and retreatment remains effective, albeit with potentially shorter remissions. Risks include shingles and peripheral neuropathy with cladribine.</span>
<span class="mb-4 block break-words text-[1em] leading-7">As in B-cell chronic lymphocytic leukemia, mutated IGHV in hairy cells is associated with better initial treatment responses and prolonged survival, whereas unmutated IGHV (particularly IGHV4-34) and TP53 mutations predict poorer outcomes.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_51abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[48]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Recovery to normal function post-treatment varies based on disease stage at diagnosis, baseline health, response completeness, side effects encountered, disease aggressiveness, and pre-treatment functioning.</span>
<h3 id="lifespan" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Lifespan<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">In classic HCL, appropriate treatment results in a near-normal lifespan.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_52qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> The highest mortality risk occurs in the first two years post-diagnosis; 5-year survival exceeds 95%, predicting good disease control.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_92qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[7]</sup> After five years of remission with normal blood counts, U.S. patients may qualify for private life insurance.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d2qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[49]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">For hairy cell leukemia variant (HCL-V), prognosis is poorer due to median diagnosis age of ~70 years, with 5-year overall survival of 60-75% and median survival around 8 years; younger patients fare better but outcomes remain inferior to classic HCL.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_53abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[23]</sup></span>
<h3 id="follow-up-care" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.428571em] font-semibold" node="[object Object]">Follow-up care<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h3>
<span class="mb-4 block break-words text-[1em] leading-7">HCL is generally considered incurable, with relapses possible even after decades, necessitating lifelong monitoring.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> However, undetectable minimal residual disease (uMRD) after chemoimmunotherapy like cladribine plus rituximab (94% uMRD-free at 8 years) or vemurafenib plus obinutuzumab (96% uMRD) suggests potential curability in some classic HCL cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_94abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Remission requires annual physician visits and biannual blood counts for life. Prompt reporting of infections or health changes is essential. HCL patients face elevated second cancer risk (observed-to-expected ratio 1.0-2.6 overall, 5.3 for hematologic), peaking ~2 years post-diagnosis and declining thereafter; lifetime risk remains below 50%.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_54qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[50]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">There is also increased autoimmune disease risk, including polyarteritis nodosa, which may remit with HCL treatment.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_55abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<h2 id="epidemiology" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Epidemiology<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">HCL is more common in men, with a male to female ratio of 4:1, and the median age at diagnosis is 55â€“60 years.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> It is extremely rare in children.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[2]</sup> HCL is more common among people of White or Caucasian ethnicity and less frequent in those of Asian, African, or Middle Eastern descent.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_d6abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[51]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">It does not appear to be hereditary, although rare familial cases that suggest a predisposition have been reported,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_56qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[52]</sup> usually showing a common human leukocyte antigen (HLA) type.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_96qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[16]</sup></span>
<h2 id="research-directions" class="group relative mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden" node="[object Object]">Research directions<button class="focus-visible:ring-ring gap-x-2 whitespace-nowrap rounded-full font-medium focus-visible:outline-none focus-visible:ring-1 disabled:pointer-events-none disabled:cursor-not-allowed disabled:opacity-50 [&amp;&gt;[data-slot=icon]]:-mx-0.5 [&amp;&gt;[data-slot=icon]]:my-0.5 [&amp;&gt;[data-slot=icon]]:size-5 [&amp;&gt;[data-slot=icon]]:shrink-0 [&amp;&gt;[data-slot=icon]]:text-[--btn-icon] [&amp;&gt;[data-slot=icon]]:sm:my-1 [&amp;&gt;[data-slot=icon]]:sm:size-4 text-primary text-xs ml-2 inline-flex h-6 w-6 items-center justify-center p-0 align-middle opacity-0 transition-opacity hover:bg-gray-100 dark:hover:bg-gray-800" type="button" aria-label="Copy link to heading" data-state="closed"><svg xmlns="http://www.w3.org/2000/svg" width="24" height="24" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-link h-4 w-4"><path d="M10 13a5 5 0 0 0 7.54.54l3-3a5 5 0 0 0-7.07-7.07l-1.72 1.71"></path><path d="M14 11a5 5 0 0 0-7.54-.54l-3 3a5 5 0 0 0 7.07 7.07l1.71-1.71"></path></svg></button></h2>
<span class="mb-4 block break-words text-[1em] leading-7">The Hairy Cell Leukemia Consortium was founded in 2008 to address researchers&#x27; concerns about the long-term future of research on the disease.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_57qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[53]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The <a href="https://www.hairycellleukemia.org" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Hairy Cell Leukemia Foundation</a> was created when the Hairy Cell Leukemia Consortium and the Hairy Cell Leukemia Research Foundation joined. The HCLF is dedicated to improving outcomes for patients and advancing research into HCL.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_98abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[54]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Three immunotoxin drugs have been studied in patients at the <span class="inline text-[1em] leading-7">NIH</span> <span class="inline text-[1em] leading-7">National Cancer Institute</span> in the U.S.: <span class="inline text-[1em] leading-7">BL22</span>, <sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_h8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[55]</sup> <span class="inline text-[1em] leading-7">HA22</span><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_n8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[56]</sup> and LMB-2.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_r8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[57]</sup> All of these protein-based drugs combine part of an anti-B cell antibody with a bacterial toxin to kill the cells on internalization. BL22 and HA22 attack a common protein called CD22, which is present on hairy cells and healthy B cells. LMB-2 attacks a protein called CD25, which is not present in HCL-variant, so LMB-2 is only useful for patients with classic HCL. HA-22, renamed moxetumomab pasudotox (Lumoxiti), was approved by the FDA in 2018 for relapsed or refractory HCL but discontinued in the US market in 2023.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_v8qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[58]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">Clinical trials, such as NCT00412594 and NCT00923013,<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59abav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[59]</sup> have demonstrated that cladribine followed by rituximab effectively eliminates <span class="inline text-[1em] leading-7">minimal residual disease</span> (MRD) in many patients after initial treatment with cladribine or pentostatin, leading to durable remissions with high complete response rates (up to 100%) and low relapse rates. It is not currently known if such MRD eradication always results in more durable remissions compared to cladribine alone.</span>
<span class="mb-4 block break-words text-[1em] leading-7">In 2020, the HCLF and the Leukemia &amp; Lymphoma Society launched HCL2025, a $10 million, 5-year initiative to accelerate the development of new therapies, including targeted agents for BRAF V600E-mutated HCL and strategies for relapsed or variant disease. In 2024, the HCL2030 program was initiated with $5-7 million to focus on MRD monitoring, HCL variants, and improving outcomes in refractory cases.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_59qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[60]</sup><sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_79qbav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[61]</sup></span>
<span class="mb-4 block break-words text-[1em] leading-7">The major remaining research questions include the underlying etiology of HCL beyond the BRAF V600E mutation and mechanisms preventing normal maturation of hairy cells.<sup class="text-fg-secondary ml-[2px] cursor-pointer text-xs hover:underline" type="button" aria-haspopup="dialog" aria-expanded="false" aria-controls="radix-_R_5aabav9fiumdb_" data-state="closed" tabindex="-1" style="outline:none">[62]</sup></span></article><div id="references" class="min-w-0 scroll-mt-8 overflow-hidden"><div class="text-[16px]"><h2 id="references" node="[object Object]" class="mb-2 mt-7 scroll-mt-24 font-serif text-[1.714286em] font-semibold border-border-l1 pb-1 border-b overflow-hidden">References</h2></div><ol class="columns-1 gap-x-12 [counter-reset:item] md:columns-2"><li id="1" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://medlineplus.gov/ency/article/000592.htm" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Hairy cell leukemia: MedlinePlus Medical Encyclopedia&quot;</a>. <em>medlineplus.gov</em>. Retrieved 2018-04-17.</span></div></li><li id="2" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Falini, Brunangelo; Tiacci, Enrico (10 October 2024). &quot;Hairy-Cell Leukemia&quot;. <em>New England Journal of Medicine</em>. <strong>391</strong> (14): 1328â€“1341. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1056%2FNEJMra2406376" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1056/NEJMra2406376</a>.</span></div></li><li id="3" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Schrek R, Donnelly WJ (February 1966). <a href="https://doi.org/10.1182%2Fblood.V27.2.199.199" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;&quot;Hairy&quot; cells in blood in lymphoreticular neoplastic disease and &quot;flagellated&quot; cells of normal lymph nodes&quot;</a>. <em>Blood</em>. <strong>27</strong> (2): 199â€“211. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood.V27.2.199.199" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood.V27.2.199.199</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/5322749" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">5322749</a>.</span></div></li><li id="4" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20191115201407/https://rarediseases.info.nih.gov/diseases/6560/hairy-cell-leukemia" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Hairy cell leukemia | Genetic and Rare Diseases Information Center (GARD) â€“ an NCATS Program&quot;</a>. <em>rarediseases.info.nih.gov</em>. Archived from <a href="https://rarediseases.info.nih.gov/diseases/6560/hairy-cell-leukemia" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on 2019-11-15. Retrieved 2018-04-17.</span></div></li><li id="5" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cancer.gov/types/leukemia/hp/hairy-cell-treatment-pdq" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Hairy Cell Leukemia Treatment&quot;</a>. <span class="inline text-[1em] leading-7">National Cancer Institute</span>. <a href="https://web.archive.org/web/20080514175103/http://www.cancer.gov/cancerinfo/pdq/treatment/hairy-cell-leukemia/patient/#Keypoint3#Keypoint3" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Archived</a> from the original on 2008-05-14. Retrieved 2007-09-07.</span></div></li><li id="6" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Zuzel M, Cawley JC, Paton RC, Burns GF, McNicol GP (1979). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1145815" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Platelet function in hairy-cell leukaemia&quot;</a>. <em>J. Clin. Pathol</em>. <strong>32</strong> (8): 814â€“21. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1136%2Fjcp.32.8.814" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1136/jcp.32.8.814</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1145815" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1145815</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/512041" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">512041</a>.</span></div></li><li id="7" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Pandolfino J, Hakimian D, Rademaker AW, Tallman MS (July 1997). <a href="https://doi.org/10.1002%2F%28SICI%291096-8652%28199707%2955%3A3%3C129%3A%3AAID-AJH2%3E3.0.CO%3B2-U" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Hypocholesterolemia in hairy cell leukemia: a marker for proliferative activity&quot;</a>. <em>Am. J. Hematol</em>. <strong>55</strong> (3): 129â€“33. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2F%28SICI%291096-8652%28199707%2955%3A3%3C129%3A%3AAID-AJH2%3E3.0.CO%3B2-U" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/(SICI)1096-8652(199707)55:3&lt;129::AID-AJH2&gt;3.0.CO;2-U</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/9256291" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">9256291</a>.</span></div></li><li id="8" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Juliusson G, Vitols S, Liliemark J (July 1995). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2550084" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Mechanisms behind hypocholesterolaemia in hairy cell leukaemia&quot;</a>. <em>BMJ</em>. <strong>311</strong> (6996): 27. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1136%2Fbmj.311.6996.27" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1136/bmj.311.6996.27</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2550084" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2550084</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/7613319" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7613319</a>.</span></div></li><li id="9" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Clavel J, Mandereau L, Cordier S, Le Goaster C, HÃ©mon D, Conso F, Flandrin G (1995). &quot;Hairy cell leukaemia, occupation, and smoking&quot;. <em>Br. J. Haematol</em>. <strong>91</strong> (1): 154â€“61. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2Fj.1365-2141.1995.tb05261.x" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/j.1365-2141.1995.tb05261.x</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/7577624" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7577624</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:6423475" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6423475</a>.</span></div></li><li id="16" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Clavel, J; HÃ©mon, D; Mandereau, L; Delemotte, B; SÃ©verin, F; Flandrin, G (August 1996). <a href="https://doi.org/10.5271%2Fsjweh.143" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Farming, pesticide use and hairy-cell leukemia&quot;</a>. <em>Scandinavian Journal of Work, Environment &amp; Health</em>. <strong>22</strong> (4): 285â€“293. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.5271%2Fsjweh.143" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.5271/sjweh.143</a>.</span></div></li><li id="11" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, FoÃ  R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (2011). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;<em>BRAF</em> Mutations in Hairy-Cell Leukemia&quot;</a>. <em>N Engl J Med</em>. <strong>364</strong> (24): 2305â€“2315. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1056%2FNEJMoa1014209" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1056/NEJMoa1014209</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3689585</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21663470" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21663470</a>.</span></div></li><li id="12" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides (Seventh Biennial Update) (2009). <a href="http://www.nap.edu/catalog.php?record_id=12662" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300"><em>Veterans and Agent Orange: Update 2008</em></a>. Institute of Medicine. pp. 349â€“350. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.17226%2F12662" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.17226/12662</a>. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-309-13884-0. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/25032343" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">25032343</a>.</span></div></li><li id="13" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Feuer G, Green PL (September 2005). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659530" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2&quot;</a>. <em>Oncogene</em>. <strong>24</strong> (39): 5996â€“6004. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fsj.onc.1208971" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/sj.onc.1208971</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659530" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2659530</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16155606" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16155606</a>.</span></div></li><li id="14" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Rosenblatt JD, Giorgi JV, Golde DW, Ezra JB, Wu A, Winberg CD, Glaspy J, Wachsman W, Chen IS (February 1988). <a href="http://www.bloodjournal.org/cgi/pmidlookup?view=long&amp;pmid=2827811" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Integrated human T-cell leukemia virus II genome in CD8 + T cells from a patient with &quot;atypical&quot; hairy cell leukemia: evidence for distinct T and B cell lymphoproliferative disorders&quot;</a>. <em>Blood</em>. <strong>71</strong> (2): 363â€“9. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood.V71.2.363.363" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood.V71.2.363.363</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/2827811" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2827811</a>.</span></div></li><li id="15" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Roucoux DF, Murphy EL (2004). &quot;The epidemiology and disease outcomes of human T-lymphotropic virus type II&quot;. <em>AIDS Rev</em>. <strong>6</strong> (3): 144â€“54. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15595431" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15595431</a>.</span></div></li><li id="17" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><span class="inline text-[1em] leading-7">Wintrobe, Maxwell Myer</span> (2004). <em>Wintrobe&#x27;s clinical hematology</em>. John G. Greer; John Foerster, John N. Lukens, George M Rodgers, Frixos Paraskevas (11 ed.). Hagerstown, MD: Lippincott Williams &amp; Wilkins. pp. 2465â€“2466. <span class="inline text-[1em] leading-7">ISBN</span> 978-0-7817-3650-3.</span></div></li><li id="18" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Wanko, Sam O.; de Castro, Carlos (July 2006). <a href="https://doi.org/10.1634%2Ftheoncologist.11-7-780" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Hairy Cell Leukemia: An Elusive but Treatable Disease&quot;</a>. <em>The Oncologist</em>. <strong>11</strong> (7): 780â€“789. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1634%2Ftheoncologist.11-7-780" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1634/theoncologist.11-7-780</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16880237" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16880237</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:27158568" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">27158568</a>.</span></div></li><li id="19" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, FoÃ  R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (June 2011). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;BRAF mutations in hairy-cell leukemia&quot;</a>. <em>N. Engl. J. Med</em>. <strong>364</strong> (24): 2305â€“15. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1056%2FNEJMoa1014209" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1056/NEJMoa1014209</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3689585</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/21663470" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">21663470</a>.</span></div></li><li id="20" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Vanhentenrijk V, De Wolf-Peeters C, Wlodarska I (2004). <a href="https://doi.org/10.1182%2Fblood-2004-01-0181" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Comparative expressed sequence hybridization studies of hairy cell leukemia show uniform expression profile and imprint of spleen signature&quot;</a>. <em>Blood</em>. <strong>104</strong> (1): 250â€“5. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood-2004-01-0181" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood-2004-01-0181</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15016649" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15016649</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:13939073" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">13939073</a>.</span></div></li><li id="21" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20071009024824/http://www.flowcases.org/casebuilder/index.cfm?fuseaction=displayCase2&amp;caseID=54" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Clinical Flow Cytometry Case #54&quot;</a>. Archived from <a href="http://www.flowcases.org/casebuilder/index.cfm?fuseaction=displayCase2&amp;caseID=54" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on 2007-10-09. Retrieved 2007-09-07.</span></div></li><li id="22" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Cannon T, Mobarek D, Wegge J, Tabbara IA (October 2008). &quot;Hairy cell leukemia: current concepts&quot;. <em>Cancer Invest</em>. <strong>26</strong> (8): 860â€“5. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1080%2F07357900801965034" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1080/07357900801965034</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/18798068" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">18798068</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:6196898" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6196898</a>.</span></div></li><li id="23" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><em><a href="http://www.emedicine.com/med/topic937.htm#section~Differentials" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Hairy Cell Leukemia~Differentials</a></em> at <span class="inline text-[1em] leading-7">eMedicine</span></span></div></li><li id="24" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Cessna, Melissa H.; Hartung, Leah; Tripp, Sheryl; Perkins, Sherrie L.; Bahler, David W. (January 2005). <a href="https://doi.org/10.1309%2F8QYTYQ1CLQMHQ9CL" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Hairy Cell Leukemia Variant: Fact or Fiction&quot;</a>. <em>American Journal of Clinical Pathology</em>. <strong>123</strong> (1): 132â€“138. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1309%2F8QYTYQ1CLQMHQ9CL" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1309/8QYTYQ1CLQMHQ9CL</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15762289" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15762289</a>.</span></div></li><li id="25" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Sainati L, Matutes E, Mulligan S, de Oliveira MP, Rani S, Lampert IA, Catovsky D (July 1990). <a href="https://ashpublications.org/blood/article/76/1/157/167900/A-variant-form-of-hairy-cell-leukemia-resistant-to" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;A variant form of hairy cell leukemia resistant to <em>alpha</em> -interferon: clinical and phenotypic characteristics of 17 patients&quot;</a>. <em>Blood</em>. <strong>76</strong> (1): 157â€“62. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood.V76.1.157.157" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood.V76.1.157.157</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/2364167" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2364167</a>.</span></div></li><li id="26" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Cawley JC, Burns GF, Hayhoe FG (1980). &quot;A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia&quot;. <em>Leukemia Research</em>. <strong>4</strong> (6): 547â€“59. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2F0145-2126%2880%2990066-1" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/0145-2126(80)90066-1</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/7206776" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">7206776</a>.</span></div></li><li id="27" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D (2001). <a href="https://doi.org/10.1038%2Fsj.leu.2401999" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The natural history and clinico-pathological features of the variant form of hairy cell leukemia&quot;</a>. <em>Leukemia</em>. <strong>15</strong> (1): 184â€“6. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1038%2Fsj.leu.2401999" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1038/sj.leu.2401999</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/11243388" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">11243388</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:6609635" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6609635</a>.</span></div></li><li id="28" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ya-In, Charin; Brandwein, Joseph; Pantalony, Dominic; Chang, Hong (1 March 2005). &quot;Hairy Cell Leukemia Variant With Features of Intrasinusoidal Bone Marrow Involvement&quot;. <em>Archives of Pathology &amp; Laboratory Medicine</em>. <strong>129</strong> (3): 395â€“398. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.5858%2F2005-129-395-HCLVWF" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.5858/2005-129-395-HCLVWF</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/15737038" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">15737038</a>.</span></div></li><li id="29" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Kreitman, Robert J.; Wilson, Wyndham; Calvo, Katherine R.; Arons, Evgeny; Roth, Laura; Sapolsky, Jeffrey; Zhou, Hong; Raffeld, Mark; Stetler-Stevenson, Maryalice (15 December 2013). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867590" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia&quot;</a>. <em>Clinical Cancer Research</em>. <strong>19</strong> (24): 6873â€“6881. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1158%2F1078-0432.CCR-13-1752" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1158/1078-0432.CCR-13-1752</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867590" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3867590</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/24277451" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">24277451</a>.</span></div></li><li id="30" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://web.archive.org/web/20160601185030/https://www.hairycellleukemia.org/about-hcl/hcl-v/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;HCL-V&quot;</a>. <em>Hairy Cell Leukemia Foundation</em>. Archived from <a href="https://www.hairycellleukemia.org/about-hcl/hcl-v/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on 2016-06-01. Retrieved 2016-05-31.</span></div></li><li id="31" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Burthem J, Cawley JC (January 1994). <a href="https://ashpublications.org/blood/article/83/2/497/170837/The-bone-marrow-fibrosis-of-hairy-cell-leukemia-is" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells&quot;</a>. <em>Blood</em>. <strong>83</strong> (2): 497â€“504. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood.V83.2.497.497" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood.V83.2.497.497</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/8286747" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8286747</a>.</span></div></li><li id="32" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">de Totero D, Tazzari PL, Lauria F, Raspadori D, di Celle PF, Carbone A, Gobbi M, Foa R (July 1993). <a href="https://ashpublications.org/blood/article/82/2/528/170402/Phenotypic-analysis-of-hairy-cell-leukemia-variant" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Phenotypic analysis of hairy cell leukemia: &quot;variant&quot; cases express the interleukin-2 receptor <em>beta</em> chain, but not the <em>alpha</em> chain (CD25)&quot;</a>. <em>Blood</em>. <strong>82</strong> (2): 528â€“35. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood.V82.2.528.528" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood.V82.2.528.528</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/8329708" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8329708</a>.</span></div></li><li id="33" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Matutes E, Wotherspoon A, Catovsky D (2003). &quot;The variant form of hairy-cell leukaemia&quot;. <em>Best Practice &amp; Research Clinical Haematology</em>. <strong>16</strong> (1): 41â€“56. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2FS1521-6926%2802%2900086-5" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/S1521-6926(02)00086-5</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/12670464" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12670464</a>.</span></div></li><li id="34" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Vallianatou K, Brito-Babapulle V, Matutes E, Atkinson S, Catovsky D (1999). &quot;p53 gene deletion and trisomy 12 in hairy cell leukemia and its variant&quot;. <em>Leukemia Research</em>. <strong>23</strong> (11): 1041â€“5. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2FS0145-2126%2899%2900127-7" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/S0145-2126(99)00127-7</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/10576509" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10576509</a>.</span></div></li><li id="35" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Arons, Evgeny; Suntum, Tara; Stetler-Stevenson, Maryalice; Kreitman, Robert J. (19 November 2009). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780305" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy&quot;</a>. <em>Blood</em>. <strong>114</strong> (21): 4687â€“4695. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood-2009-01-201731" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood-2009-01-201731</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780305" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">2780305</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/19745070" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">19745070</a>.</span></div></li><li id="36" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Robak T, Jamroziak K, Gora-Tybor J, Blonski JZ, Kasznicki M, Dwilewicz-Trojaczek J, Wiater E, Zdunczyk A, Dybowicz J, Dmoszynska A, Wojtaszko M, Zdziarska B, Calbecka M, Kostyra A, Hellmann A, Lewandowski K, Stella-Holowiecka B, Sulek K, Gawronski K, Skotnicki AB, Nowak W, Zawilska K, Molendowicz-Portala L, Kloczko J, Sokolowski J, Warzocha K, Seferynska I, Ceglarek B, Konopka L (2007). <a href="https://doi.org/10.1182%2Fblood-2006-08-042929" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial&quot;</a>. <em>Blood</em>. <strong>109</strong> (9): 3672â€“5. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood-2006-08-042929" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood-2006-08-042929</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/17209059" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">17209059</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:9279754" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">9279754</a>.</span></div></li><li id="37" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D (2005). <a href="https://doi.org/10.1002%2Fcncr.21447" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years&quot;</a>. <em>Cancer</em>. <strong>104</strong> (11): 2442â€“8. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Fcncr.21447" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/cncr.21447</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16245328" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16245328</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:43282431" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">43282431</a>.</span></div></li><li id="38" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Saven, Alan; Piro, LD (15 August 1993). &quot;Complete Remissions in Hairy Cell Leukemia with 2-Chlorodeoxyadenosine after Failure with 2-Deoxycoformycin&quot;. <em>Annals of Internal Medicine</em>. <strong>119</strong> (4): 278â€“283. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.7326%2F0003-4819-119-4-199308150-00005" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.7326/0003-4819-119-4-199308150-00005</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/8101069" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8101069</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:34812778" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">34812778</a>.</span></div></li><li id="39" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Thomas, Deborah A.; O&#x27;Brien, Susan; Bueso-Ramos, Carlos; Faderl, Stefan; Keating, Michael J.; Giles, Francis J.; Cortes, Jorge; Kantarjian, Hagop M. (1 December 2003). <a href="https://doi.org/10.1182%2Fblood-2003-02-0630" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Rituximab in relapsed or refractory hairy cell leukemia&quot;</a>. <em>Blood</em>. <strong>102</strong> (12): 3906â€“3911. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood-2003-02-0630" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood-2003-02-0630</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/12816862" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12816862</a>.</span></div></li><li id="40" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Nieva, Jorge; Bethel, Kelly; Saven, Alan (1 August 2003). &quot;Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia&quot;. <em>Blood</em>. <strong>102</strong> (3): 810â€“813. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood-2003-01-0014" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood-2003-01-0014</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/12663446" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">12663446</a>.</span></div></li><li id="41" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Narat S, Gandla J, Dogan A, Mehta A (August 2005). &quot;Successful treatment of hairy cell leukemia variant with rituximab&quot;. <em>Leuk. Lymphoma</em>. <strong>46</strong> (8): 1229â€“32. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1080%2F10428190500083433" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1080/10428190500083433</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16085567" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16085567</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:20116705" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">20116705</a>.</span></div></li><li id="42" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Karmacharya, Paras; Poudel, Dilli Ram; Pathak, Ranjan; Donato, Anthony A.; Ghimire, Sushil; Giri, Smith; Aryal, Madan Raj; Bingham, Clifton O. (December 2015). &quot;Rituximab-induced serum sickness: A systematic review&quot;. <em>Seminars in Arthritis and Rheumatism</em>. <strong>45</strong> (3): 334â€“340. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1016%2Fj.semarthrit.2015.06.014" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1016/j.semarthrit.2015.06.014</a>.</span></div></li><li id="https://www.cancer.gov/types/leukemia/hp/hairy-cell-treatment-pdq" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.cancer.gov/types/leukemia/hp/hairy-cell-treatment-pdq" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.cancer.gov/types/leukemia/hp/hairy-cell-treatment-pdq</a></span></div></li><li id="43" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><em><a href="http://www.emedicine.com/med/topic937.htm#section~medication" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Hairy Cell Leukemia~medication</a></em> at <span class="inline text-[1em] leading-7">eMedicine</span></span></div></li><li id="44" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU (January 1984). &quot;Alpha interferon for induction of remission in hairy-cell leukemia&quot;. <em>N. Engl. J. Med</em>. <strong>310</strong> (1): 15â€“8. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1056%2FNEJM198401053100104" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1056/NEJM198401053100104</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/6689734" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">6689734</a>.</span></div></li><li id="45" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Assanto, Giovanni M.; Riemma, Costantino; Malaspina, Francesco; Perrone, Salvatore; De Luca, Maria L.; Pucciarini, Alessandra; Annechini, Giorgia; D&#x27;Elia, Gianna M.; Martelli, Maurizio; FoÃ , Robin; Tiacci, Enrico; Pulsoni, Alessandro (July 2021). <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360059" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The current role of interferon in hairy cell leukaemia: clinical and molecular aspects&quot;</a>. <em>British Journal of Haematology</em>. <strong>194</strong> (1): 78â€“82. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1111%2Fbjh.17440" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1111/bjh.17440</a>. <span class="inline text-[1em] leading-7">ISSN</span> <a href="https://search.worldcat.org/issn/1365-2141" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">1365-2141</a>. <span class="inline text-[1em] leading-7">PMC</span> <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360059" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8360059</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/33932027" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">33932027</a>.</span></div></li><li id="46" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K (1985). <a href="https://doi.org/10.1182%2Fblood.V65.3.644.644" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Treatment of hairy cell leukemia with recombinant alpha 2 interferon&quot;</a>. <em>Blood</em>. <strong>65</strong> (3): 644â€“8. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood.V65.3.644.644" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood.V65.3.644.644</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/3971043" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">3971043</a>.</span></div></li><li id="49" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D (December 2005). <a href="https://doi.org/10.1002%2Fcncr.21447" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years&quot;</a>. <em>Cancer</em>. <strong>104</strong> (11): 2442â€“8. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Fcncr.21447" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/cncr.21447</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/16245328" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">16245328</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:43282431" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">43282431</a>.</span></div></li><li id="50" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C, Rigacci L, Gherlinzoni F, Cantaffa R, Baraldi A, Gallamini A, Zaccaria A, Pulsoni A, Gobbi M, Tassi M, Raspadori D, Leoncini L, Rinaldi A, Sabattini E, Bertoni F, Pileri SA, Lauria F (November 2009). <a href="http://bloodjournal.hematologylibrary.org/cgi/content/full/114/21/4696" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single agent cladribine and with more aggressive behavior&quot;</a>. <em>Blood</em>. <strong>114</strong> (21): 4696â€“4702. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood-2009-03-212449" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood-2009-03-212449</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/19667403" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">19667403</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:90241" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">90241</a>.</span></div></li><li id="51" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Brown, Richard T. (August 2002). <a href="https://web.archive.org/web/20120224123933/http://www.euclidmanagers.com/downloads/legrev/rblegrev/RTBaugust.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Hairy Cell Leukemia&quot;</a> (PDF). <em>Brokerage Bulletin</em>. <strong>7</strong> (5): 3. Archived from <a href="http://www.euclidmanagers.com/downloads/legrev/rblegrev/RTBaugust.pdf" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> (PDF) on 2012-02-24. Retrieved 2018-11-29.</span></div></li><li id="54" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM (August 1998). <a href="http://www.bloodjournal.org/cgi/pmidlookup?view=long&amp;pmid=9694703" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Second malignancies in patients with hairy cell leukemia in British columbia: a 20-year experience&quot;</a>. <em>Blood</em>. <strong>92</strong> (4): 1160â€“4. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1182%2Fblood.V92.4.1160" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1182/blood.V92.4.1160</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/9694703" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">9694703</a>.</span></div></li><li id="https://emedicine.medscape.com/article/200580-overview" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://emedicine.medscape.com/article/200580-overview" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://emedicine.medscape.com/article/200580-overview</a></span></div></li><li id="55" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Gramatovici M, Bennett JM, Hiscock JG, Grewal KS (April 1993). &quot;Three cases of familial hairy cell leukemia&quot;. <em>Am. J. Hematol</em>. <strong>42</strong> (4): 337â€“9. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1002%2Fajh.2830420402" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1002/ajh.2830420402</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/8493982" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">8493982</a>. <span class="inline text-[1em] leading-7">S2CID</span> <a href="https://api.semanticscholar.org/CorpusID:34449485" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">34449485</a>.</span></div></li><li id="56" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Holzman D (March 2009). <a href="https://doi.org/10.1093%2Fjnci%2Fdjp051" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Has success spoiled hairy cell leukemia research? Key questions go unanswered, despite big gains&quot;</a>. <em>J. Natl. Cancer Inst</em>. <strong>101</strong> (6): 370â€“3. <span class="inline text-[1em] leading-7">doi</span>:<a href="https://doi.org/10.1093%2Fjnci%2Fdjp051" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">10.1093/jnci/djp051</a>. <span class="inline text-[1em] leading-7">PMID</span> <a href="https://pubmed.ncbi.nlm.nih.gov/19276454" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">19276454</a>.</span></div></li><li id="57" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="http://www.hairycellleukemia.org/" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;| Hairy Cell Leukemia Foundation&quot;</a>. Hairycellleukemia.org. 2014-06-20. Retrieved 2015-12-24.</span></div></li><li id="58" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Clinical trial number <em><a href="https://www.clinicaltrials.gov/show/NCT00074048" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">NCT00074048</a></em> for &quot;BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia&quot; at <span class="inline text-[1em] leading-7">ClinicalTrials.gov</span></span></div></li><li id="59" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Clinical trial number <em><a href="https://www.clinicaltrials.gov/show/NCT00462189" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">NCT00462189</a></em> for &quot;Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease&quot; at <span class="inline text-[1em] leading-7">ClinicalTrials.gov</span></span></div></li><li id="60" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Clinical trial number <em><a href="https://www.clinicaltrials.gov/show/NCT00337311" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">NCT00337311</a></em> for &quot;LMB-2 to Treat Hairy Cell Leukemia&quot; at <span class="inline text-[1em] leading-7">ClinicalTrials.gov</span></span></div></li><li id="61" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://clinicaltrials.gov/ct2/show/NCT01829711?term=Hairy+cell+leukemia&amp;rank=14" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia - Full Text View&quot;</a>. ClinicalTrials.gov. Retrieved 2015-12-24.</span></div></li><li id="62" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">For example, trial <a href="https://clinicaltrials.gov/show/NCT00412594" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">NCT00412594</a> and <a href="https://clinicaltrials.gov/show/NCT00923013" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">NCT00923013</a></span></div></li><li id="https://www.hairycellleukemia.org/hcl2025" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.hairycellleukemia.org/hcl2025" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.hairycellleukemia.org/hcl2025</a></span></div></li><li id="https://www.hairycellleukemia.org/hcl2030" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7"><a href="https://www.hairycellleukemia.org/hcl2030" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">https://www.hairycellleukemia.org/hcl2030</a></span></div></li><li id="63" class="mb-2 grid break-inside-avoid grid-cols-[auto_1fr] gap-2 text-sm leading-relaxed [counter-increment:item] before:font-semibold before:content-[counter(item)&#x27;.&#x27;]"><div class="relative -top-[3px] overflow-hidden break-words text-[16px] [&amp;_*]:mb-0"><span class="mb-4 block break-words text-[1em] leading-7">Cawley, John. <a href="https://web.archive.org/web/20110726135436/http://www.hairycell.org/content/researchers/unanswered-questions/biology-disease-including-unanswered-questions" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">&quot;The Biology of the Disease Including Unanswered Questions | HairyCell.org&quot;</a>. Archived from <a href="http://www.hairycell.org/content/researchers/unanswered-questions/biology-disease-including-unanswered-questions" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">the original</a> on 2011-07-26. Retrieved 2010-06-23.</span></div></li></ol></div><div class="text-fg-secondary text-xs [&amp;_*]:mb-2"><hr class="border-border-l1 my-8 rounded-sm border-t"/>
<span class="mb-4 block break-words text-[1em] leading-7">The content is adapted from <a href="https://en.wikipedia.org/wiki/Hairy_cell_leukemia" target="_blank" rel="noopener noreferrer" class="break-all text-[1em] text-blue-500 hover:underline dark:text-blue-300">Wikipedia</a>, licensed under Creative Commons Attribution-ShareAlike 4.0 License.</span></div></div></div><div class="hidden min-[1400px]:block"></div></div></div><!--$--><!--/$--><div role="region" aria-label="Notifications (F8)" tabindex="-1" style="pointer-events:none"><ol tabindex="-1" class="pointer-events-none fixed top-0 z-[100] flex max-h-screen w-full flex-col-reverse p-4 max-sm:left-0 sm:bottom-0 sm:right-0 sm:top-auto sm:max-w-[420px] sm:flex-col pl-16 pr-2 pt-16 sm:px-4"></ol></div><script type="application/json" id="server-client-data-experimentation">{"status":"uninitialized"}</script><script src="/_next/static/chunks/webpack-e121ed42680f327e.js" nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl" id="_R_" async=""></script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">(self.__next_f=self.__next_f||[]).push([0])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"1:\"$Sreact.fragment\"\n3:I[91363,[],\"\"]\n4:I[23775,[],\"\"]\n5:I[57654,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"PageHeaderProvider\"]\n6:I[17618,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"3699\",\"static/chunks/app/page/%5Bslug%5D/layout-55a344716dd57c44.js\"],\"HeaderContent\"]\n7:I[25529,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"6751\",\"static/chunks/app/page/%5Bslug%5D/not-found-69a3edc7db5749d6.js\"],\"default\"]\n9:I[6666,[],\"OutletBoundary\"]\nb:I[80415,[],\"AsyncMetadataOutlet\"]\nd:I[6666,[],\"ViewportBoundary\"]\nf:I[6666,[],\"MetadataBoundary\"]\n10:\"$Sreact.suspense\"\n12:I[95909,[\"4219\",\"static/chunks/app/global-error-4d07d20223cd4b4c.js\"],\"default\"]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"13:I[51498,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"ConstantsProvider\"]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"14:I[91073,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"15:I[38642,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"16:I[99648,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"17:I[78825,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"18:I[8550,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MixpanelProvider\"]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"19:I[12290,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"MobileTocProvider\"]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"1a:I[53947,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"NuqsAdapter\"]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"1b:I[91873,[\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8039\",\"static/chunks/app/error-4a29e9399afba038.js\"],\"default\"]\n1c:I[5091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"7618\",\"static/chunks/7618-43536a8fb0dd3bfe.js\",\"4345\",\"static/chunks/app/not-found-dd95690acf732f18.js\"],\"default\"]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"1d:I[16091,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"927\",\"static/chunks/927-34e2a6da3e15e26b.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"2660\",\"static/chunks/2660-d983a7f287e89f18.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"3655\",\"static/chunks/3655-6717081f7512305a.js\",\"8945\",\"static/chunks/8945-e4e3cf487f5e27c7.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"2225\",\"static/chunks/2225-454cf9f44775e7ce.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"7177\",\"static/chunks/app/layout-226f2bd71acf9f9e.js\"],\"default\"]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,":HL[\"/_next/static/media/1f2316909698f815.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/3d4419af2cf8609b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/4dec29efcaeb336c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/74452ea3ef0f9101.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/904ef0a86fe32a00.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/d886a03bcda7ad8f.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/e1447589d6f59c4b.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/media/f5a90156f8995c8c.p.woff2\",\"font\",{\"crossOrigin\":\"\",\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\",\"type\":\"font/woff2\"}]\n:HL[\"/_next/static/css/62c4caba71dfda84.css\",\"style\",{\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\"}]\n:HL[\"/_next/static/css/eb3d87f98fe1565f.css\",\"style\",{\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\"}]\n:HL[\"/_next/static/css/1b5e561215938d4d.css\",\"style\",{\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\"}]\n:HL[\"/_next/static/css/0227d069a630d414.css\",\"style\",{\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\"}]\n:HL[\"/_next/static/css/f87fff2ab93d05a7.css\",\"style\",{\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\"}]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"0:{\"P\":null,\"b\":\"BpM29AX4fmgcUxZ_6t0le\",\"p\":\"\",\"c\":[\"\",\"page\",\"Hairy_cell_leukemia\"],\"i\":false,\"f\":[[[\"\",{\"children\":[\"page\",{\"children\":[[\"slug\",\"Hairy_cell_leukemia\",\"d\"],{\"children\":[\"__PAGE__\",{}]}]}]},\"$undefined\",\"$undefined\",true],[\"\",[\"$\",\"$1\",\"c\",{\"children\":[[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/62c4caba71dfda84.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\"}],[\"$\",\"link\",\"1\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/eb3d87f98fe1565f.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\"}],[\"$\",\"link\",\"2\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/1b5e561215938d4d.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\"}],[\"$\",\"link\",\"3\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/0227d069a630d414.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\"}]],\"$L2\"]}],{\"children\":[\"page\",[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":\"$undefined\",\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}],{\"children\":[[\"slug\",\"Hairy_cell_leukemia\",\"d\"],[\"$\",\"$1\",\"c\",{\"children\":[null,[\"$\",\"$L5\",null,{\"children\":[[\"$\",\"$L6\",null,{\"maxWidth\":\"full\",\"mobileOptions\":{\"right\":{\"showFixedIssues\":true,\"showThemeSwitcher\":true,\"showSearch\":true,\"showTableOfContents\":true}}}],[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$undefined\",\"errorStyles\":\"$undefined\",\"errorScripts\":\"$undefined\",\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L7\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}]]}]]}],{\"children\":[\"__PAGE__\",[\"$\",\"$1\",\"c\",{\"children\":[\"$L8\",[[\"$\",\"link\",\"0\",{\"rel\":\"stylesheet\",\"href\":\"/_next/static/css/f87fff2ab93d05a7.css\",\"precedence\":\"next\",\"crossOrigin\":\"$undefined\",\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\"}]],[\"$\",\"$L9\",null,{\"children\":[\"$La\",[\"$\",\"$Lb\",null,{\"promise\":\"$@c\"}]]}]]}],{},null,false]},null,false]},null,false]},null,false],[\"$\",\"$1\",\"h\",{\"children\":[null,[[\"$\",\"$Ld\",null,{\"children\":\"$Le\"}],[\"$\",\"meta\",null,{\"name\":\"next-size-adjust\",\"content\":\"\"}]],[\"$\",\"$Lf\",null,{\"children\":[\"$\",\"div\",null,{\"hidden\":true,\"children\":[\"$\",\"$10\",null,{\"fallback\":null,\"children\":\"$L11\"}]}]}]]}],false]],\"m\":\"$undefined\",\"G\":[\"$12\",[]],\"s\":false,\"S\":false}\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"2:[\"$\",\"html\",null,{\"lang\":\"en\",\"className\":\"bg-surface-base antialiased\",\"suppressHydrationWarning\":true,\"children\":[[\"$\",\"head\",null,{\"children\":[[\"$\",\"title\",null,{\"children\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"type\":\"image/x-icon\",\"href\":\"/favicon.ico\",\"sizes\":\"48x48\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-dark.png\",\"media\":\"(prefers-color-scheme: light)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"icon\",\"href\":\"/images/icon-light.png\",\"media\":\"(prefers-color-scheme: dark)\",\"type\":\"image/png\"}],[\"$\",\"link\",null,{\"rel\":\"apple-touch-icon\",\"href\":\"/icon-192x192.png\"}],[\"$\",\"link\",null,{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\"}],[\"$\",\"meta\",null,{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",null,{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"meta\",null,{\"property\":\"og:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"property\":\"og:url\",\"content\":\"https://grokipedia.com\"}],[\"$\",\"meta\",null,{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"property\":\"og:locale\",\"content\":\"en_US\"}],[\"$\",\"meta\",null,{\"property\":\"og:type\",\"content\":\"website\"}],[\"$\",\"meta\",null,{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",null,{\"property\":\"og:image:alt\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:title\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:description\",\"content\":\"Grokipedia is an open source, comprehensive collection of all knowledge.\"}],[\"$\",\"meta\",null,{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}]]}],[\"$\",\"body\",null,{\"className\":\"flex h-[100svh] w-full flex-col __variable_13c637 __variable_8a0ba0 __variable_779740 __variable_2484fd __variable_525cc3 __variable_13486b\",\"children\":[[\"$\",\"$L13\",null,{\"children\":[\"$\",\"$L14\",null,{\"children\":[\"$\",\"$L15\",null,{\"defaultTheme\":\"dark\",\"nonce\":\"NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl\",\"children\":[\"$\",\"$L16\",null,{\"children\":[\"$\",\"$L17\",null,{\"children\":[\"$\",\"$L18\",null,{\"children\":[\"$\",\"$L19\",null,{\"children\":[\"$\",\"$L1a\",null,{\"children\":[[\"$\",\"$L3\",null,{\"parallelRouterKey\":\"children\",\"error\":\"$1b\",\"errorStyles\":[],\"errorScripts\":[],\"template\":[\"$\",\"$L4\",null,{}],\"templateStyles\":\"$undefined\",\"templateScripts\":\"$undefined\",\"notFound\":[[\"$\",\"$L1c\",null,{}],[]],\"forbidden\":\"$undefined\",\"unauthorized\":\"$undefined\"}],[\"$\",\"$L1d\",null,{}]]}]}]}]}]}]}]}]}],[\"$\",\"script\",null,{\"type\":\"application/json\",\"id\":\"server-client-data-experimentation\",\"children\":\"{\\\"status\\\":\\\"uninitialized\\\"}\"}]]}]]}]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"e:[[\"$\",\"meta\",\"0\",{\"charSet\":\"utf-8\"}],[\"$\",\"meta\",\"1\",{\"name\":\"viewport\",\"content\":\"width=device-width, initial-scale=1, interactive-widget=resizes-content\"}]]\na:null\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"1e:I[42712,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"HydrationBoundary\"]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"21:I[6367,[],\"IconMark\"]\n1f:T6cf3,"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"# Hairy cell leukemia\n\n| **Attribute** | **Details** |\n|---------------|-------------|\n| [Specialty](Medical_specialty \"Medical specialty\") | [Hematology](Hematology \"Hematology\") and [oncology](Oncology \"Oncology\") |\n\nHairy cell leukemia is an uncommon [hematological malignancy](Hematological_malignancy \"Hematological malignancy\") characterized by an accumulation of abnormal [B lymphocytes](B_lymphocyte \"B lymphocyte\").[1] The incidence of hairy cell leukemia (HCL) is 0.28-0.30 cases per 100,000 people in Europe and the United States and the prevalence is approximately 3.12 cases per 100,000 in Europe with a lower prevalence in Asia, Africa and the Middle East.[2]\n\nHCL has an indolent course but patients frequently relapse. Despite this, with treatment, life expectancy is usually the same as that for the general population.[2]\n\nHCL was originally described as histiocytic leukemia, malignant reticulosis, or lymphoid myelofibrosis in publications dating back to the 1920s. The disease was formally named leukemic reticuloendotheliosis, and its characterization was significantly advanced by [Bertha Bouroncle](Bertha_Bouroncle \"Bertha Bouroncle\") and colleagues at the [Ohio State University College of Medicine](Ohio_State_University_College_of_Medicine \"Ohio State University College of Medicine\") in 1958. Its common name, which was coined in 1966,[3] is derived from the \"hairy\" appearance of the cytoplasmic projections from malignant B cells under a microscope.[4]\n## Signs and symptoms\n\nIn HCL, the \"hairy cells\" (malignant B lymphocytes) accumulate in the bone marrow, interfering with the production of normal white blood cells, red blood cells, and platelets. Consequently, patients may develop infections related to low white blood cell count, anemia and fatigue due to a lack of red blood cells, or easy bleeding due to a low platelet count.[5]\n\nSplenomegaly is present in 70-100% of patients and may cause abdominal fullness, discomfort, or pain below the ribs.[5]\n\nPlatelet function may be somewhat impaired in HCL patients, although this does not appear to have any significant practical effect.[6]\n\nPatients with a high tumor burden may also have somewhat reduced levels of cholesterol,[7] especially in patients with an enlarged spleen.[8]\n\nThose with HCL rarely have constitutional symptoms such as fevers, chills, weight loss or rigors. 20-30% may have opportunistic infections due to an impairment in immune function. Rarely, in recurrent disease, bone lesions may be present which can be confused for other malignancies such as multiple myeloma.[2]\n## Cause\n\nAs with many cancers, the cause of HCL is unknown. Recent studies suggest possible associations with certain environmental exposures. Tobacco smoking appears to have a protective effect.[9] Ionizing radiation, farming, exposure to pesticides, petroleum derivatives, and diesel exhaust are suspected risk factors, though causation is not established.[9][16]\n\nA 2011 study identified somatic _BRAF_ V600E mutations in all 47 HCL patients studied, and no such mutations in the 193 peripheral B-cell lymphomas/leukemias other than HCL.[11] This mutation is now confirmed in nearly all (90-100%) classic HCL cases and is considered a key driver.[11]\n\nThe U.S. Institute of Medicine (IOM) found a correlation which permits an association between exposure to herbicides and later development of chronic B-cell leukemias and lymphomas in general. The IOM report emphasizes that neither animal nor human studies indicate an association of herbicides with HCL specifically. However, the IOM extrapolated data from chronic lymphocytic leukemia and non-Hodgkin lymphoma to conclude that HCL and other rare B-cell neoplasms may share this risk factor.[12] Based on this, the U.S. Department of Veterans Affairs recognizes chronic B-cell leukemias, including HCL, as presumptive conditions for veterans exposed to Agent Orange.\n\nHuman T-lymphotropic virus 2 (HTLV-2) has been isolated in a small number of patients with the variant form of HCL.[13] In the 1980s, HTLV-2 was identified in a patient with a T-cell lymphoproliferative disease; this patient later developed HCL, but HTLV-2 was not found in the hairy cell clones.[14] There is no evidence that HTLV-2 causes any sort of hematological malignancy, including HCL.[15]\n\nIn a small population-based study, there was an increased incidence of HCL in those who used or handled pesticides.[16]\n## Pathophysiology\n\n[Pancytopenia](Pancytopenia \"Pancytopenia\") in HCL is caused primarily by marrow failure and [splenomegaly](Splenomegaly \"Splenomegaly\"). Bone-marrow failure is caused by the accumulation of hairy cells and reticulin [fibrosis](Fibrosis \"Fibrosis\") in the bone marrow, as well as by the detrimental effects of dysregulated cytokine production.[17] Splenomegaly reduces blood counts through sequestration, marginalization, and destruction of healthy blood cells inside the spleen.[17]\n\nHairy cells are nearly mature [B cells](B_cell \"B cell\"), which are activated clonal cells with signs of _[VH](Organization_and_expression_of_immunoglobulin_genes \"Organization and expression of immunoglobulin genes\")_ gene differentiation.[18] They may be related to pre-plasma [marginal zone](Marginal_zone \"Marginal zone\") B cells[17] or [memory B cells](Memory_B_cell \"Memory B cell\").[18]\n\n[Cytokine](Cytokine \"Cytokine\") production is disturbed in HCL. Hairy cells produce and thrive on [TNF-alpha](TNF-alpha \"TNF-alpha\").[17] This cytokine also suppresses normal production of healthy blood cells in the bone marrow.[17]\n\nUnlike healthy B cells, hairy cells express and secrete an immune system protein called [interleukin-2 receptor](Interleukin-2_receptor \"Interleukin-2 receptor\") (IL-2R).[17] In HCL-V, only part of this receptor is expressed.[17] As a result, disease status can be monitored by measuring changes in the amount of IL-2R in the blood serum.[17]\n\nHairy cells respond to normal production of some cytokines by [T cells](T_cell \"T cell\") with increased growth. Treatment with interferon-alpha suppresses the production of this pro-growth cytokine from T cells.[17] A low level of T cells, which is commonly seen after treatment with [cladribine](Cladribine \"Cladribine\") or [pentostatin](Pentostatin \"Pentostatin\"), and the consequent reduction of these cytokines, is also associated with reduced levels of hairy cells. \n\nNearly all cases of HCL have the [_BRAF_](BRAF_\\(gene\\) \"BRAF \\(gene\\)\") mutation V600E, which drives the disease through constitutive activation of the MAPK/ERK signaling pathway, promoting survival and accumulation of the neoplastic cells in the bone marrow and spleen.[19][2] The BRAF V600E mutation leads to resistance to apoptosis and enhanced responsiveness to microenvironmental stimuli. Prior to the identification of BRAF mutations, only a few genomic imbalances had been reported in hairy cells, such as trisomy 5.[17] Subsequent genomic studies have identified recurrent copy number alterations, including deletions of 7q and 13q and gains of 5q.[2] The [expression of genes](Gene_expression \"Gene expression\") is also dysregulated in a complex and specific pattern. The cells underexpress 3p24, 3p21, 3q13.3-q22, 4p16, 11q23, 14q22-q24, 15q21-q22, 15q24-q25, and 17q22-q24 and overexpress 13q31 and Xq13.3-q21.[20] It has not yet been demonstrated that any of these changes have any practical significance to the patient.\n# Diagnosis\n\nThe diagnosis of HCL may be suggested by abnormal results on a [complete blood count](Complete_blood_count \"Complete blood count\") (CBC), but additional testing is necessary to confirm the diagnosis. A CBC normally shows low counts for white blood cells, red blood cells, and platelets in HCL patients, with monocytopenia (absolute monocyte count \u0026lt; 0.1 Ã— 10^9/L) present in almost all cases. However, if large numbers of hairy cells are in the blood stream, then normal or even [high lymphocyte counts](Lymphocytosis \"Lymphocytosis\") may be found. \n\nOn physical examination, 80â€“90% of patients have an [enlarged spleen](Splenomegaly \"Splenomegaly\"), which can be massive.[17] This is less likely among patients who are diagnosed at an early stage. Peripheral [lymphadenopathy](Lymphadenopathy \"Lymphadenopathy\") (enlarged lymph nodes) is uncommon (less than 5% of patients), but abdominal lymphadenopathy is a relatively common finding on [computed tomography](Computed_tomography \"Computed tomography\") scans.[17]\n\nThe most important laboratory finding is the presence of hairy cells in the bloodstream.[17] Hairy cells are abnormal white blood cells with hair-like projections of [cytoplasm](Cytoplasm \"Cytoplasm\"); they can be seen by examining a [blood smear](Blood_smear \"Blood smear\") or [bone marrow biopsy](Bone_marrow_biopsy \"Bone marrow biopsy\") specimen. The blood film examination is done by [staining](Staining \"Staining\") the blood cells with [Wright's stain](Wright's_stain \"Wright's stain\") and looking at them under a [microscope](Microscope \"Microscope\"). Hairy cells are visible in this test in about 85% of cases.[17] Along with the characteristic surface projections, hairy cells also have large amounts of cytoplasm, an oval (sometimes cleaved) nuclei with homogenous chromatin and without distinct nucleoli giving the cells a \"fried egg\" appearance.[2]\n\nMost patients require a bone-marrow biopsy for final diagnosis. The bone marrow biopsy is used both to confirm the presence of HCL and also the absence of any additional diseases, such as [Splenic marginal zone lymphoma](Splenic_marginal_zone_lymphoma \"Splenic marginal zone lymphoma\") or [B-cell prolymphocytic leukemia](B-cell_prolymphocytic_leukemia \"B-cell prolymphocytic leukemia\"). The bone marrow in HCL may show a diffuse infiltration of leukemic cells or an interstitial infiltration with partial preservation of fat and hematopoietic stem cells.[2] The diagnosis can be confirmed by viewing the cells with a special stain known as [tartrate resistant acid phosphatase](Tartrate_resistant_acid_phosphatase \"Tartrate resistant acid phosphatase\") (TRAP). While TRAP and DBA.44 are useful, immunohistochemistry for BRAF V600E and annexin A1 provides more accurate results. \n\nDefinitively diagnosing HCL is also possible through [flow cytometry](Flow_cytometry \"Flow cytometry\") on blood or bone marrow. The hairy cells are larger than normal and positive for [CD19](CD19 \"CD19\"), [CD20](CD20 \"CD20\"), [CD22](CD22 \"CD22\"), [CD11c](CD11c \"CD11c\"), [CD25](CD25 \"CD25\"), [CD103](CD103 \"CD103\"), [CD123](CD123 \"CD123\"), and [FMC7](FMC7 \"FMC7\") antigens.[21] ([CD103](CD103 \"CD103\"), [CD22](CD22 \"CD22\"), and [CD11c](CD11c \"CD11c\") are strongly expressed.)[22]\n\n[Annexin A1](Annexin_A1 \"Annexin A1\") and the BRAF v600E mutant protein are the most sensitive and specific cell markers associated with HCL. Diseases mimicking HCL are usually negative for both markers.[2]\n\nHairy cell leukemia-variant (HCL-V), which shares some characteristics with B cell prolymphocytic leukemia (B-PLL), does not show CD25 (also called the interleukin-2 receptor, alpha). \n\nThe differential diagnoses include several kinds of anemia, including [myelophthisis](Myelophthisis \"Myelophthisis\") and [aplastic anemia](Aplastic_anemia \"Aplastic anemia\"),[23] and most kinds of blood neoplasms, including hypoplastic [myelodysplastic syndrome](Myelodysplastic_syndrome \"Myelodysplastic syndrome\"), atypical chronic lymphocytic leukemia, [B-cell prolymphocytic leukemia](B-cell_prolymphocytic_leukemia \"B-cell prolymphocytic leukemia\"), or idiopathic [myelofibrosis](Myelofibrosis \"Myelofibrosis\").[18]\n\n## Classification\n\nThe \"classic\" form is often implied, but hairy cell leukemia-variant has also been described.[24]\n\n### HCL-V\n\nHairy cell leukemia-variant (HCL-V) is usually described as a prolymphocytic variant of HCL.[25] It was first described in 1980.[26] About 10-20% of people with HCL have this variant form of the disease, representing approximately 100-260 new cases of HCL-V each year in the U.S. While classic HCL primarily affects men, HCL-V is more evenly divided between males and females.[27] While the disease can appear at any age, the median age at diagnosis is over 70.[28]\n\nSimilar to [B-cell prolymphocytic leukemia](B-cell_prolymphocytic_leukemia \"B-cell prolymphocytic leukemia\") (B-PLL) in [chronic lymphocytic leukemia](Chronic_lymphocytic_leukemia \"Chronic lymphocytic leukemia\"), HCL-V is a more aggressive disease. Historically, it has been considered less likely to be treated successfully than is classic HCL, and remissions have tended to be shorter. The introduction of combination therapy with concurrent rituximab and cladribine therapy, though, has shown excellent results in early follow-up.[29] As of 2016, this therapy is considered the first-line treatment of choice for many people with HCL-V.[30]\n\nMany older treatment approaches, such as interferon-alpha, the combination chemotherapy regimen \"CHOP\", and common alkylating agents such as [cyclophosphamide](Cyclophosphamide \"Cyclophosphamide\"), showed very little benefit.[27] Pentostatin and cladribine administered as monotherapy (without concurrent rituximab) provide some benefit to many people with HCL-V, but typically induce shorter remission periods and lower response rates than when they are used in classic HCL. More than half of people respond partially to splenectomy.[27]\n\nHCL-V differs from classic HCL principally in these respects: \n\n* Higher [white blood cell](White_blood_cell \"White blood cell\") counts, sometimes exceeding 100,000 cells per microliter\n* A more aggressive course of disease requiring more frequent treatment\n* Hairy cells with an unusually large [nucleolus](Nucleolus \"Nucleolus\") for their size\n* Production of little excess [fibronectin](Fibronectin \"Fibronectin\") produced by classic hairy cells[31] to interfere with bone marrow biopsies\n* Low or no cell-surface expression of CD25 (interleukin-2 [IL-2] receptor alpha chain, or p55).[32]\n\nLow levels of CD25, a part of the receptor for a key immunoregulating hormone, may explain why HCL-V cases are generally much more resistant to treatment by immune-system hormones.[25]\n\nHCL-V, which usually features a high proportion of hairy cells without a functional _[p53](P53 \"P53\")_ [tumor suppressor gene](Tumor_suppressor_gene \"Tumor suppressor gene\"), is somewhat more likely to transform into a higher-grade malignancy. A typical transformation rate of 5-6% has been postulated in the UK, similar to the [Richter's transformation](Richter's_transformation \"Richter's transformation\") rate for [splenic lymphoma with villous lymphocytes](Splenic_lymphoma_with_villous_lymphocytes \"Splenic lymphoma with villous lymphocytes\") (SLVL) and CLL.[27][33] Among HCL-V patients, the most aggressive cases normally have the least amount of p53 gene activity.[34] Hairy cells without the _p53_ gene tend, over time, to displace the less aggressive p53(+) hairy cells. \n\nSome evidence suggests that a rearrangement of the immunoglobulin gene _VH4-34_ , which is found in about 40% of HCL-V patients and 10% of classic HCL patients, may be a more important poor prognostic factor than variant status, with HCL-V patients without the VH4-34 rearrangement responding about as well as classic HCL patients.[35]\n# Treatment\n\nSeveral treatments are available, and successful control of the disease is common. \n\n- Not everyone requires treatment immediately. Due to the indolent nature of HCL, a \"[watchful waiting](Watchful_waiting \"Watchful waiting\")\" approach may be done for those without significant cytopenia (low hemoglobin, [absolute neutrophil count](Absolute_neutrophil_count \"Absolute neutrophil count\"), and platelet count), symptomatic organomegaly, recurrent infections or constitutional symptoms. This watchful waiting approach is used in about 10-20% of people.[2]\n\n### First-line therapy\n\n[Purine analogs](Purine_analog \"Purine analog\") such as [cladribine](Cladribine \"Cladribine\") and [pentostatin](Pentostatin \"Pentostatin\") are the first-line therapies for HCL. Purine analogs are very effective in the treatment of HCL, achieving remission rates of 80-90%; with remission being defined as normal or near normal blood counts, no palpable splenomegaly and no hairy cells on bone marrow biopsy or peripheral blood without immunostaining, or minimal hairy cells with immunostaining (known as measurable residual disease).[2] The benefits of treating measurable residual disease are not well established.[2] The median relapse free time for purine analogs is greater than 10 years.[2] The possible side effects of purine analogs include rash, fever, neutropenia, infections and a low T-cell counts (especially CD4+ T-cells).[2] Purine analogs may cause immunosuppression over time and should not be used if the patients have an active infection.[2]\n\n[Rituximab](Rituximab \"Rituximab\"), the anti-CD20 monoclonal antibody, may be added to purine analogs during initial treatment and is associated with increasing the remission rate to nearly 100%.[2] Purine analogs may be restarted in those with relapsed disease, with or without rituximab.[2]\n\nCladribine can be administered by injection under the skin, by infusion over a few hours into a vein (intravenous - IV), or by a pump worn by the patient that provides a slow drip into a vein throughout the day. Most patients receive cladribine by IV infusion once a day for five to seven days, but more patients are being given the option of taking this drug once a week for six weeks. The different dosing schedules used with cladribine are roughly equally effective and safe.[36] Relatively few patients have significant side effects other than fatigue and a high fever caused by the cancer cells dying, although complications such as infection and acute kidney failure have been seen. Pentostatin is chemically similar to cladribine, and has a similar success rate and side effect profile, but it is always given over a much longer period of time, usually one dose by IV infusion every two weeks for 3â€“6 months. \n\nDuring the weeks following treatment, the patients' immune systems are severely weakened, but their bone marrow will begin to produce normal blood cells again. Treatment often results in long-term remission. If the cancer cells return, the treatment may be repeated and should again result in remission, although the treatment response may decline with repeated treatment.[37]\n\n[Cladribine](Cladribine \"Cladribine\") induced complete responses in patients with hairy cell leukemia resistant to pentostatin, suggesting a lack of cross-resistance..[38]\n\n### Second-line therapy\n\nIf a patient is resistant to either cladribine or pentostatin, or in those with relapsed disease, then second-line therapy is pursued. \n\n- BRAF inhibitors such as [vemurafenib](Vemurafenib \"Vemurafenib\") or [dabrafenib](Dabrafenib \"Dabrafenib\") inhibit the [MAPK/ERK pathway](MAPK/ERK_pathway \"MAPK/ERK pathway\") which is constitutively active in those with a BRAF V600E kinase activating mutation (which is 95% of those with HCL). Constitutively active MAPK kinase activity is what leads to disease activity in HCL by increasing cell survival, increasing proliferation and reducing apoptosis of the leukemic cells.[2] BRAF inhibitors have an overall response rate of greater than 90% with a complete response of 30-35% in people with relapsed or refractory HCL.[2] They are also known to have less toxic effects than the purine analogs.[2] They may be combined with rituximab to increase the remission rate. The median duration of response with BRAF inhibitors is 1.5 years (more than 3 years if combined with rituximab), after which remission occurs. BRAF inhibitors with or without rituximab may be restarted if there is relapsed disease.[2]\n- Ritixumab: Two partial and 10 complete responses resulted from 15 patients with relapsed disease, for a total of 80% responding.[39] The median response time is greater than 3 years.[40] Rituximab has successfully induced a complete response in Hairy Cell-Variant.[41]\n\nRituximab may cause a [serum sickness](Serum_sickness \"Serum sickness\") reaction which presents with fevers, joint pain and rash approximately 4-10 days after any infusion. The reaction is successfully treated with steroids.[42]\n\n- BTK inhibitors such as ibrutinib may be used for relapsed or refractory HCL, with an overall response rate of 54% and 36-month progression-free survival of 73% as of 2025.[](https://www.cancer.gov/types/leukemia/hp/hairy-cell-treatment-pdq)\n- If progression of disease or relapse is seen in those previously on BRAF inhibitors plus rituximab, the combination can be retried. Or a BRAF inhibitor can be restarted plus MEK inhibitors [trametinib](Trametinib \"Trametinib\") or [cobimetinib](Cobimetinib \"Cobimetinib\").[2]\n- Interferon-alpha is an immune system hormone that is very helpful to a relatively small number of patients, and somewhat helpful to most patients. Standard interferon alfa is no longer available as production has been halted; pegylated interferon (e.g., ropeginterferon alfa-2b-njft) may be substituted but is not FDA-approved for HCL. In about 65% of patients,[43] the drug helps stabilize the disease or produce a slow, minor improvement for a partial response.[44] Some patients can achieve the negativization of minimal residual disease by BRAF-V600E status [45]\n\nSome patients tolerate IFN-alpha very well after the first few weeks, while others find that its characteristic [flu-like symptoms](Flu-like_symptoms \"Flu-like symptoms\") persist. About 10% of patients develop a level of [depression](Depression_\\(mood\\) \"Depression \\(mood\\)\"). \n\nA drop in blood counts is usually seen during the first 1â€“2 months of treatment. Most patients find that their blood counts get worse for a few weeks immediately after starting treatment, although some patients find their blood counts begin to improve within just 2 weeks.[46]\n\nTypically, 6 months are needed to figure out whether this therapy is useful. Common criteria for treatment success include: \n\n- Normalization of hemoglobin levels (above 12.0 g/dL),\n- A normal or somewhat low platelet count (above 100 K/Î¼L), and\n- A normal or somewhat low absolute neutrophil count (above 1.5 K/Î¼L).[46]\n\nPegylated interferon-alpha may be considered for pregnant women with active HCL, or splenectomy/watchful waiting as alternatives.[2]\n## Prognosis\n\n### Treatment success\n\nFirst-line therapy with cladribine or pentostatin achieves overall response rates exceeding 95% in classic hairy cell leukemia (HCL), with complete response (CR) rates of 76-85%.[49] Combining cladribine with rituximab yields CR in nearly 100% of patients.[2] A majority of patients can expect relapse-free survival of about 10 years or longer after a single course, though relapses occur and retreatment remains effective, albeit with potentially shorter remissions. Risks include shingles and peripheral neuropathy with cladribine.\n\nAs in B-cell chronic lymphocytic leukemia, mutated IGHV in hairy cells is associated with better initial treatment responses and prolonged survival, whereas unmutated IGHV (particularly IGHV4-34) and TP53 mutations predict poorer outcomes.[50]\n\nRecovery to normal function post-treatment varies based on disease stage at diagnosis, baseline health, response completeness, side effects encountered, disease aggressiveness, and pre-treatment functioning.\n\n### Lifespan\n\nIn classic HCL, appropriate treatment results in a near-normal lifespan.[2] The highest mortality risk occurs in the first two years post-diagnosis; 5-year survival exceeds 95%, predicting good disease control.[7] After five years of remission with normal blood counts, U.S. patients may qualify for private life insurance.[51]\n\nFor hairy cell leukemia variant (HCL-V), prognosis is poorer due to median diagnosis age of ~70 years, with 5-year overall survival of 60-75% and median survival around 8 years; younger patients fare better but outcomes remain inferior to classic HCL.[24]\n\n### Follow-up care\n\nHCL is generally considered incurable, with relapses possible even after decades, necessitating lifelong monitoring.[2] However, undetectable minimal residual disease (uMRD) after chemoimmunotherapy like cladribine plus rituximab (94% uMRD-free at 8 years) or vemurafenib plus obinutuzumab (96% uMRD) suggests potential curability in some classic HCL cases.[2]\n\nRemission requires annual physician visits and biannual blood counts for life. Prompt reporting of infections or health changes is essential. HCL patients face elevated second cancer risk (observed-to-expected ratio 1.0-2.6 overall, 5.3 for hematologic), peaking ~2 years post-diagnosis and declining thereafter; lifetime risk remains below 50%.[54]\n\nThere is also increased autoimmune disease risk, including polyarteritis nodosa, which may remit with HCL treatment.[17]\n## Epidemiology\n\nHCL is more common in men, with a male to female ratio of 4:1, and the median age at diagnosis is 55â€“60 years.[2] It is extremely rare in children.[2] HCL is more common among people of White or Caucasian ethnicity and less frequent in those of Asian, African, or Middle Eastern descent.[](https://emedicine.medscape.com/article/200580-overview)\n\nIt does not appear to be hereditary, although rare familial cases that suggest a predisposition have been reported,[55] usually showing a common human leukocyte antigen (HLA) type.[17]\n## Research directions\n\nThe Hairy Cell Leukemia Consortium was founded in 2008 to address researchers' concerns about the long-term future of research on the disease.[56]\n\nThe [Hairy Cell Leukemia Foundation](https://www.hairycellleukemia.org) was created when the Hairy Cell Leukemia Consortium and the Hairy Cell Leukemia Research Foundation joined. The HCLF is dedicated to improving outcomes for patients and advancing research into HCL.[57]\n\nThree immunotoxin drugs have been studied in patients at the [NIH](https://en.wikipedia.org/wiki/National_Institutes_of_Health) [National Cancer Institute](https://en.wikipedia.org/wiki/National_Cancer_Institute) in the U.S.: [BL22](https://en.wikipedia.org/wiki/BL22), [58] [HA22](https://en.wikipedia.org/wiki/HA22)[59] and LMB-2.[60] All of these protein-based drugs combine part of an anti-B cell antibody with a bacterial toxin to kill the cells on internalization. BL22 and HA22 attack a common protein called CD22, which is present on hairy cells and healthy B cells. LMB-2 attacks a protein called CD25, which is not present in HCL-variant, so LMB-2 is only useful for patients with classic HCL. HA-22, renamed moxetumomab pasudotox (Lumoxiti), was approved by the FDA in 2018 for relapsed or refractory HCL but discontinued in the US market in 2023.[61]\n\nClinical trials, such as NCT00412594 and NCT00923013,[62] have demonstrated that cladribine followed by rituximab effectively eliminates [minimal residual disease](https://en.wikipedia.org/wiki/Minimal_residual_disease) (MRD) in many patients after initial treatment with cladribine or pentostatin, leading to durable remissions with high complete response rates (up to 100%) and low relapse rates. It is not currently known if such MRD eradication always results in more durable remissions compared to cladribine alone.\n\nIn 2020, the HCLF and the Leukemia \u0026 Lymphoma Society launched HCL2025, a $10 million, 5-year initiative to accelerate the development of new therapies, including targeted agents for BRAF V600E-mutated HCL and strategies for relapsed or variant disease. In 2024, the HCL2030 program was initiated with $5-7 million to focus on MRD monitoring, HCL variants, and improving outcomes in refractory cases.[](https://www.hairycellleukemia.org/hcl2025)[](https://www.hairycellleukemia.org/hcl2030)\n\nThe major remaining research questions include the underlying etiology of HCL beyond the BRAF V600E mutation and mechanisms preventing normal maturation of hairy cells.[63]"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"8:[\"$\",\"$L1e\",null,{\"state\":{\"mutations\":[],\"queries\":[{\"dehydratedAt\":1761883442327,\"state\":{\"data\":{\"page\":{\"citations\":[{\"id\":\"1\",\"title\":\"** [\\\"Hairy cell leukemia: MedlinePlus Medical Encyclopedia\\\"](https://medlineplus.gov/ency/article/000592.htm). _medlineplus.gov_. Retrieved 2018-04-17.\",\"description\":\"1. **^** [\\\"Hairy cell leukemia: MedlinePlus Medical Encyclopedia\\\"](https://medlineplus.gov/ency/article/000592.htm). _medlineplus.gov_. Retrieved 2018-04-17.\",\"url\":\"https://medlineplus.gov/ency/article/000592.htm\",\"favicon\":\"\"},{\"id\":\"2\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ _**r**_ _**s**_ _**t**_ _**u**_ _**v**_ _**w**_ _**x**_ _**y**_ _**z**_ Falini, Brunangelo; Tiacci, Enrico (10 October 2024). \\\"Hairy-Cell Leukemia\\\". _New England Journal of Medicine_. **391** (14): 1328â€“1341\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMra2406376](https://doi.org/10.1056%2FNEJMra2406376).\",\"description\":\"2. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ _**r**_ _**s**_ _**t**_ _**u**_ _**v**_ _**w**_ _**x**_ _**y**_ _**z**_ Falini, Brunangelo; Tiacci, Enrico (10 October 2024). \\\"Hairy-Cell Leukemia\\\". _New England Journal of Medicine_. **391** (14): 1328â€“1341\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMra2406376](https://doi.org/10.1056%2FNEJMra2406376).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"3\",\"title\":\"** Schrek R, Donnelly WJ (February 1966). [\\\"\\\"Hairy\\\" cells in blood in lymphoreticular neoplastic disease and \\\"flagellated\\\" cells of normal lymph nodes\\\"](https://doi.org/10.1182%2Fblood.V27.2.199.199). _Blood_. **27** (2): 199â€“211\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V27.2.199.199](https://doi.org/10.1182%2Fblood.V27.2.199.199). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [5322749](https://pubmed.ncbi.nlm.nih.gov/5322749).\",\"description\":\"3. **^** Schrek R, Donnelly WJ (February 1966). [\\\"\\\"Hairy\\\" cells in blood in lymphoreticular neoplastic disease and \\\"flagellated\\\" cells of normal lymph nodes\\\"](https://doi.org/10.1182%2Fblood.V27.2.199.199). _Blood_. **27** (2): 199â€“211\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V27.2.199.199](https://doi.org/10.1182%2Fblood.V27.2.199.199). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [5322749](https://pubmed.ncbi.nlm.nih.gov/5322749).\",\"url\":\"https://doi.org/10.1182%2Fblood.V27.2.199.199\",\"favicon\":\"\"},{\"id\":\"4\",\"title\":\"** [\\\"Hairy cell leukemia | Genetic and Rare Diseases Information Center (GARD) â€“ an NCATS Program\\\"](https://web.archive.org/web/20191115201407/https://rarediseases.info.nih.gov/diseases/6560/hairy-cell-leukemia). _rarediseases.info.nih.gov_. Archived from [the original](https://rarediseases.info.nih.gov/diseases/6560/hairy-cell-leukemia) on 2019-11-15. Retrieved 2018-04-17.\",\"description\":\"4. **^** [\\\"Hairy cell leukemia | Genetic and Rare Diseases Information Center (GARD) â€“ an NCATS Program\\\"](https://web.archive.org/web/20191115201407/https://rarediseases.info.nih.gov/diseases/6560/hairy-cell-leukemia). _rarediseases.info.nih.gov_. Archived from [the original](https://rarediseases.info.nih.gov/diseases/6560/hairy-cell-leukemia) on 2019-11-15. Retrieved 2018-04-17.\",\"url\":\"https://web.archive.org/web/20191115201407/https://rarediseases.info.nih.gov/diseases/6560/hairy-cell-leukemia\",\"favicon\":\"\"},{\"id\":\"5\",\"title\":\"** [\\\"Hairy Cell Leukemia Treatment\\\"](https://www.cancer.gov/types/leukemia/hp/hairy-cell-treatment-pdq). [National Cancer Institute](National_Cancer_Institute \\\"National Cancer Institute\\\"). [Archived](https://web.archive.org/web/20080514175103/http://www.cancer.gov/cancerinfo/pdq/treatment/hairy-cell-leukemia/patient/#Keypoint3#Keypoint3) from the original on 2008-05-14. Retrieved 2007-09-07.\",\"description\":\"5. **^** [\\\"Hairy Cell Leukemia Treatment\\\"](https://www.cancer.gov/types/leukemia/hp/hairy-cell-treatment-pdq). [National Cancer Institute](National_Cancer_Institute \\\"National Cancer Institute\\\"). [Archived](https://web.archive.org/web/20080514175103/http://www.cancer.gov/cancerinfo/pdq/treatment/hairy-cell-leukemia/patient/#Keypoint3#Keypoint3) from the original on 2008-05-14. Retrieved 2007-09-07.\",\"url\":\"https://www.cancer.gov/types/leukemia/hp/hairy-cell-treatment-pdq\",\"favicon\":\"\"},{\"id\":\"6\",\"title\":\"** Zuzel M, Cawley JC, Paton RC, Burns GF, McNicol GP (1979). [\\\"Platelet function in hairy-cell leukaemia\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1145815). _J. Clin. Pathol_. **32** (8): 814â€“21\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1136/jcp.32.8.814](https://doi.org/10.1136%2Fjcp.32.8.814). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [1145815](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1145815). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [512041](https://pubmed.ncbi.nlm.nih.gov/512041).\",\"description\":\"6. **^** Zuzel M, Cawley JC, Paton RC, Burns GF, McNicol GP (1979). [\\\"Platelet function in hairy-cell leukaemia\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1145815). _J. Clin. Pathol_. **32** (8): 814â€“21\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1136/jcp.32.8.814](https://doi.org/10.1136%2Fjcp.32.8.814). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [1145815](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1145815). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [512041](https://pubmed.ncbi.nlm.nih.gov/512041).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1145815\",\"favicon\":\"\"},{\"id\":\"7\",\"title\":\"** Pandolfino J, Hakimian D, Rademaker AW, Tallman MS (July 1997). [\\\"Hypocholesterolemia in hairy cell leukemia: a marker for proliferative activity\\\"](https://doi.org/10.1002%2F%28SICI%291096-8652%28199707%2955%3A3%3C129%3A%3AAID-AJH2%3E3.0.CO%3B2-U). _Am. J. Hematol_. **55** (3): 129â€“33\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/(SICI)1096-8652(199707)55:3\u003c129::AID-AJH2\u003e3.0.CO;2-U](https://doi.org/10.1002%2F%28SICI%291096-8652%28199707%2955%3A3%3C129%3A%3AAID-AJH2%3E3.0.CO%3B2-U). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9256291](https://pubmed.ncbi.nlm.nih.gov/9256291).\",\"description\":\"7. **^** Pandolfino J, Hakimian D, Rademaker AW, Tallman MS (July 1997). [\\\"Hypocholesterolemia in hairy cell leukemia: a marker for proliferative activity\\\"](https://doi.org/10.1002%2F%28SICI%291096-8652%28199707%2955%3A3%3C129%3A%3AAID-AJH2%3E3.0.CO%3B2-U). _Am. J. Hematol_. **55** (3): 129â€“33\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/(SICI)1096-8652(199707)55:3\u003c129::AID-AJH2\u003e3.0.CO;2-U](https://doi.org/10.1002%2F%28SICI%291096-8652%28199707%2955%3A3%3C129%3A%3AAID-AJH2%3E3.0.CO%3B2-U). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9256291](https://pubmed.ncbi.nlm.nih.gov/9256291).\",\"url\":\"https://doi.org/10.1002%2F%28SICI%291096-8652%28199707%2955%3A3%3C129%3A%3AAID-AJH2%3E3.0.CO%3B2-U\",\"favicon\":\"\"},{\"id\":\"8\",\"title\":\"** Juliusson G, Vitols S, Liliemark J (July 1995). [\\\"Mechanisms behind hypocholesterolaemia in hairy cell leukaemia\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2550084). _BMJ_. **311** (6996): 27. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1136/bmj.311.6996.27](https://doi.org/10.1136%2Fbmj.311.6996.27). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2550084](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2550084). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7613319](https://pubmed.ncbi.nlm.nih.gov/7613319).\",\"description\":\"8. **^** Juliusson G, Vitols S, Liliemark J (July 1995). [\\\"Mechanisms behind hypocholesterolaemia in hairy cell leukaemia\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2550084). _BMJ_. **311** (6996): 27. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1136/bmj.311.6996.27](https://doi.org/10.1136%2Fbmj.311.6996.27). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2550084](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2550084). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7613319](https://pubmed.ncbi.nlm.nih.gov/7613319).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2550084\",\"favicon\":\"\"},{\"id\":\"9\",\"title\":\"** Clavel J, Mandereau L, Cordier S, Le Goaster C, HÃ©mon D, Conso F, Flandrin G (1995). \\\"Hairy cell leukaemia, occupation, and smoking\\\". _Br. J. Haematol_. **91** (1): 154â€“61\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1365-2141.1995.tb05261.x](https://doi.org/10.1111%2Fj.1365-2141.1995.tb05261.x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7577624](https://pubmed.ncbi.nlm.nih.gov/7577624). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6423475](https://api.semanticscholar.org/CorpusID:6423475).\",\"description\":\"9. **^** Clavel J, Mandereau L, Cordier S, Le Goaster C, HÃ©mon D, Conso F, Flandrin G (1995). \\\"Hairy cell leukaemia, occupation, and smoking\\\". _Br. J. Haematol_. **91** (1): 154â€“61\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/j.1365-2141.1995.tb05261.x](https://doi.org/10.1111%2Fj.1365-2141.1995.tb05261.x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7577624](https://pubmed.ncbi.nlm.nih.gov/7577624). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6423475](https://api.semanticscholar.org/CorpusID:6423475).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"10\",\"title\":\"** Orlandi G, Fanucchi S, Strata G, Pataleo L, Landucci Pellegrini L, Prontera C, Martini A, Murri L (2000). [\\\"Transient autonomic nervous system dysfunction during hyperacute stroke\\\"](https://doi.org/10.1034%2Fj.1600-0404.2000.102005317.x). _Acta Neurol. Scand_. **102** (5): 317â€“21\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1034/j.1600-0404.2000.102005317.x](https://doi.org/10.1034%2Fj.1600-0404.2000.102005317.x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11083509](https://pubmed.ncbi.nlm.nih.gov/11083509). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [46685771](https://api.semanticscholar.org/CorpusID:46685771).\",\"description\":\"10. **^** Orlandi G, Fanucchi S, Strata G, Pataleo L, Landucci Pellegrini L, Prontera C, Martini A, Murri L (2000). [\\\"Transient autonomic nervous system dysfunction during hyperacute stroke\\\"](https://doi.org/10.1034%2Fj.1600-0404.2000.102005317.x). _Acta Neurol. Scand_. **102** (5): 317â€“21\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1034/j.1600-0404.2000.102005317.x](https://doi.org/10.1034%2Fj.1600-0404.2000.102005317.x). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11083509](https://pubmed.ncbi.nlm.nih.gov/11083509). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [46685771](https://api.semanticscholar.org/CorpusID:46685771).\",\"url\":\"https://doi.org/10.1034%2Fj.1600-0404.2000.102005317.x\",\"favicon\":\"\"},{\"id\":\"11\",\"title\":\"** Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, FoÃ  R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (2011). [\\\"_BRAF_ Mutations in Hairy-Cell Leukemia\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585). _N Engl J Med_. **364** (24): 2305â€“2315\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMoa1014209](https://doi.org/10.1056%2FNEJMoa1014209). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3689585](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21663470](https://pubmed.ncbi.nlm.nih.gov/21663470).\",\"description\":\"11. **^** Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, FoÃ  R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (2011). [\\\"_BRAF_ Mutations in Hairy-Cell Leukemia\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585). _N Engl J Med_. **364** (24): 2305â€“2315\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMoa1014209](https://doi.org/10.1056%2FNEJMoa1014209). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3689585](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21663470](https://pubmed.ncbi.nlm.nih.gov/21663470).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585\",\"favicon\":\"\"},{\"id\":\"12\",\"title\":\"** Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides (Seventh Biennial Update) (2009). [_Veterans and Agent Orange: Update 2008_](http://www.nap.edu/catalog.php?record_id=12662). Institute of Medicine. pp. 349â€“350\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.17226/12662](https://doi.org/10.17226%2F12662). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-309-13884-0. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25032343](https://pubmed.ncbi.nlm.nih.gov/25032343).\",\"description\":\"12. **^** Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides (Seventh Biennial Update) (2009). [_Veterans and Agent Orange: Update 2008_](http://www.nap.edu/catalog.php?record_id=12662). Institute of Medicine. pp. 349â€“350\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.17226/12662](https://doi.org/10.17226%2F12662). [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-309-13884-0. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [25032343](https://pubmed.ncbi.nlm.nih.gov/25032343).\",\"url\":\"http://www.nap.edu/catalog.php?record_id=12662\",\"favicon\":\"\"},{\"id\":\"13\",\"title\":\"** Feuer G, Green PL (September 2005). [\\\"Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659530). _Oncogene_. **24** (39): 5996â€“6004\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/sj.onc.1208971](https://doi.org/10.1038%2Fsj.onc.1208971). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2659530](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659530). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16155606](https://pubmed.ncbi.nlm.nih.gov/16155606).\",\"description\":\"13. **^** Feuer G, Green PL (September 2005). [\\\"Comparative biology of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659530). _Oncogene_. **24** (39): 5996â€“6004\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/sj.onc.1208971](https://doi.org/10.1038%2Fsj.onc.1208971). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2659530](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659530). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16155606](https://pubmed.ncbi.nlm.nih.gov/16155606).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659530\",\"favicon\":\"\"},{\"id\":\"14\",\"title\":\"** Rosenblatt JD, Giorgi JV, Golde DW, Ezra JB, Wu A, Winberg CD, Glaspy J, Wachsman W, Chen IS (February 1988). [\\\"Integrated human T-cell leukemia virus II genome in CD8 + T cells from a patient with \\\"atypical\\\" hairy cell leukemia: evidence for distinct T and B cell lymphoproliferative disorders\\\"](http://www.bloodjournal.org/cgi/pmidlookup?view=long\u0026pmid=2827811). _Blood_. **71** (2): 363â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V71.2.363.363](https://doi.org/10.1182%2Fblood.V71.2.363.363). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2827811](https://pubmed.ncbi.nlm.nih.gov/2827811).\",\"description\":\"14. **^** Rosenblatt JD, Giorgi JV, Golde DW, Ezra JB, Wu A, Winberg CD, Glaspy J, Wachsman W, Chen IS (February 1988). [\\\"Integrated human T-cell leukemia virus II genome in CD8 + T cells from a patient with \\\"atypical\\\" hairy cell leukemia: evidence for distinct T and B cell lymphoproliferative disorders\\\"](http://www.bloodjournal.org/cgi/pmidlookup?view=long\u0026pmid=2827811). _Blood_. **71** (2): 363â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V71.2.363.363](https://doi.org/10.1182%2Fblood.V71.2.363.363). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2827811](https://pubmed.ncbi.nlm.nih.gov/2827811).\",\"url\":\"http://www.bloodjournal.org/cgi/pmidlookup?view=long\u0026pmid=2827811\",\"favicon\":\"\"},{\"id\":\"15\",\"title\":\"** Roucoux DF, Murphy EL (2004). \\\"The epidemiology and disease outcomes of human T-lymphotropic virus type II\\\". _AIDS Rev_. **6** (3): 144â€“54\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15595431](https://pubmed.ncbi.nlm.nih.gov/15595431).\",\"description\":\"15. **^** Roucoux DF, Murphy EL (2004). \\\"The epidemiology and disease outcomes of human T-lymphotropic virus type II\\\". _AIDS Rev_. **6** (3): 144â€“54\\\\. [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15595431](https://pubmed.ncbi.nlm.nih.gov/15595431).\",\"url\":\"PMID_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"16\",\"title\":\"** Clavel, J; HÃ©mon, D; Mandereau, L; Delemotte, B; SÃ©verin, F; Flandrin, G (August 1996). [\\\"Farming, pesticide use and hairy-cell leukemia\\\"](https://doi.org/10.5271%2Fsjweh.143). _Scandinavian Journal of Work, Environment \u0026 Health_. **22** (4): 285â€“293\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.5271/sjweh.143](https://doi.org/10.5271%2Fsjweh.143).\",\"description\":\"16. **^** Clavel, J; HÃ©mon, D; Mandereau, L; Delemotte, B; SÃ©verin, F; Flandrin, G (August 1996). [\\\"Farming, pesticide use and hairy-cell leukemia\\\"](https://doi.org/10.5271%2Fsjweh.143). _Scandinavian Journal of Work, Environment \u0026 Health_. **22** (4): 285â€“293\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.5271/sjweh.143](https://doi.org/10.5271%2Fsjweh.143).\",\"url\":\"https://doi.org/10.5271%2Fsjweh.143\",\"favicon\":\"\"},{\"id\":\"17\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ [Wintrobe, Maxwell Myer](Maxwell_Wintrobe \\\"Maxwell Wintrobe\\\") (2004). _Wintrobe's clinical hematology_. John G. Greer; John Foerster, John N. Lukens, George M Rodgers, Frixos Paraskevas (11 ed.). Hagerstown, MD: Lippincott Williams \u0026 Wilkins. pp. 2465â€“2466\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-7817-3650-3.\",\"description\":\"17. ^ _**a**_ _**b**_ _**c**_ _**d**_ _**e**_ _**f**_ _**g**_ _**h**_ _**i**_ _**j**_ _**k**_ _**l**_ _**m**_ _**n**_ _**o**_ _**p**_ _**q**_ [Wintrobe, Maxwell Myer](Maxwell_Wintrobe \\\"Maxwell Wintrobe\\\") (2004). _Wintrobe's clinical hematology_. John G. Greer; John Foerster, John N. Lukens, George M Rodgers, Frixos Paraskevas (11 ed.). Hagerstown, MD: Lippincott Williams \u0026 Wilkins. pp. 2465â€“2466\\\\. [ISBN](ISBN_\\\\(identifier\\\\) \\\"ISBN \\\\(identifier\\\\)\\\") 978-0-7817-3650-3.\",\"url\":\"Maxwell_Wintrobe \\\"Maxwell Wintrobe\\\"\",\"favicon\":\"\"},{\"id\":\"18\",\"title\":\"_**a**_ _**b**_ _**c**_ Wanko, Sam O.; de Castro, Carlos (July 2006). [\\\"Hairy Cell Leukemia: An Elusive but Treatable Disease\\\"](https://doi.org/10.1634%2Ftheoncologist.11-7-780). _The Oncologist_. **11** (7): 780â€“789\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1634/theoncologist.11-7-780](https://doi.org/10.1634%2Ftheoncologist.11-7-780). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16880237](https://pubmed.ncbi.nlm.nih.gov/16880237). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [27158568](https://api.semanticscholar.org/CorpusID:27158568).\",\"description\":\"18. ^ _**a**_ _**b**_ _**c**_ Wanko, Sam O.; de Castro, Carlos (July 2006). [\\\"Hairy Cell Leukemia: An Elusive but Treatable Disease\\\"](https://doi.org/10.1634%2Ftheoncologist.11-7-780). _The Oncologist_. **11** (7): 780â€“789\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1634/theoncologist.11-7-780](https://doi.org/10.1634%2Ftheoncologist.11-7-780). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16880237](https://pubmed.ncbi.nlm.nih.gov/16880237). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [27158568](https://api.semanticscholar.org/CorpusID:27158568).\",\"url\":\"https://doi.org/10.1634%2Ftheoncologist.11-7-780\",\"favicon\":\"\"},{\"id\":\"19\",\"title\":\"** Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, FoÃ  R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (June 2011). [\\\"BRAF mutations in hairy-cell leukemia\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585). _N. Engl. J. Med_. **364** (24): 2305â€“15\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMoa1014209](https://doi.org/10.1056%2FNEJMoa1014209). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3689585](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21663470](https://pubmed.ncbi.nlm.nih.gov/21663470).\",\"description\":\"19. **^** Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, FoÃ  R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (June 2011). [\\\"BRAF mutations in hairy-cell leukemia\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585). _N. Engl. J. Med_. **364** (24): 2305â€“15\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJMoa1014209](https://doi.org/10.1056%2FNEJMoa1014209). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3689585](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [21663470](https://pubmed.ncbi.nlm.nih.gov/21663470).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689585\",\"favicon\":\"\"},{\"id\":\"20\",\"title\":\"** Vanhentenrijk V, De Wolf-Peeters C, Wlodarska I (2004). [\\\"Comparative expressed sequence hybridization studies of hairy cell leukemia show uniform expression profile and imprint of spleen signature\\\"](https://doi.org/10.1182%2Fblood-2004-01-0181). _Blood_. **104** (1): 250â€“5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2004-01-0181](https://doi.org/10.1182%2Fblood-2004-01-0181). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15016649](https://pubmed.ncbi.nlm.nih.gov/15016649). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [13939073](https://api.semanticscholar.org/CorpusID:13939073).\",\"description\":\"20. **^** Vanhentenrijk V, De Wolf-Peeters C, Wlodarska I (2004). [\\\"Comparative expressed sequence hybridization studies of hairy cell leukemia show uniform expression profile and imprint of spleen signature\\\"](https://doi.org/10.1182%2Fblood-2004-01-0181). _Blood_. **104** (1): 250â€“5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2004-01-0181](https://doi.org/10.1182%2Fblood-2004-01-0181). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15016649](https://pubmed.ncbi.nlm.nih.gov/15016649). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [13939073](https://api.semanticscholar.org/CorpusID:13939073).\",\"url\":\"https://doi.org/10.1182%2Fblood-2004-01-0181\",\"favicon\":\"\"},{\"id\":\"21\",\"title\":\"** [\\\"Clinical Flow Cytometry Case #54\\\"](https://web.archive.org/web/20071009024824/http://www.flowcases.org/casebuilder/index.cfm?fuseaction=displayCase2\u0026caseID=54). Archived from [the original](http://www.flowcases.org/casebuilder/index.cfm?fuseaction=displayCase2\u0026caseID=54) on 2007-10-09. Retrieved 2007-09-07.\",\"description\":\"21. **^** [\\\"Clinical Flow Cytometry Case #54\\\"](https://web.archive.org/web/20071009024824/http://www.flowcases.org/casebuilder/index.cfm?fuseaction=displayCase2\u0026caseID=54). Archived from [the original](http://www.flowcases.org/casebuilder/index.cfm?fuseaction=displayCase2\u0026caseID=54) on 2007-10-09. Retrieved 2007-09-07.\",\"url\":\"https://web.archive.org/web/20071009024824/http://www.flowcases.org/casebuilder/index.cfm?fuseaction=displayCase2\u0026caseID=54\",\"favicon\":\"\"},{\"id\":\"22\",\"title\":\"** Cannon T, Mobarek D, Wegge J, Tabbara IA (October 2008). \\\"Hairy cell leukemia: current concepts\\\". _Cancer Invest_. **26** (8): 860â€“5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/07357900801965034](https://doi.org/10.1080%2F07357900801965034). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18798068](https://pubmed.ncbi.nlm.nih.gov/18798068). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6196898](https://api.semanticscholar.org/CorpusID:6196898).\",\"description\":\"22. **^** Cannon T, Mobarek D, Wegge J, Tabbara IA (October 2008). \\\"Hairy cell leukemia: current concepts\\\". _Cancer Invest_. **26** (8): 860â€“5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/07357900801965034](https://doi.org/10.1080%2F07357900801965034). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [18798068](https://pubmed.ncbi.nlm.nih.gov/18798068). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6196898](https://api.semanticscholar.org/CorpusID:6196898).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"23\",\"title\":\"** _[Hairy Cell Leukemia~Differentials](http://www.emedicine.com/med/topic937.htm#section~Differentials)_ at [eMedicine](EMedicine \\\"EMedicine\\\")\",\"description\":\"23. **^** _[Hairy Cell Leukemia~Differentials](http://www.emedicine.com/med/topic937.htm#section~Differentials)_ at [eMedicine](EMedicine \\\"EMedicine\\\")\",\"url\":\"http://www.emedicine.com/med/topic937.htm#section~Differentials\",\"favicon\":\"\"},{\"id\":\"24\",\"title\":\"** Cessna, Melissa H.; Hartung, Leah; Tripp, Sheryl; Perkins, Sherrie L.; Bahler, David W. (January 2005). [\\\"Hairy Cell Leukemia Variant: Fact or Fiction\\\"](https://doi.org/10.1309%2F8QYTYQ1CLQMHQ9CL). _American Journal of Clinical Pathology_. **123** (1): 132â€“138\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1309/8QYTYQ1CLQMHQ9CL](https://doi.org/10.1309%2F8QYTYQ1CLQMHQ9CL). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15762289](https://pubmed.ncbi.nlm.nih.gov/15762289).\",\"description\":\"24. **^** Cessna, Melissa H.; Hartung, Leah; Tripp, Sheryl; Perkins, Sherrie L.; Bahler, David W. (January 2005). [\\\"Hairy Cell Leukemia Variant: Fact or Fiction\\\"](https://doi.org/10.1309%2F8QYTYQ1CLQMHQ9CL). _American Journal of Clinical Pathology_. **123** (1): 132â€“138\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1309/8QYTYQ1CLQMHQ9CL](https://doi.org/10.1309%2F8QYTYQ1CLQMHQ9CL). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15762289](https://pubmed.ncbi.nlm.nih.gov/15762289).\",\"url\":\"https://doi.org/10.1309%2F8QYTYQ1CLQMHQ9CL\",\"favicon\":\"\"},{\"id\":\"25\",\"title\":\"_**a**_ _**b**_ Sainati L, Matutes E, Mulligan S, de Oliveira MP, Rani S, Lampert IA, Catovsky D (July 1990). [\\\"A variant form of hairy cell leukemia resistant to _alpha_ -interferon: clinical and phenotypic characteristics of 17 patients\\\"](https://ashpublications.org/blood/article/76/1/157/167900/A-variant-form-of-hairy-cell-leukemia-resistant-to). _Blood_. **76** (1): 157â€“62\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V76.1.157.157](https://doi.org/10.1182%2Fblood.V76.1.157.157). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2364167](https://pubmed.ncbi.nlm.nih.gov/2364167).\",\"description\":\"25. ^ _**a**_ _**b**_ Sainati L, Matutes E, Mulligan S, de Oliveira MP, Rani S, Lampert IA, Catovsky D (July 1990). [\\\"A variant form of hairy cell leukemia resistant to _alpha_ -interferon: clinical and phenotypic characteristics of 17 patients\\\"](https://ashpublications.org/blood/article/76/1/157/167900/A-variant-form-of-hairy-cell-leukemia-resistant-to). _Blood_. **76** (1): 157â€“62\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V76.1.157.157](https://doi.org/10.1182%2Fblood.V76.1.157.157). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [2364167](https://pubmed.ncbi.nlm.nih.gov/2364167).\",\"url\":\"https://ashpublications.org/blood/article/76/1/157/167900/A-variant-form-of-hairy-cell-leukemia-resistant-to\",\"favicon\":\"\"},{\"id\":\"26\",\"title\":\"** Cawley JC, Burns GF, Hayhoe FG (1980). \\\"A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia\\\". _Leukemia Research_. **4** (6): 547â€“59\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/0145-2126(80)90066-1](https://doi.org/10.1016%2F0145-2126%2880%2990066-1). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7206776](https://pubmed.ncbi.nlm.nih.gov/7206776).\",\"description\":\"26. **^** Cawley JC, Burns GF, Hayhoe FG (1980). \\\"A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia\\\". _Leukemia Research_. **4** (6): 547â€“59\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/0145-2126(80)90066-1](https://doi.org/10.1016%2F0145-2126%2880%2990066-1). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [7206776](https://pubmed.ncbi.nlm.nih.gov/7206776).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"27\",\"title\":\"_**a**_ _**b**_ _**c**_ _**d**_ Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D (2001). [\\\"The natural history and clinico-pathological features of the variant form of hairy cell leukemia\\\"](https://doi.org/10.1038%2Fsj.leu.2401999). _Leukemia_. **15** (1): 184â€“6\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/sj.leu.2401999](https://doi.org/10.1038%2Fsj.leu.2401999). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11243388](https://pubmed.ncbi.nlm.nih.gov/11243388). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6609635](https://api.semanticscholar.org/CorpusID:6609635).\",\"description\":\"27. ^ _**a**_ _**b**_ _**c**_ _**d**_ Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D (2001). [\\\"The natural history and clinico-pathological features of the variant form of hairy cell leukemia\\\"](https://doi.org/10.1038%2Fsj.leu.2401999). _Leukemia_. **15** (1): 184â€“6\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1038/sj.leu.2401999](https://doi.org/10.1038%2Fsj.leu.2401999). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [11243388](https://pubmed.ncbi.nlm.nih.gov/11243388). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6609635](https://api.semanticscholar.org/CorpusID:6609635).\",\"url\":\"https://doi.org/10.1038%2Fsj.leu.2401999\",\"favicon\":\"\"},{\"id\":\"28\",\"title\":\"** Ya-In, Charin; Brandwein, Joseph; Pantalony, Dominic; Chang, Hong (1 March 2005). \\\"Hairy Cell Leukemia Variant With Features of Intrasinusoidal Bone Marrow Involvement\\\". _Archives of Pathology \u0026 Laboratory Medicine_. **129** (3): 395â€“398\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.5858/2005-129-395-HCLVWF](https://doi.org/10.5858%2F2005-129-395-HCLVWF). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15737038](https://pubmed.ncbi.nlm.nih.gov/15737038).\",\"description\":\"28. **^** Ya-In, Charin; Brandwein, Joseph; Pantalony, Dominic; Chang, Hong (1 March 2005). \\\"Hairy Cell Leukemia Variant With Features of Intrasinusoidal Bone Marrow Involvement\\\". _Archives of Pathology \u0026 Laboratory Medicine_. **129** (3): 395â€“398\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.5858/2005-129-395-HCLVWF](https://doi.org/10.5858%2F2005-129-395-HCLVWF). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [15737038](https://pubmed.ncbi.nlm.nih.gov/15737038).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"29\",\"title\":\"** Kreitman, Robert J.; Wilson, Wyndham; Calvo, Katherine R.; Arons, Evgeny; Roth, Laura; Sapolsky, Jeffrey; Zhou, Hong; Raffeld, Mark; Stetler-Stevenson, Maryalice (15 December 2013). [\\\"Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867590). _Clinical Cancer Research_. **19** (24): 6873â€“6881\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/1078-0432.CCR-13-1752](https://doi.org/10.1158%2F1078-0432.CCR-13-1752). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3867590](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867590). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24277451](https://pubmed.ncbi.nlm.nih.gov/24277451).\",\"description\":\"29. **^** Kreitman, Robert J.; Wilson, Wyndham; Calvo, Katherine R.; Arons, Evgeny; Roth, Laura; Sapolsky, Jeffrey; Zhou, Hong; Raffeld, Mark; Stetler-Stevenson, Maryalice (15 December 2013). [\\\"Cladribine with Immediate Rituximab for the Treatment of Patients with Variant Hairy Cell Leukemia\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867590). _Clinical Cancer Research_. **19** (24): 6873â€“6881\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1158/1078-0432.CCR-13-1752](https://doi.org/10.1158%2F1078-0432.CCR-13-1752). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [3867590](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867590). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [24277451](https://pubmed.ncbi.nlm.nih.gov/24277451).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867590\",\"favicon\":\"\"},{\"id\":\"30\",\"title\":\"** [\\\"HCL-V\\\"](https://web.archive.org/web/20160601185030/https://www.hairycellleukemia.org/about-hcl/hcl-v/). _Hairy Cell Leukemia Foundation_. Archived from [the original](https://www.hairycellleukemia.org/about-hcl/hcl-v/) on 2016-06-01. Retrieved 2016-05-31.\",\"description\":\"30. **^** [\\\"HCL-V\\\"](https://web.archive.org/web/20160601185030/https://www.hairycellleukemia.org/about-hcl/hcl-v/). _Hairy Cell Leukemia Foundation_. Archived from [the original](https://www.hairycellleukemia.org/about-hcl/hcl-v/) on 2016-06-01. Retrieved 2016-05-31.\",\"url\":\"https://web.archive.org/web/20160601185030/https://www.hairycellleukemia.org/about-hcl/hcl-v/\",\"favicon\":\"\"},{\"id\":\"31\",\"title\":\"** Burthem J, Cawley JC (January 1994). [\\\"The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells\\\"](https://ashpublications.org/blood/article/83/2/497/170837/The-bone-marrow-fibrosis-of-hairy-cell-leukemia-is). _Blood_. **83** (2): 497â€“504\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V83.2.497.497](https://doi.org/10.1182%2Fblood.V83.2.497.497). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [8286747](https://pubmed.ncbi.nlm.nih.gov/8286747).\",\"description\":\"31. **^** Burthem J, Cawley JC (January 1994). [\\\"The bone marrow fibrosis of hairy-cell leukemia is caused by the synthesis and assembly of a fibronectin matrix by the hairy cells\\\"](https://ashpublications.org/blood/article/83/2/497/170837/The-bone-marrow-fibrosis-of-hairy-cell-leukemia-is). _Blood_. **83** (2): 497â€“504\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V83.2.497.497](https://doi.org/10.1182%2Fblood.V83.2.497.497). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [8286747](https://pubmed.ncbi.nlm.nih.gov/8286747).\",\"url\":\"https://ashpublications.org/blood/article/83/2/497/170837/The-bone-marrow-fibrosis-of-hairy-cell-leukemia-is\",\"favicon\":\"\"},{\"id\":\"32\",\"title\":\"** de Totero D, Tazzari PL, Lauria F, Raspadori D, di Celle PF, Carbone A, Gobbi M, Foa R (July 1993). [\\\"Phenotypic analysis of hairy cell leukemia: \\\"variant\\\" cases express the interleukin-2 receptor _beta_ chain, but not the _alpha_ chain (CD25)\\\"](https://ashpublications.org/blood/article/82/2/528/170402/Phenotypic-analysis-of-hairy-cell-leukemia-variant). _Blood_. **82** (2): 528â€“35\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V82.2.528.528](https://doi.org/10.1182%2Fblood.V82.2.528.528). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [8329708](https://pubmed.ncbi.nlm.nih.gov/8329708).\",\"description\":\"32. **^** de Totero D, Tazzari PL, Lauria F, Raspadori D, di Celle PF, Carbone A, Gobbi M, Foa R (July 1993). [\\\"Phenotypic analysis of hairy cell leukemia: \\\"variant\\\" cases express the interleukin-2 receptor _beta_ chain, but not the _alpha_ chain (CD25)\\\"](https://ashpublications.org/blood/article/82/2/528/170402/Phenotypic-analysis-of-hairy-cell-leukemia-variant). _Blood_. **82** (2): 528â€“35\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V82.2.528.528](https://doi.org/10.1182%2Fblood.V82.2.528.528). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [8329708](https://pubmed.ncbi.nlm.nih.gov/8329708).\",\"url\":\"https://ashpublications.org/blood/article/82/2/528/170402/Phenotypic-analysis-of-hairy-cell-leukemia-variant\",\"favicon\":\"\"},{\"id\":\"33\",\"title\":\"** Matutes E, Wotherspoon A, Catovsky D (2003). \\\"The variant form of hairy-cell leukaemia\\\". _Best Practice \u0026 Research Clinical Haematology_. **16** (1): 41â€“56\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S1521-6926(02)00086-5](https://doi.org/10.1016%2FS1521-6926%2802%2900086-5). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12670464](https://pubmed.ncbi.nlm.nih.gov/12670464).\",\"description\":\"33. **^** Matutes E, Wotherspoon A, Catovsky D (2003). \\\"The variant form of hairy-cell leukaemia\\\". _Best Practice \u0026 Research Clinical Haematology_. **16** (1): 41â€“56\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S1521-6926(02)00086-5](https://doi.org/10.1016%2FS1521-6926%2802%2900086-5). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12670464](https://pubmed.ncbi.nlm.nih.gov/12670464).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"34\",\"title\":\"** Vallianatou K, Brito-Babapulle V, Matutes E, Atkinson S, Catovsky D (1999). \\\"p53 gene deletion and trisomy 12 in hairy cell leukemia and its variant\\\". _Leukemia Research_. **23** (11): 1041â€“5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S0145-2126(99)00127-7](https://doi.org/10.1016%2FS0145-2126%2899%2900127-7). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [10576509](https://pubmed.ncbi.nlm.nih.gov/10576509).\",\"description\":\"34. **^** Vallianatou K, Brito-Babapulle V, Matutes E, Atkinson S, Catovsky D (1999). \\\"p53 gene deletion and trisomy 12 in hairy cell leukemia and its variant\\\". _Leukemia Research_. **23** (11): 1041â€“5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/S0145-2126(99)00127-7](https://doi.org/10.1016%2FS0145-2126%2899%2900127-7). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [10576509](https://pubmed.ncbi.nlm.nih.gov/10576509).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"35\",\"title\":\"** Arons, Evgeny; Suntum, Tara; Stetler-Stevenson, Maryalice; Kreitman, Robert J. (19 November 2009). [\\\"VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780305). _Blood_. **114** (21): 4687â€“4695\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2009-01-201731](https://doi.org/10.1182%2Fblood-2009-01-201731). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2780305](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780305). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19745070](https://pubmed.ncbi.nlm.nih.gov/19745070).\",\"description\":\"35. **^** Arons, Evgeny; Suntum, Tara; Stetler-Stevenson, Maryalice; Kreitman, Robert J. (19 November 2009). [\\\"VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780305). _Blood_. **114** (21): 4687â€“4695\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2009-01-201731](https://doi.org/10.1182%2Fblood-2009-01-201731). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [2780305](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780305). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19745070](https://pubmed.ncbi.nlm.nih.gov/19745070).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780305\",\"favicon\":\"\"},{\"id\":\"36\",\"title\":\"** Robak T, Jamroziak K, Gora-Tybor J, Blonski JZ, Kasznicki M, Dwilewicz-Trojaczek J, Wiater E, Zdunczyk A, Dybowicz J, Dmoszynska A, Wojtaszko M, Zdziarska B, Calbecka M, Kostyra A, Hellmann A, Lewandowski K, Stella-Holowiecka B, Sulek K, Gawronski K, Skotnicki AB, Nowak W, Zawilska K, Molendowicz-Portala L, Kloczko J, Sokolowski J, Warzocha K, Seferynska I, Ceglarek B, Konopka L (2007). [\\\"Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial\\\"](https://doi.org/10.1182%2Fblood-2006-08-042929). _Blood_. **109** (9): 3672â€“5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2006-08-042929](https://doi.org/10.1182%2Fblood-2006-08-042929). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17209059](https://pubmed.ncbi.nlm.nih.gov/17209059). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [9279754](https://api.semanticscholar.org/CorpusID:9279754).\",\"description\":\"36. **^** Robak T, Jamroziak K, Gora-Tybor J, Blonski JZ, Kasznicki M, Dwilewicz-Trojaczek J, Wiater E, Zdunczyk A, Dybowicz J, Dmoszynska A, Wojtaszko M, Zdziarska B, Calbecka M, Kostyra A, Hellmann A, Lewandowski K, Stella-Holowiecka B, Sulek K, Gawronski K, Skotnicki AB, Nowak W, Zawilska K, Molendowicz-Portala L, Kloczko J, Sokolowski J, Warzocha K, Seferynska I, Ceglarek B, Konopka L (2007). [\\\"Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial\\\"](https://doi.org/10.1182%2Fblood-2006-08-042929). _Blood_. **109** (9): 3672â€“5\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2006-08-042929](https://doi.org/10.1182%2Fblood-2006-08-042929). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [17209059](https://pubmed.ncbi.nlm.nih.gov/17209059). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [9279754](https://api.semanticscholar.org/CorpusID:9279754).\",\"url\":\"https://doi.org/10.1182%2Fblood-2006-08-042929\",\"favicon\":\"\"},{\"id\":\"37\",\"title\":\"** Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D (2005). [\\\"Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years\\\"](https://doi.org/10.1002%2Fcncr.21447). _Cancer_. **104** (11): 2442â€“8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/cncr.21447](https://doi.org/10.1002%2Fcncr.21447). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16245328](https://pubmed.ncbi.nlm.nih.gov/16245328). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [43282431](https://api.semanticscholar.org/CorpusID:43282431).\",\"description\":\"37. **^** Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D (2005). [\\\"Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years\\\"](https://doi.org/10.1002%2Fcncr.21447). _Cancer_. **104** (11): 2442â€“8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/cncr.21447](https://doi.org/10.1002%2Fcncr.21447). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16245328](https://pubmed.ncbi.nlm.nih.gov/16245328). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [43282431](https://api.semanticscholar.org/CorpusID:43282431).\",\"url\":\"https://doi.org/10.1002%2Fcncr.21447\",\"favicon\":\"\"},{\"id\":\"38\",\"title\":\"** Saven, Alan; Piro, LD (15 August 1993). \\\"Complete Remissions in Hairy Cell Leukemia with 2-Chlorodeoxyadenosine after Failure with 2-Deoxycoformycin\\\". _Annals of Internal Medicine_. **119** (4): 278â€“283\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.7326/0003-4819-119-4-199308150-00005](https://doi.org/10.7326%2F0003-4819-119-4-199308150-00005). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [8101069](https://pubmed.ncbi.nlm.nih.gov/8101069). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [34812778](https://api.semanticscholar.org/CorpusID:34812778).\",\"description\":\"38. **^** Saven, Alan; Piro, LD (15 August 1993). \\\"Complete Remissions in Hairy Cell Leukemia with 2-Chlorodeoxyadenosine after Failure with 2-Deoxycoformycin\\\". _Annals of Internal Medicine_. **119** (4): 278â€“283\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.7326/0003-4819-119-4-199308150-00005](https://doi.org/10.7326%2F0003-4819-119-4-199308150-00005). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [8101069](https://pubmed.ncbi.nlm.nih.gov/8101069). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [34812778](https://api.semanticscholar.org/CorpusID:34812778).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"39\",\"title\":\"** Thomas, Deborah A.; O'Brien, Susan; Bueso-Ramos, Carlos; Faderl, Stefan; Keating, Michael J.; Giles, Francis J.; Cortes, Jorge; Kantarjian, Hagop M. (1 December 2003). [\\\"Rituximab in relapsed or refractory hairy cell leukemia\\\"](https://doi.org/10.1182%2Fblood-2003-02-0630). _Blood_. **102** (12): 3906â€“3911\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2003-02-0630](https://doi.org/10.1182%2Fblood-2003-02-0630). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12816862](https://pubmed.ncbi.nlm.nih.gov/12816862).\",\"description\":\"39. **^** Thomas, Deborah A.; O'Brien, Susan; Bueso-Ramos, Carlos; Faderl, Stefan; Keating, Michael J.; Giles, Francis J.; Cortes, Jorge; Kantarjian, Hagop M. (1 December 2003). [\\\"Rituximab in relapsed or refractory hairy cell leukemia\\\"](https://doi.org/10.1182%2Fblood-2003-02-0630). _Blood_. **102** (12): 3906â€“3911\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2003-02-0630](https://doi.org/10.1182%2Fblood-2003-02-0630). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12816862](https://pubmed.ncbi.nlm.nih.gov/12816862).\",\"url\":\"https://doi.org/10.1182%2Fblood-2003-02-0630\",\"favicon\":\"\"},{\"id\":\"40\",\"title\":\"** Nieva, Jorge; Bethel, Kelly; Saven, Alan (1 August 2003). \\\"Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia\\\". _Blood_. **102** (3): 810â€“813\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2003-01-0014](https://doi.org/10.1182%2Fblood-2003-01-0014). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12663446](https://pubmed.ncbi.nlm.nih.gov/12663446).\",\"description\":\"40. **^** Nieva, Jorge; Bethel, Kelly; Saven, Alan (1 August 2003). \\\"Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia\\\". _Blood_. **102** (3): 810â€“813\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2003-01-0014](https://doi.org/10.1182%2Fblood-2003-01-0014). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12663446](https://pubmed.ncbi.nlm.nih.gov/12663446).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"41\",\"title\":\"** Narat S, Gandla J, Dogan A, Mehta A (August 2005). \\\"Successful treatment of hairy cell leukemia variant with rituximab\\\". _Leuk. Lymphoma_. **46** (8): 1229â€“32\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/10428190500083433](https://doi.org/10.1080%2F10428190500083433). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16085567](https://pubmed.ncbi.nlm.nih.gov/16085567). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [20116705](https://api.semanticscholar.org/CorpusID:20116705).\",\"description\":\"41. **^** Narat S, Gandla J, Dogan A, Mehta A (August 2005). \\\"Successful treatment of hairy cell leukemia variant with rituximab\\\". _Leuk. Lymphoma_. **46** (8): 1229â€“32\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1080/10428190500083433](https://doi.org/10.1080%2F10428190500083433). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16085567](https://pubmed.ncbi.nlm.nih.gov/16085567). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [20116705](https://api.semanticscholar.org/CorpusID:20116705).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"42\",\"title\":\"** Karmacharya, Paras; Poudel, Dilli Ram; Pathak, Ranjan; Donato, Anthony A.; Ghimire, Sushil; Giri, Smith; Aryal, Madan Raj; Bingham, Clifton O. (December 2015). \\\"Rituximab-induced serum sickness: A systematic review\\\". _Seminars in Arthritis and Rheumatism_. **45** (3): 334â€“340\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.semarthrit.2015.06.014](https://doi.org/10.1016%2Fj.semarthrit.2015.06.014).\",\"description\":\"42. **^** Karmacharya, Paras; Poudel, Dilli Ram; Pathak, Ranjan; Donato, Anthony A.; Ghimire, Sushil; Giri, Smith; Aryal, Madan Raj; Bingham, Clifton O. (December 2015). \\\"Rituximab-induced serum sickness: A systematic review\\\". _Seminars in Arthritis and Rheumatism_. **45** (3): 334â€“340\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1016/j.semarthrit.2015.06.014](https://doi.org/10.1016%2Fj.semarthrit.2015.06.014).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"43\",\"title\":\"** _[Hairy Cell Leukemia~medication](http://www.emedicine.com/med/topic937.htm#section~medication)_ at [eMedicine](EMedicine \\\"EMedicine\\\")\",\"description\":\"43. **^** _[Hairy Cell Leukemia~medication](http://www.emedicine.com/med/topic937.htm#section~medication)_ at [eMedicine](EMedicine \\\"EMedicine\\\")\",\"url\":\"http://www.emedicine.com/med/topic937.htm#section~medication\",\"favicon\":\"\"},{\"id\":\"44\",\"title\":\"** Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU (January 1984). \\\"Alpha interferon for induction of remission in hairy-cell leukemia\\\". _N. Engl. J. Med_. **310** (1): 15â€“8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJM198401053100104](https://doi.org/10.1056%2FNEJM198401053100104). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [6689734](https://pubmed.ncbi.nlm.nih.gov/6689734).\",\"description\":\"44. **^** Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU (January 1984). \\\"Alpha interferon for induction of remission in hairy-cell leukemia\\\". _N. Engl. J. Med_. **310** (1): 15â€“8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1056/NEJM198401053100104](https://doi.org/10.1056%2FNEJM198401053100104). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [6689734](https://pubmed.ncbi.nlm.nih.gov/6689734).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"45\",\"title\":\"** Assanto, Giovanni M.; Riemma, Costantino; Malaspina, Francesco; Perrone, Salvatore; De Luca, Maria L.; Pucciarini, Alessandra; Annechini, Giorgia; D'Elia, Gianna M.; Martelli, Maurizio; FoÃ , Robin; Tiacci, Enrico; Pulsoni, Alessandro (July 2021). [\\\"The current role of interferon in hairy cell leukaemia: clinical and molecular aspects\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360059). _British Journal of Haematology_. **194** (1): 78â€“82\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/bjh.17440](https://doi.org/10.1111%2Fbjh.17440). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1365-2141](https://search.worldcat.org/issn/1365-2141). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8360059](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360059). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [33932027](https://pubmed.ncbi.nlm.nih.gov/33932027).\",\"description\":\"45. **^** Assanto, Giovanni M.; Riemma, Costantino; Malaspina, Francesco; Perrone, Salvatore; De Luca, Maria L.; Pucciarini, Alessandra; Annechini, Giorgia; D'Elia, Gianna M.; Martelli, Maurizio; FoÃ , Robin; Tiacci, Enrico; Pulsoni, Alessandro (July 2021). [\\\"The current role of interferon in hairy cell leukaemia: clinical and molecular aspects\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360059). _British Journal of Haematology_. **194** (1): 78â€“82\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1111/bjh.17440](https://doi.org/10.1111%2Fbjh.17440). [ISSN](ISSN_\\\\(identifier\\\\) \\\"ISSN \\\\(identifier\\\\)\\\") [1365-2141](https://search.worldcat.org/issn/1365-2141). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [8360059](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360059). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [33932027](https://pubmed.ncbi.nlm.nih.gov/33932027).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360059\",\"favicon\":\"\"},{\"id\":\"46\",\"title\":\"_**a**_ _**b**_ Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K (1985). [\\\"Treatment of hairy cell leukemia with recombinant alpha 2 interferon\\\"](https://doi.org/10.1182%2Fblood.V65.3.644.644). _Blood_. **65** (3): 644â€“8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V65.3.644.644](https://doi.org/10.1182%2Fblood.V65.3.644.644). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [3971043](https://pubmed.ncbi.nlm.nih.gov/3971043).\",\"description\":\"46. ^ _**a**_ _**b**_ Ratain MJ, Golomb HM, Vardiman JW, Vokes EE, Jacobs RH, Daly K (1985). [\\\"Treatment of hairy cell leukemia with recombinant alpha 2 interferon\\\"](https://doi.org/10.1182%2Fblood.V65.3.644.644). _Blood_. **65** (3): 644â€“8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V65.3.644.644](https://doi.org/10.1182%2Fblood.V65.3.644.644). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [3971043](https://pubmed.ncbi.nlm.nih.gov/3971043).\",\"url\":\"https://doi.org/10.1182%2Fblood.V65.3.644.644\",\"favicon\":\"\"},{\"id\":\"47\",\"title\":\"_**a**_ _**b**_ Baker PK, Pettitt AR, Slupsky JR, Chen HJ, Glenn MA, Zuzel M, Cawley JC (2002). [\\\"Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion\\\"](https://doi.org/10.1182%2Fblood.V100.2.647). _Blood_. **100** (2): 647â€“53\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V100.2.647](https://doi.org/10.1182%2Fblood.V100.2.647). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12091360](https://pubmed.ncbi.nlm.nih.gov/12091360). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6712599](https://api.semanticscholar.org/CorpusID:6712599).\",\"description\":\"47. ^ _**a**_ _**b**_ Baker PK, Pettitt AR, Slupsky JR, Chen HJ, Glenn MA, Zuzel M, Cawley JC (2002). [\\\"Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion\\\"](https://doi.org/10.1182%2Fblood.V100.2.647). _Blood_. **100** (2): 647â€“53\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V100.2.647](https://doi.org/10.1182%2Fblood.V100.2.647). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [12091360](https://pubmed.ncbi.nlm.nih.gov/12091360). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [6712599](https://api.semanticscholar.org/CorpusID:6712599).\",\"url\":\"https://doi.org/10.1182%2Fblood.V100.2.647\",\"favicon\":\"\"},{\"id\":\"48\",\"title\":\"** Saven, Alan; Burian, Carol; Adusumalli, Jasvant; Koziol, James A. (15 April 1999). \\\"Filgrastim for Cladribine-Induced Neutropenic Fever in Patients With Hairy Cell Leukemia\\\". _Blood_. **93** (8): 2471â€“2477\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V93.8.2471](https://doi.org/10.1182%2Fblood.V93.8.2471). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [10194424](https://pubmed.ncbi.nlm.nih.gov/10194424).\",\"description\":\"48. **^** Saven, Alan; Burian, Carol; Adusumalli, Jasvant; Koziol, James A. (15 April 1999). \\\"Filgrastim for Cladribine-Induced Neutropenic Fever in Patients With Hairy Cell Leukemia\\\". _Blood_. **93** (8): 2471â€“2477\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V93.8.2471](https://doi.org/10.1182%2Fblood.V93.8.2471). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [10194424](https://pubmed.ncbi.nlm.nih.gov/10194424).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"49\",\"title\":\"** Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D (December 2005). [\\\"Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years\\\"](https://doi.org/10.1002%2Fcncr.21447). _Cancer_. **104** (11): 2442â€“8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/cncr.21447](https://doi.org/10.1002%2Fcncr.21447). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16245328](https://pubmed.ncbi.nlm.nih.gov/16245328). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [43282431](https://api.semanticscholar.org/CorpusID:43282431).\",\"description\":\"49. **^** Else M, Ruchlemer R, Osuji N, Del Giudice I, Matutes E, Woodman A, Wotherspoon A, Swansbury J, Dearden C, Catovsky D (December 2005). [\\\"Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years\\\"](https://doi.org/10.1002%2Fcncr.21447). _Cancer_. **104** (11): 2442â€“8\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/cncr.21447](https://doi.org/10.1002%2Fcncr.21447). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [16245328](https://pubmed.ncbi.nlm.nih.gov/16245328). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [43282431](https://api.semanticscholar.org/CorpusID:43282431).\",\"url\":\"https://doi.org/10.1002%2Fcncr.21447\",\"favicon\":\"\"},{\"id\":\"50\",\"title\":\"** Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C, Rigacci L, Gherlinzoni F, Cantaffa R, Baraldi A, Gallamini A, Zaccaria A, Pulsoni A, Gobbi M, Tassi M, Raspadori D, Leoncini L, Rinaldi A, Sabattini E, Bertoni F, Pileri SA, Lauria F (November 2009). [\\\"Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single agent cladribine and with more aggressive behavior\\\"](http://bloodjournal.hematologylibrary.org/cgi/content/full/114/21/4696). _Blood_. **114** (21): 4696â€“4702\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2009-03-212449](https://doi.org/10.1182%2Fblood-2009-03-212449). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19667403](https://pubmed.ncbi.nlm.nih.gov/19667403). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [90241](https://api.semanticscholar.org/CorpusID:90241).\",\"description\":\"50. **^** Forconi F, Sozzi E, Cencini E, Zaja F, Intermesoli T, Stelitano C, Rigacci L, Gherlinzoni F, Cantaffa R, Baraldi A, Gallamini A, Zaccaria A, Pulsoni A, Gobbi M, Tassi M, Raspadori D, Leoncini L, Rinaldi A, Sabattini E, Bertoni F, Pileri SA, Lauria F (November 2009). [\\\"Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single agent cladribine and with more aggressive behavior\\\"](http://bloodjournal.hematologylibrary.org/cgi/content/full/114/21/4696). _Blood_. **114** (21): 4696â€“4702\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood-2009-03-212449](https://doi.org/10.1182%2Fblood-2009-03-212449). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19667403](https://pubmed.ncbi.nlm.nih.gov/19667403). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [90241](https://api.semanticscholar.org/CorpusID:90241).\",\"url\":\"http://bloodjournal.hematologylibrary.org/cgi/content/full/114/21/4696\",\"favicon\":\"\"},{\"id\":\"51\",\"title\":\"** Brown, Richard T. (August 2002). [\\\"Hairy Cell Leukemia\\\"](https://web.archive.org/web/20120224123933/http://www.euclidmanagers.com/downloads/legrev/rblegrev/RTBaugust.pdf) (PDF). _Brokerage Bulletin_. **7** (5): 3. Archived from [the original](http://www.euclidmanagers.com/downloads/legrev/rblegrev/RTBaugust.pdf) (PDF) on 2012-02-24. Retrieved 2018-11-29.\",\"description\":\"51. **^** Brown, Richard T. (August 2002). [\\\"Hairy Cell Leukemia\\\"](https://web.archive.org/web/20120224123933/http://www.euclidmanagers.com/downloads/legrev/rblegrev/RTBaugust.pdf) (PDF). _Brokerage Bulletin_. **7** (5): 3. Archived from [the original](http://www.euclidmanagers.com/downloads/legrev/rblegrev/RTBaugust.pdf) (PDF) on 2012-02-24. Retrieved 2018-11-29.\",\"url\":\"https://web.archive.org/web/20120224123933/http://www.euclidmanagers.com/downloads/legrev/rblegrev/RTBaugust.pdf\",\"favicon\":\"\"},{\"id\":\"52\",\"title\":\"** Robak, T. and P. (2022). [\\\"Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684202). _Frontiers in Oncology_. **12**. NIH: 976374. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3389/fonc.2022.976374](https://doi.org/10.3389%2Ffonc.2022.976374). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [9684202](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684202). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [36439497](https://pubmed.ncbi.nlm.nih.gov/36439497).\",\"description\":\"52. **^** Robak, T. and P. (2022). [\\\"Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance\\\"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684202). _Frontiers in Oncology_. **12**. NIH: 976374. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.3389/fonc.2022.976374](https://doi.org/10.3389%2Ffonc.2022.976374). [PMC](PMC_\\\\(identifier\\\\) \\\"PMC \\\\(identifier\\\\)\\\") [9684202](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684202). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [36439497](https://pubmed.ncbi.nlm.nih.gov/36439497).\",\"url\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9684202\",\"favicon\":\"\"},{\"id\":\"53\",\"title\":\"** [\\\"Update on Hairy Cell Leukemia â€“ Hematology \u0026 Oncology\\\"](http://www.hematologyandoncology.net/archives/march-2018/update-on-hairy-cell-leukemia/).\",\"description\":\"53. **^** [\\\"Update on Hairy Cell Leukemia â€“ Hematology \u0026 Oncology\\\"](http://www.hematologyandoncology.net/archives/march-2018/update-on-hairy-cell-leukemia/).\",\"url\":\"http://www.hematologyandoncology.net/archives/march-2018/update-on-hairy-cell-leukemia/\",\"favicon\":\"\"},{\"id\":\"54\",\"title\":\"** Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM (August 1998). [\\\"Second malignancies in patients with hairy cell leukemia in British columbia: a 20-year experience\\\"](http://www.bloodjournal.org/cgi/pmidlookup?view=long\u0026pmid=9694703). _Blood_. **92** (4): 1160â€“4\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V92.4.1160](https://doi.org/10.1182%2Fblood.V92.4.1160). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9694703](https://pubmed.ncbi.nlm.nih.gov/9694703).\",\"description\":\"54. **^** Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM (August 1998). [\\\"Second malignancies in patients with hairy cell leukemia in British columbia: a 20-year experience\\\"](http://www.bloodjournal.org/cgi/pmidlookup?view=long\u0026pmid=9694703). _Blood_. **92** (4): 1160â€“4\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1182/blood.V92.4.1160](https://doi.org/10.1182%2Fblood.V92.4.1160). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [9694703](https://pubmed.ncbi.nlm.nih.gov/9694703).\",\"url\":\"http://www.bloodjournal.org/cgi/pmidlookup?view=long\u0026pmid=9694703\",\"favicon\":\"\"},{\"id\":\"55\",\"title\":\"** Gramatovici M, Bennett JM, Hiscock JG, Grewal KS (April 1993). \\\"Three cases of familial hairy cell leukemia\\\". _Am. J. Hematol_. **42** (4): 337â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/ajh.2830420402](https://doi.org/10.1002%2Fajh.2830420402). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [8493982](https://pubmed.ncbi.nlm.nih.gov/8493982). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [34449485](https://api.semanticscholar.org/CorpusID:34449485).\",\"description\":\"55. **^** Gramatovici M, Bennett JM, Hiscock JG, Grewal KS (April 1993). \\\"Three cases of familial hairy cell leukemia\\\". _Am. J. Hematol_. **42** (4): 337â€“9\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1002/ajh.2830420402](https://doi.org/10.1002%2Fajh.2830420402). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [8493982](https://pubmed.ncbi.nlm.nih.gov/8493982). [S2CID](S2CID_\\\\(identifier\\\\) \\\"S2CID \\\\(identifier\\\\)\\\") [34449485](https://api.semanticscholar.org/CorpusID:34449485).\",\"url\":\"Doi_\\\\(identifier\\\\\",\"favicon\":\"\"},{\"id\":\"56\",\"title\":\"** Holzman D (March 2009). [\\\"Has success spoiled hairy cell leukemia research? Key questions go unanswered, despite big gains\\\"](https://doi.org/10.1093%2Fjnci%2Fdjp051). _J. Natl. Cancer Inst_. **101** (6): 370â€“3\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jnci/djp051](https://doi.org/10.1093%2Fjnci%2Fdjp051). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19276454](https://pubmed.ncbi.nlm.nih.gov/19276454).\",\"description\":\"56. **^** Holzman D (March 2009). [\\\"Has success spoiled hairy cell leukemia research? Key questions go unanswered, despite big gains\\\"](https://doi.org/10.1093%2Fjnci%2Fdjp051). _J. Natl. Cancer Inst_. **101** (6): 370â€“3\\\\. [doi](Doi_\\\\(identifier\\\\) \\\"Doi \\\\(identifier\\\\)\\\"):[10.1093/jnci/djp051](https://doi.org/10.1093%2Fjnci%2Fdjp051). [PMID](PMID_\\\\(identifier\\\\) \\\"PMID \\\\(identifier\\\\)\\\") [19276454](https://pubmed.ncbi.nlm.nih.gov/19276454).\",\"url\":\"https://doi.org/10.1093%2Fjnci%2Fdjp051\",\"favicon\":\"\"},{\"id\":\"57\",\"title\":\"** [\\\"| Hairy Cell Leukemia Foundation\\\"](http://www.hairycellleukemia.org/). Hairycellleukemia.org. 2014-06-20. Retrieved 2015-12-24.\",\"description\":\"57. **^** [\\\"| Hairy Cell Leukemia Foundation\\\"](http://www.hairycellleukemia.org/). Hairycellleukemia.org. 2014-06-20. Retrieved 2015-12-24.\",\"url\":\"http://www.hairycellleukemia.org/\",\"favicon\":\"\"},{\"id\":\"58\",\"title\":\"** Clinical trial number _[NCT00074048](https://www.clinicaltrials.gov/show/NCT00074048)_ for \\\"BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia\\\" at [ClinicalTrials.gov](ClinicalTrials.gov \\\"ClinicalTrials.gov\\\")\",\"description\":\"58. **^** Clinical trial number _[NCT00074048](https://www.clinicaltrials.gov/show/NCT00074048)_ for \\\"BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia\\\" at [ClinicalTrials.gov](ClinicalTrials.gov \\\"ClinicalTrials.gov\\\")\",\"url\":\"https://www.clinicaltrials.gov/show/NCT00074048\",\"favicon\":\"\"},{\"id\":\"59\",\"title\":\"** Clinical trial number _[NCT00462189](https://www.clinicaltrials.gov/show/NCT00462189)_ for \\\"Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease\\\" at [ClinicalTrials.gov](ClinicalTrials.gov \\\"ClinicalTrials.gov\\\")\",\"description\":\"59. **^** Clinical trial number _[NCT00462189](https://www.clinicaltrials.gov/show/NCT00462189)_ for \\\"Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease\\\" at [ClinicalTrials.gov](ClinicalTrials.gov \\\"ClinicalTrials.gov\\\")\",\"url\":\"https://www.clinicaltrials.gov/show/NCT00462189\",\"favicon\":\"\"},{\"id\":\"60\",\"title\":\"** Clinical trial number _[NCT00337311](https://www.clinicaltrials.gov/show/NCT00337311)_ for \\\"LMB-2 to Treat Hairy Cell Leukemia\\\" at [ClinicalTrials.gov](ClinicalTrials.gov \\\"ClinicalTrials.gov\\\")\",\"description\":\"60. **^** Clinical trial number _[NCT00337311](https://www.clinicaltrials.gov/show/NCT00337311)_ for \\\"LMB-2 to Treat Hairy Cell Leukemia\\\" at [ClinicalTrials.gov](ClinicalTrials.gov \\\"ClinicalTrials.gov\\\")\",\"url\":\"https://www.clinicaltrials.gov/show/NCT00337311\",\"favicon\":\"\"},{\"id\":\"61\",\"title\":\"** [\\\"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia - Full Text View\\\"](https://clinicaltrials.gov/ct2/show/NCT01829711?term=Hairy+cell+leukemia\u0026rank=14). ClinicalTrials.gov. Retrieved 2015-12-24.\",\"description\":\"61. **^** [\\\"Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia - Full Text View\\\"](https://clinicaltrials.gov/ct2/show/NCT01829711?term=Hairy+cell+leukemia\u0026rank=14). ClinicalTrials.gov. Retrieved 2015-12-24.\",\"url\":\"https://clinicaltrials.gov/ct2/show/NCT01829711?term=Hairy+cell+leukemia\u0026rank=14\",\"favicon\":\"\"},{\"id\":\"62\",\"title\":\"** For example, trial [NCT00412594](https://clinicaltrials.gov/show/NCT00412594) and [NCT00923013](https://clinicaltrials.gov/show/NCT00923013)\",\"description\":\"62. **^** For example, trial [NCT00412594](https://clinicaltrials.gov/show/NCT00412594) and [NCT00923013](https://clinicaltrials.gov/show/NCT00923013)\",\"url\":\"https://clinicaltrials.gov/show/NCT00412594\",\"favicon\":\"\"},{\"id\":\"63\",\"title\":\"** Cawley, John. [\\\"The Biology of the Disease Including Unanswered Questions | HairyCell.org\\\"](https://web.archive.org/web/20110726135436/http://www.hairycell.org/content/researchers/unanswered-questions/biology-disease-including-unanswered-questions). Archived from [the original](http://www.hairycell.org/content/researchers/unanswered-questions/biology-disease-including-unanswered-questions) on 2011-07-26. Retrieved 2010-06-23.\",\"description\":\"63. **^** Cawley, John. [\\\"The Biology of the Disease Including Unanswered Questions | HairyCell.org\\\"](https://web.archive.org/web/20110726135436/http://www.hairycell.org/content/researchers/unanswered-questions/biology-disease-including-unanswered-questions). Archived from [the original](http://www.hairycell.org/content/researchers/unanswered-questions/biology-disease-including-unanswered-questions) on 2011-07-26. Retrieved 2010-06-23.\",\"url\":\"https://web.archive.org/web/20110726135436/http://www.hairycell.org/content/researchers/unanswered-questions/biology-disease-including-unanswered-questions\",\"favicon\":\"\"}],\"images\":[],\"fixedIssues\":[{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific problematic text; the entire section lacks mention of splenomegaly.]\",\"explanation\":\"Splenomegaly is a hallmark sign of hairy cell leukemia, present in approximately 70-100% of patients at diagnosis, often causing abdominal fullness, discomfort, or pain below the ribs. Omitting this common clinical feature misrepresents the typical presentation and could mislead readers on expected symptoms.\",\"fixedText\":\"Add description of splenomegaly and associated symptoms after the paragraph on cytopenias, citing existing [5] or new authoritative source.\",\"evidenceSource\":\"[5] and [](https://www.onclive.com/view/hairy-cell-leukemia-a-review-of-epidemiology-and-disease-presentation)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"Farming and gardening correlate with an increased risk of HCL development in some studies which does not necessarily imply causation.[10]\",\"explanation\":\"The cited reference [10] discusses transient autonomic nervous system dysfunction in stroke patients, unrelated to HCL risk factors. This mismatch misleads on sourcing for the farming/gardening correlation.\",\"fixedText\":\"Remove [10]; recite with [9] or [16], which support associations with farming and pesticides. Clarify that gardening may relate to pesticide exposure.\",\"evidenceSource\":\"References [10]\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Exposure to tobacco smoke, ionizing radiation, or industrial chemicals (with the possible exception of diesel) does not appear to increase the risk of developing it.[9]\",\"explanation\":\"Reference [9] (1995) predates current understanding. As of 2024, ionizing radiation and diesel exhaust are suspected risk factors; tobacco smoking shows an inverse association (protective effect). This outdated claim misstates health risks and could mislead on prevention.\",\"fixedText\":\"Update to reflect suspected risks for radiation, diesel, and petroleum products; note protective effect of smoking. Retain [9] for smoking; add recent review citation.\",\"evidenceSource\":\"[9]; [](https://onlinelibrary.wiley.com/doi/10.1002/ajh.27240)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"\",\"explanation\":\"The BRAF V600E mutation section reports a 2011 study's finding of 100% prevalence but omits updates confirming it in 90-100% of cases, a key etiological driver. Missing recent recognition of Agent Orange exposure as a presumptive risk via VA policy, stemming from IOM findings.\",\"fixedText\":\"Add: BRAF V600E found in nearly all cases; note VA presumptive service connection for Agent Orange-exposed veterans.\",\"evidenceSource\":\"[11]; [](https://onlinelibrary.wiley.com/doi/10.1002/ajh.27240); [](https://www.publichealth.va.gov/exposures/agentorange/conditions/bcell-leukemia.asp)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"Definitively diagnosing HCL is also possible through [flow cytometry](Flow_cytometry \\\"Flow cytometry\\\") on blood or bone marrow. The hairy cells are larger than normal and positive for [CD19](CD19 \\\"CD19\\\"), [CD20](CD20 \\\"CD20\\\"), [CD22](CD22 \\\"CD22\\\"), [CD11c](CD11c \\\"CD11c\\\"), [CD25](CD25 \\\"CD25\\\"), [CD103](CD103 \\\"CD103\\\"), and [FMC7](FMC7 \\\"FMC7\\\") antigens.\",\"explanation\":\"CD123 is a key immunophenotypic marker for HCL, included in the standard HCL immunologic score (CD11c, CD103, CD123, CD25). Its omission provides incomplete diagnostic information, potentially affecting accuracy in distinguishing HCL from mimics like splenic marginal zone lymphoma.\",\"fixedText\":\"Add CD123 to the list of positive antigens in flow cytometry.\",\"evidenceSource\":\"[2] Falini, Brunangelo; Tiacci, Enrico (10 October 2024). \\\"Hairy-Cell Leukemia\\\". New England Journal of Medicine.\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"A CBC normally shows low counts for white blood cells, red blood cells, and platelets in HCL patients.\",\"explanation\":\"Monocytopenia (absolute monocyte count \u0026lt;0.1 Ã— 10^9/L) is present in almost all classic HCL cases and is a characteristic finding aiding diagnosis, distinguishing from HCL-V and other lymphoproliferative disorders.\",\"fixedText\":\"Add mention of monocytopenia to CBC findings for classic HCL.\",\"evidenceSource\":\"[2] Falini, Brunangelo; Tiacci, Enrico (10 October 2024). \\\"Hairy-Cell Leukemia\\\". New England Journal of Medicine.\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"The diagnosis can be confirmed by viewing the cells with a special stain known as [tartrate resistant acid phosphatase](Tartrate_resistant_acid_phosphatase \\\"Tartrate resistant acid phosphatase\\\") (TRAP). More recently, DB44 testing assures more accurate results.\",\"explanation\":\"TRAP and DBA.44 (not DB44) are older confirmatory stains, but current standards emphasize immunohistochemistry for BRAF V600E and annexin A1 for higher specificity and sensitivity in confirming HCL, especially with fibrosis complicating biopsies. Name error and outdated emphasis on less specific methods.\",\"fixedText\":\"Correct to DBA.44; update to note that while TRAP and DBA.44 are used, IHC for BRAF V600E and annexin A1 provide more accurate confirmation, as already mentioned later in the section.\",\"evidenceSource\":\"[2] Falini, Brunangelo; Tiacci, Enrico (10 October 2024). \\\"Hairy-Cell Leukemia\\\". New England Journal of Medicine.\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"About 10% of people with HCL have this variant form of the disease, representing about 60-75 new cases of HCL-V each year in the U.S.\",\"explanation\":\"Current estimates place HCL incidence at 1,000-1,300 cases/year in the US, with HCL-V comprising 10-20% (100-260 cases/year). The 60-75 figure is outdated (from 2001 data), underestimating by ~2x, which misrepresents rarity and epidemiology.\",\"fixedText\":\"Update to \\\"10-20% of HCL cases, representing approximately 100-260 new cases per year in the U.S., based on recent incidence data.\\\"\",\"evidenceSource\":\"[](https://www.ncbi.nlm.nih.gov/books/NBK499845/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Or the anti-CD22 immunotoxin moxetumomab pasudotox can be tried.\",\"explanation\":\"The drug moxetumomab pasudotox (Lumoxiti) was discontinued by AstraZeneca in the US market in 2023 and is no longer available as of 2025, making this recommendation outdated and potentially misleading for current clinical practice.\",\"fixedText\":\"Remove the mention of moxetumomab pasudotox or note that it has been discontinued; suggest alternative options such as BTK inhibitors like ibrutinib for relapsed disease.\",\"evidenceSource\":\"[](https://www.onclive.com/view/astrazeneca-to-discontinue-moxetumomab-pasudotox-in-us-for-hairy-cell-leukemia)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Interferon-alpha is an immune system hormone that is very helpful to a relatively small number of patients... IFN-alpha is considered the drug of choice for pregnant women with active HCL.[2]\",\"explanation\":\"Standard interferon alfa production has been halted and is no longer available as of 2025; while pegylated alternatives like ropeginterferon alfa-2b-njft are suggested, they are not FDA-approved for HCL. This affects recommendations for use, including in pregnancy, where alternatives like splenectomy or watchful waiting may be preferred.\",\"fixedText\":\"Update to note discontinuation of standard IFN-alpha; mention pegylated IFN as a potential alternative not approved for HCL; for pregnancy, indicate interferon (pegylated) or splenectomy as options based on recent reviews.\",\"evidenceSource\":\"[](https://www.cancer.gov/types/leukemia/hp/hairy-cell-treatment-pdq)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No specific quote; general second-line therapy section]\",\"explanation\":\"The section lacks mention of newer targeted therapies for relapsed/refractory HCL, such as BTK inhibitors (e.g., ibrutinib), which have shown response rates of around 54% with 36-month PFS of 73%, representing a significant knowledge gap in current treatment options as of 2025.\",\"fixedText\":\"Add ibrutinib (or BTK inhibitors) as a second-line option for relapsed/refractory HCL, citing response rates and PFS from NCI PDQ.\",\"evidenceSource\":\"[](https://www.cancer.gov/types/leukemia/hp/hairy-cell-treatment-pdq)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"More than 95% of new patients are treated well or at least adequately by cladribine or pentostatin.[49]\",\"explanation\":\"While older studies report high overall response rates (ORR) of 91-100% with purine nucleoside analogs (PNAs) like cladribine, complete response (CR) rates are typically 65-85% without rituximab. Current first-line therapy often combines cladribine with rituximab (CDA+R), achieving 100% CR and better long-term outcomes. The claim lacks recency, as treatment standards have evolved by 2024, potentially misleading on efficacy of PNA monotherapy.\",\"fixedText\":\"Update to reflect current standards: First-line therapy with cladribine plus rituximab achieves complete response in nearly all patients, with overall response rates exceeding 95% for purine analogs alone in classic HCL.\",\"evidenceSource\":\"2024 review: https://onlinelibrary.wiley.com/doi/10.1002/ajh.27240\"},{\"criticality\":\"Critical\",\"issueType\":\"Quantitative/Units Error\",\"problematicText\":\"HCL-V patients routinely survive for more than 10 years, and younger patients can likely expect a long life.\",\"explanation\":\"The median age at diagnosis for HCL-V is ~70 years, with 5-year overall survival (OS) rates of 57-74% reported in recent studies. Median OS is approximately 6-9 years, meaning not all patients \\\"routinely\\\" survive \u003e10 years; this overstates survival, especially given aggressive course and poorer prognosis compared to classic HCL.\",\"fixedText\":\"Revise to: For HCL-V, 5-year OS is approximately 60-75%, with median survival around 8 years, though younger patients may have better outcomes.\",\"evidenceSource\":\"2024 review: https://onlinelibrary.wiley.com/doi/10.1002/ajh.27240; Orphanet: https://www.orpha.net/en/disease/detail/300878\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"A majority of new patients can expect a disease-free remission time span of about ten years, or sometimes much longer after taking one of these drugs just once.\",\"explanation\":\"Ref [49] (Else et al., 2005) reports median time to relapse of 12.5 years in 219 patients but does not specify \\\"majority\\\" achieve ~10 years disease-free; recent data with CDA+R shows 94.8% 5-year failure-free survival, but long-term relapse common. Mismatch as claim implies higher durability than supported without updated context.\",\"fixedText\":\"Add citation to recent data and qualify: Median relapse-free survival exceeds 10 years with purine analogs, longer with chemoimmunotherapy.\",\"evidenceSource\":\"Ref [49]; 2024 review: https://onlinelibrary.wiley.com/doi/10.1002/ajh.27240\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[Entire subsection on Lifespan lacks distinction between classic HCL and HCL-V]\",\"explanation\":\"Prognosis differs significantly: classic HCL has near-normal lifespan, while HCL-V has poorer OS. Article structure has separate HCL-V classification; omitting this gap misleads on applicability for variant form.\",\"fixedText\":\"Add: In classic HCL, lifespan is near-normal with treatment; HCL-V has shorter OS.\",\"evidenceSource\":\"2024 review: https://onlinelibrary.wiley.com/doi/10.1002/ajh.27240\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"[No mention of risk stratification factors like IGHV4-34 or TP53 affecting prognosis]\",\"explanation\":\"Recent data identifies IGHV4-34+ (unmutated) and TP53 mutations as poor prognostic factors in HCL, influencing treatment response and survival; essential for comprehensive prognosis, especially as targeted therapies emerge.\",\"fixedText\":\"Incorporate: Poor prognosis associated with unmutated IGHV4-34 and TP53 mutations.\",\"evidenceSource\":\"2024 review: https://onlinelibrary.wiley.com/doi/10.1002/ajh.27240\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"Of the original 358-patient cohort treated with cladribine at the Scripps Clinic, 9 of 19 in continuous CR for a median of 16 years were free of HCL â€” even sensitive testing for measurable or minimal residual disease (MRD)[52] found an absence of hairy cells.\",\"explanation\":\"Data from 2005-2018; recent 2024 updates show higher rates of undetectable MRD (uMRD) with modern regimens like CDA+R (94%) or vemurafenib+obinutuzumab (96%), suggesting increased potential for cure in classic HCL.\",\"fixedText\":\"Update with recent uMRD rates to reflect improved curability potential.\",\"evidenceSource\":\"2024 review: https://onlinelibrary.wiley.com/doi/10.1002/ajh.27240\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"It does not occur in children.[2]\\\"\",\"explanation\":\"This claim is overly absolute and potentially inaccurate, as there are documented case reports of hairy cell leukemia occurring in children, though it is extremely rare. The citation [2] likely describes it as rare rather than impossible, leading to a mismatch between the statement and available evidence.\",\"fixedText\":\"Revise to: \\\"It is extremely rare in children.[2]\\\"\",\"evidenceSource\":\"Case reports in peer-reviewed literature, e.g., https://ashpublications.org/blood/article/132/11/1216/39373/Hairy-cell-leukemia-in-a-child and https://pubmed.ncbi.nlm.nih.gov/23652869/\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific mention of racial or ethnic distribution.\",\"explanation\":\"The section omits key demographic details on racial and ethnic prevalence, which is a significant knowledge gap in epidemiology. HCL is more common among individuals of White or Caucasian ethnicity and less common in those of Asian, African, or Middle Eastern descent, which complements the geographic variations already noted in the introduction.\",\"fixedText\":\"Add: \\\"HCL is more common among people of White or Caucasian ethnicity and less frequent in those of Asian, African, or Middle Eastern descent.[](https://emedicine.medscape.com/article/200580-overview)\\\"\",\"evidenceSource\":\"Multiple sources, e.g., https://emedicine.medscape.com/article/200580-overview and https://www.onclive.com/view/hairy-cell-leukemia-a-review-of-epidemiology-and-disease-presentation\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"HA-22, now renamed moxetumomab pasudotox, is being studied in patients with relapsed hairy cell leukemia.\\\"\",\"explanation\":\"The drug (Lumoxiti) was FDA-approved in 2018 for relapsed/refractory HCL but was discontinued in the US market in 2023 by AstraZeneca for commercial reasons. As of October 2025, it is no longer available or actively studied for HCL, making the present-tense claim outdated and misleading.\",\"fixedText\":\"Revise to: \\\"HA-22, renamed moxetumomab pasudotox (Lumoxiti), was approved by the FDA in 2018 for relapsed or refractory HCL but discontinued in the US in 2023.\\\"\",\"evidenceSource\":\"[](https://www.onclive.com/view/astrazeneca-to-discontinue-moxetumomab-pasudotox-in-us-for-hairy-cell-leukemia)\"},{\"criticality\":\"Critical\",\"issueType\":\"Timeliness/Currency\",\"problematicText\":\"\\\"Other clinical trials[62] are studying the effectiveness of cladribine followed by rituximab in eliminating residual hairy cells that remain after treatment by cladribine or pentostatin.\\\"\",\"explanation\":\"The cited trials (NCT00412594 and NCT00923013) were completed years ago (around 2010s), with long-term results published showing high efficacy in achieving MRD-negative responses. Using present tense implies ongoing studies, which is inaccurate as of 2025; no active trials specifically for this combination targeting residual disease are prominently ongoing.\",\"fixedText\":\"Revise to past tense and summarize key outcomes: \\\"Clinical trials, such as NCT00412594 and NCT00923013, have demonstrated that cladribine followed by rituximab effectively eliminates minimal residual disease (MRD) in many patients after initial treatment with cladribine or pentostatin, leading to durable remissions.\\\"\",\"evidenceSource\":\"[](https://clinicaltrials.gov/study/NCT00412594) [](https://clinicaltrials.gov/study/NCT00923013) [](https://pmc.ncbi.nlm.nih.gov/articles/PMC11646483/)\"},{\"criticality\":\"Critical\",\"issueType\":\"Source/Citation Mismatch\",\"problematicText\":\"\\\"In 2013 the Hairy Cell Leukemia Foundation was created when the Hairy Cell Leukemia Consortium and the Hairy Cell Leukemia Research Foundation joined.\\\"\",\"explanation\":\"The reference [57] is an archived 2014 webpage, but the current official foundation website and other sources confirm the merger occurred without specifying 2013. No independent sources verify the exact year, creating a mismatch and potential inaccuracy.\",\"fixedText\":\"Remove the specific year: \\\"The Hairy Cell Leukemia Foundation was created when the Hairy Cell Leukemia Consortium and the Hairy Cell Leukemia Research Foundation joined.\\\"\",\"evidenceSource\":\"[](https://www.hairycellleukemia.org/about-us)\"},{\"criticality\":\"Critical\",\"issueType\":\"Missing Information\",\"problematicText\":\"No specific text; overall section lacks recent developments.\",\"explanation\":\"The section focuses on older research (pre-2011) but omits major ongoing initiatives as of 2025, such as the HCL2025 program (launched 2020, $10M for targeted therapies) and HCL2030 ($5-7M for MRD and variant HCL), which are key to current research directions. This creates knowledge gaps on contemporary efforts.\",\"fixedText\":\"Add a paragraph: \\\"In 2020, the HCLF and the Leukemia \u0026 Lymphoma Society launched HCL2025, a $10 million initiative to develop new therapies, including targeted agents for BRAF-mutated HCL. In 2024, HCL2030 was initiated with $5-7 million to address minimal residual disease and HCL variants.\\\"\",\"evidenceSource\":\"[](https://www.hairycellleukemia.org/hcl2025) [](https://www.hairycellleukemia.org/hcl2030)\"}],\"slug\":\"Hairy_cell_leukemia\",\"title\":\"Hairy cell leukemia\",\"content\":\"$1f\",\"description\":\"Hairy cell leukemia\\n\\n| Attribute | Details |\\n|---------------|-------------|\\n| Specialty | Hematology and oncology |\\n\\nHairy cell leukemia is an uncommon hematological malignancy characterized by an...\",\"metadata\":{\"categories\":[\"HCL\",\"Hairy cell leukaemia\",\"Leukemic reticuloendotheliosis\"],\"lastModified\":\"1761552815\",\"contentLength\":\"27891\",\"version\":\"1.0\",\"lastEditor\":\"system\",\"language\":\"en\",\"isRedirect\":false,\"redirectTarget\":\"\",\"isWithheld\":false},\"stats\":{\"totalViews\":\"45974\",\"recentViews\":\"45974\",\"dailyAvgViews\":1532.4666748046875,\"qualityScore\":1,\"lastViewed\":\"1761883441\"},\"linkedPages\":null},\"found\":true},\"dataUpdateCount\":1,\"dataUpdatedAt\":1761883442325,\"error\":null,\"errorUpdateCount\":0,\"errorUpdatedAt\":0,\"fetchFailureCount\":0,\"fetchFailureReason\":null,\"fetchMeta\":null,\"isInvalidated\":false,\"status\":\"success\",\"fetchStatus\":\"idle\"},\"queryKey\":[\"page\",\"Hairy_cell_leukemia\"],\"queryHash\":\"[\\\"page\\\",\\\"Hairy_cell_leukemia\\\"]\"}]},\"children\":\"$L20\"}]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"c:{\"metadata\":[[\"$\",\"title\",\"0\",{\"children\":\"Hairy cell leukemia\"}],[\"$\",\"meta\",\"1\",{\"name\":\"description\",\"content\":\"Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes.[1] The incidence of hairy cell leukemia (HCL) is 0.28-0.30 cases per 100,000 people in Europe and the United States and the prevalence is approximately 3.12 cases per 100,000 in Europe with a lower prevalence in Asia, Africa and the Middle East.[2] HCL has an indolent course but patients frequently relapse. Despite this, with treatment, life expectancy is usually the same as...\"}],[\"$\",\"meta\",\"2\",{\"name\":\"author\",\"content\":\"system\"}],[\"$\",\"link\",\"3\",{\"rel\":\"manifest\",\"href\":\"/manifest.webmanifest\",\"crossOrigin\":\"$undefined\"}],[\"$\",\"meta\",\"4\",{\"name\":\"keywords\",\"content\":\"HCL, Hairy cell leukaemia, Leukemic reticuloendotheliosis\"}],[\"$\",\"meta\",\"5\",{\"name\":\"robots\",\"content\":\"index, follow\"}],[\"$\",\"meta\",\"6\",{\"name\":\"googlebot\",\"content\":\"index, follow, max-snippet:-1\"}],[\"$\",\"link\",\"7\",{\"rel\":\"canonical\",\"href\":\"https://grokipedia.com/page/Hairy_cell_leukemia\"}],[\"$\",\"meta\",\"8\",{\"property\":\"og:title\",\"content\":\"Hairy cell leukemia\"}],[\"$\",\"meta\",\"9\",{\"property\":\"og:description\",\"content\":\"Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes.[1] The incidence of hairy cell leukemia (HCL) is 0.28-0.30 cases per 100,000 people in Europe and the United States and the prevalence is approximately 3.12 cases per 100,000 in Europe with a lower prevalence in Asia, Africa and the Middle East.[2] HCL has an indolent course but patients frequently relapse. Despite this, with treatment, life expectancy is usually the same as...\"}],[\"$\",\"meta\",\"10\",{\"property\":\"og:url\",\"content\":\"https://grokipedia.com/page/Hairy_cell_leukemia\"}],[\"$\",\"meta\",\"11\",{\"property\":\"og:site_name\",\"content\":\"Grokipedia\"}],[\"$\",\"meta\",\"12\",{\"property\":\"og:locale\",\"content\":\"en\"}],[\"$\",\"meta\",\"13\",{\"property\":\"og:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"meta\",\"14\",{\"property\":\"og:image:width\",\"content\":\"512\"}],[\"$\",\"meta\",\"15\",{\"property\":\"og:image:height\",\"content\":\"512\"}],[\"$\",\"meta\",\"16\",{\"property\":\"og:image:alt\",\"content\":\"Hairy cell leukemia\"}],[\"$\",\"meta\",\"17\",{\"property\":\"og:type\",\"content\":\"article\"}],[\"$\",\"meta\",\"18\",{\"property\":\"article:modified_time\",\"content\":\"1970-01-21T09:19:12.815Z\"}],[\"$\",\"meta\",\"19\",{\"name\":\"twitter:card\",\"content\":\"summary\"}],[\"$\",\"meta\",\"20\",{\"name\":\"twitter:creator\",\"content\":\"@Grokipedia\"}],[\"$\",\"meta\",\"21\",{\"name\":\"twitter:title\",\"content\":\"Hairy cell leukemia\"}],[\"$\",\"meta\",\"22\",{\"name\":\"twitter:description\",\"content\":\"Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal B lymphocytes.[1] The incidence of hairy cell leukemia (HCL) is 0.28-0.30 cases per 100,000 people in Europe and the United States and the prevalence is approximately 3.12 cases per 100,000 in Europe with a lower prevalence in Asia, Africa and the Middle East.[2] HCL has an indolent course but patients frequently relapse. Despite this, with treatment, life expectancy is usually the same as...\"}],[\"$\",\"meta\",\"23\",{\"name\":\"twitter:image\",\"content\":\"https://grokipedia.com/icon-512x512.png\"}],[\"$\",\"link\",\"24\",{\"rel\":\"icon\",\"href\":\"/favicon.ico\",\"type\":\"image/x-icon\",\"sizes\":\"16x16\"}],[\"$\",\"$L21\",\"25\",{}]],\"error\":null,\"digest\":\"$undefined\"}\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"11:\"$c:metadata\"\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"22:I[61172,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"PageEditorProvider\"]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"23:I[63493,[\"8739\",\"static/chunks/63f0ec43-8ee6a76d70472249.js\",\"2254\",\"static/chunks/8208b75a-a48e5a4507a0de91.js\",\"4684\",\"static/chunks/24cf1b50-159cca90b09285e0.js\",\"1829\",\"static/chunks/9ffa21ba-c069766d809bd4c7.js\",\"7670\",\"static/chunks/7670-7326298c9856172b.js\",\"282\",\"static/chunks/282-691fffb366e24ca5.js\",\"7515\",\"static/chunks/7515-336759ef5dad2b52.js\",\"5497\",\"static/chunks/5497-ab85ef3ea59dd353.js\",\"7720\",\"static/chunks/7720-3a1e7e411adba2d3.js\",\"6281\",\"static/chunks/6281-c6e84786dade3614.js\",\"7086\",\"static/chunks/7086-1f1c4891d766e04f.js\",\"600\",\"static/chunks/600-9a9fcafaaa6c1c4c.js\",\"5002\",\"static/chunks/5002-9735c25beda556ba.js\",\"5448\",\"static/chunks/5448-2a3cfd853d899c9a.js\",\"5855\",\"static/chunks/5855-243eeca8f0e4cabd.js\",\"4393\",\"static/chunks/4393-1c8dff25ec904469.js\",\"9214\",\"static/chunks/9214-a10614844a67ba31.js\",\"8\",\"static/chunks/8-8ca70ca619d8e099.js\",\"4789\",\"static/chunks/4789-2080f6497f78b5b6.js\",\"6304\",\"static/chunks/app/page/%5Bslug%5D/page-540a27b6839afde5.js\"],\"default\"]\n"])</script><script nonce="NWNiM2I5ZWEtZjJiYy00MjgzLTlmMWUtMGM0MWExYTJkNmFl">self.__next_f.push([1,"20:[\"$\",\"$L22\",null,{\"children\":[\"$\",\"$L23\",null,{\"slug\":\"Hairy_cell_leukemia\"}]}]\n"])</script></body></html>